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ABSTRACT
Apolipoprotein B (apoB)-100-derived peptides previously used by others in vaccine 
preparations to treat atherosclerosis were shown to reduce atherosclerotic plaque 
development by 50% in experimental animals. This was associated with the induction of 
T helper-2 (Th2) immune responses. This study aimed to characterise some of the innate 
and T cell-mediated mechanisms underpinning these responses, including the role of 
regulatory T cells (T regS). The presence of peptide-specific antibodies in the plasma of 
well-defined patient groups and its correlation with disease status, gender and race was 
also studied.
Apolipoprotein E deficient (apoE"A) mice were immunised with apoB-100-derived 
peptides P2, P45 and P210, either conjugated to BSA or loaded onto bone marrow- 
derived dendritic cells (DCs). The numbers of spleen-derived CD4+ and CD8+ T ^  in 
these animals were measured by flow cytometry and enzyme-linked immunosorbent 
assays (ELISA) was used to assess the synthesis of anti-peptide IgGl and IgG2a, as well 
as the levels of interleukin (IL)-IO and interferon gamma (IFN-y) in the plasma of 
immunised animals. Immunisation with peptides and peptide-loaded DCs resulted in 
significantly increased levels of peptide-specific immunoglobulins and IE-10.
Our experiments also showed that T ^  induced by treatment with apoB-100-derived 
peptides were able to reduce mixed leukocyte proliferation induced by DCs treated with 
low density lipoprotein (ox-LDL) and Staphylococcal enterotoxin B (SEB), suggesting a 
tolerogenic mechanism. We also showed that these peptides can also modulate the 
homing properties of DCs, can decrease the expression of Toll like receptors (TLRs) and 
can increase the numbers of T ^  in vivo.
Depletion of CD4+CD25+ TregS with PC61, an anti-CD25 monoclonal antibody, showed 
an increase in the synthesis of interferon gamma (IFN-y), a decrease in IL-10 secretion 
and an increase in the levels of IE-4 consistent with a pro-inflammatory effect. The
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treatment was also accompanied by an increase in cholesterol and triglyceride plasma 
levels and a decrease in HDL. PC61-treated mice also showed larger atherosclerotic 
plaques demonstrating the athero-protective effect of TregS.
The study using patient samples revealed strong correlation between plasma levels of 
anti-P45 and anti-P210 and CVD. East Indian-descendents were found to have higher 
levels of anti-P45, while levels of anti-P210 were higher in African descendents. The 
presence of anti-P210 antibodies was significantly higher in all age groups. No 
significant differences in anti-peptide antibody levels were found between gender groups. 
The findings support the hypothesis that epitope-specific immune responses are 
characteristic of specific disease status and may be linked to genetic differences in the 
population.
Overall, the study provides evidence for the induction of antigen-specific T cell-mediated 
immuno-suppressive effect by the apoB-100-derived peptides and also highlights the role 
of Tregs in athero-protection. In addition, the study highlights that potential differences of 
the immune response elicited by these peptides in vivo may be explained by genetic 
differences in the population. These features could be used to propose the use of these 
peptides as biomarkers to study and understand differences in susceptibility to CVD in 
different population groups.
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CHAPTER 1. 
GENERAL INTRODUCTION
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1.1 Cardiovascular Disease and Atherosclerosis. An overview
Cardiovascular Disease (CVD) kills one in three people in the UK and is the 
main cause of death in the world (30% of deaths or about 17.5 million people in 
2005), leaving behind diseases such as cancer, diabetes and other chronic conditions 
[1]. While there is no single cause and some of the contributing factors cannot be 
changed (e.g. family history), some of the risk factors are potentially reversible or 
could be modified (increased levels of low-density lipoprotein (LDL) in the blood).
Atherosclerosis, derived from the Greek words athero (gruel or paste) and 
sclerosis (hardness), is the main underlying cause and the most common pathological 
process that leads to CVD and it is regarded as a chronic inflammatory disease 
affecting the medium and large sized arteries. It is characterised by the formation of 
atherosclerotic plaques which consist of  necrotic cores, calcified regions, accumulated 
modified lipids, inflamed smooth muscle cells (SMCs), endothelial cells (ECs), 
leukocytes and foam cells [2]. Due to the high plasma concentrations of LDL 
cholesterol, considered as one of the principle risk factors for atherosclerosis, 
atherogenesis has been described as the accumulation of lipids within the artery wall, 
despite the yarious.pharmacologic approaches used to lower plasma cholesterol [2-4]. 
Atherosclerotic lesions are rich in immune cells, particularly monocytes/macrophages 
and T lymphocytes [5, 6], which are responsible for a series of highly specific cellular 
and molecular responses, classifying atherosclerosis as an inflammatory disease [2, 
7]. The inflammatory response observed in atherosclerosis involves the infiltration 
and activation of mononuclear cells, the activation of humoral cascade systems, 
cytokine secretion, cell death and fibroproliferative repair process. This process is
controlled by components of the immune system that are abundant within 
atherosclerotic plaques, such as autoantigens, autoantibodies and reactive 
lymphocytes [5, 8]. Inflammation also results in lipid accumulation within the artery 
wall consequently narrowing the lumen of the artery (stenosis) and limiting the blood 
flow. As previously mentioned, atherosclerosis mainly occurs in large and medium 
sized elastic and muscular arteries leading to ischemia of the heart, brain or limbs, 
often resulting in infarction [2, 7].
1.2 Risk factors related to atherosclerosis development
Being described as a slow, but complex disease, atherosclerosis is thought to 
start in childhood progressing steadily through the whole adult life. The rate of 
progress of the disease differs in individuals and in some cases it progresses rapidly 
and becomes apparent even in their third decade. Evidence shows that about 25% of 
coronary patients have sudden death or nonfatal myocardial infarction without any 
prior symptoms [9] and that conventional risk factors predict less than half of 
potential cardiovascular events [10]. This is a fact which strongly emphasizes the 
need for the identification of risk factors in patients to improve life expectancy 
through better primary prevention [11]. Identification of new risk factors is also 
important in order to enhance the understanding of the etiology of atherosclerosis and 
to facilitate the development of novel therapeutic approaches [10].
The term ‘risk factor’ is used to describe characteristics that are found to be 
related to the consequent occurrence of cardiovascular disease, including modifiable
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lifestyle, biochemical and physiological characteristics, as well as un-modifiable 
personal characteristics, such as age, sex and family history [12]. Such risk factors can 
be related to one another, for example, family history involving elevated LDL- 
cholesterol [12]. Whilst there is no single cause of atherosclerosis, a number of risk 
factors have been identified as causing damage to the innermost layer of the artery, 
the endothelium, an action that has been described as the initial step of atherosclerosis 
development [13].
Well-established and traditional risk factors include age, sex, smoking, blood 
pressure, total serum cholesterol, HDL cholesterol and blood glucose (history of 
diabetes), whereas newer risk factors, such as homocysteine, C-reactive protein, 
lipoprotein (a) serum levels [14] and inflammatory-infectious markers [10] have most 
recently being proposed. These risk factors, some of which can be treated or 
controlled, are listed in Table I and the most important ones are analysed later on. 
Some non-traditional factors, such as high-density lipoprotein (HDL) subtractions, 
apolipoproteins and hemostatic factors (such as fibrinogen level, Factor VII and VIII 
activity, von Willebrand factor level, Antithrombin III activity, Protein C level and 
leukocyte count), are also thought to be independently related to atherosclerosis by 
the Atherosclerosis Risk in Communities (ARIC) Study [15].
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Table I. Traditional risk factors associated with atherosclerosis development 
[12]. (* indicates controllable risk factors)
Age Risk increases with age Increased prevalence as 
population ages
Gender Males are at higher risk Risk equalized after menopause
Socioeconomic Status Lower status increases risk Highly related to other factors, 
such as diet, smoking and 
physical inactivity
Ethnic Group People from the Indian 
subcontinent are at higher risk
Possibly reflects genetic 
predisposition to obesity, 
hypertension and insulin 
resistance
Smoking Smoking increases risk Increases oxidative stress and 
impairs endothelial function
Serum total cholesterol 
concentration
Higher levels increase risk Uptake of cholesterol by 
macrophages is the origin of the 
core of the atherosclerotic 
plaque
Serum LDL-cholesterol 
concentration
Higher levels increase risk LDL particles carry cholesterol 
and is deposited in arterial walls
Serum HDL-cholesterol 
concentration
Lower levels increase risk HDL transports excess 
cholesterol to the liver for 
excretion
Serum triglyceride 
concentration
Higher levels increase risk Inversely related to HDL- 
cholesterol
Blood pressure (b.p)* Higher b.p. increases risk Hypertension increases the risk 
of stroke, induces endothelial 
dysfunction, aggravates the 
atherosclerotic process and 
contributes to atherosclerotic 
plaque instability
Diabetes* Diabetes increases risk Glycation of proteins. Effect on 
blood/vessel homeostasis.
Physical inactivity* Physical inactivity increases risk Related with hypertension.
Obesity* Risk is greater in people with 
greater body fat percentage
Overweight and obesity 
ncrease risk via other risk 
Factors, such as b.p., diabetes 
and blood cholesterol
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1.3. Atherosclerosis: basic concepts
1.3.1. Atherosclerosis as a chronic, inflammatory and autoimmune disease
It is now widely accepted that atherosclerosis is an immune-mediated disease, 
in which risk factors contribute but do not determine its appearance and outcomes [6]. 
This is supported by the fact that approximately 40% of patients suffering from 
myocardial infarction (MI) or cerebrovascular accident (CVA) are not exposed to any 
of the traditional risk factors for atherosclerosis (Table I). Additionally, accelerated 
progression of atherosclerosis is observed in patients of classical autoimmune 
rheumatic diseases, such as systemic lupus erythematosus (SLE), anti-phospholipid 
syndrome (APS), rheumatoid arthritis and vasculitis, suggesting the involvement of 
inflammatory and immune mechanisms in the process of plaque formation [6].
Atherosclerosis has also been proven to fulfil the four criteria delineated by 
Witebsky and Rose to define a condition as autoimmune (Table II), as several 
autoantigens and their respective autoantibodies are associated with the disease [16]. 
OxLDL is the prime candidate for an autoantigen in atherosclerosis, as it is mainly 
used in foam cell generation through uptake by scavenger receptors on macrophages. 
The presence in serum of anti-oxLDL antibodies positively correlates with MI, CVA, 
coronary atherosclerosis and the restenosis of angioplastic vessels [6].
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Table II. The Witebsky and Rose criteria for autoimmunity are fulfilled in
atherosclerosis [6,17,18].
Defining the autoantigen. Defined autoantigens: oxLDL, HSP-60 and 
(32GPI.
Defining the autoantibody or autoreactive T 
cells.
Autoantibodies: the pathogenic role of anti- 
oxLDL, anti-HSP-60 and anti- (32GPI has 
been delineated in clinical studies and 
experimental models.
Induction of the disease by active 
immunisation with the autoantigen emulsifies 
with adjuvant.
Active immunisation of naïve animals with 
HSP-60 or P2GPI induces the respective 
autoantibodies and accelerates the formation 
of atherosclerosis. Immunisation with oxLDL 
leads to the formation of protective 
autoantibodies. Immunomodulation of mice 
with atherosclerosis ameliorates the disease 
symptoms.
Induction of the disease by passive transfer 
of the autoantibody or autoreactive T cells or 
transfer of the Al disease from the sick 
mother to the offspring.
The passive transfer of T cells leads to 
atherosclerosis development in naïve mice.
1.4. Antigens in atherosclerosis
A number of endogenous autoantigens and exogenous bacterial antigens have 
been identified and linked to atherogenesis. Table III displays some of the most 
studied antigens related to atherogenesis and atherosclerotic plaque development [19].
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Table III. Antigens involved in atherogenesis.
Autoantigens Low density lipoprotein (LDL) [5] 
[3-2-glycoprotein 1 ((32GP1) [20]
Lipoprotein (a) [LP(a)] [21]
Lipoprotein-lipase (LPL) [20]
Advanced glycation-end (AGE) products [22] 
Heat-shock proteins (HSPs) [5]
Collagen [5]
Fibrinogen [5]
Microbial antigens Porphyromonas gingivalis [23] 
Chlamydia pneumoniae [20] 
Bacteroides forsythus [24] 
Streptococcus mutans [25] 
Helicobacter pylori [24] 
Echerichia coli [26]
Enterovirus [27] 
Cytomegalovirus [24]
Vipérin [28]
Amongst those viruses, bacteria and parasites claimed to affect atherosclerotic 
development, there is Chlamydia pneumoniae, with IgG and IgM titers correlated 
with increased evidence o f MI, CVA and peripheral vascular disease (PVD). 
Localisation of C. pneumoniae antigens in atherosclerotic plaques and T cell reaction 
to these antigens have also been demonstrated [6]. Other pathogens associated with 
atherosclerosis are Helicobacter pylori, cytomegalovirus and Epstein-Barr. Recent 
studies have shown a correlation between atherosclerosis and chronic bronchitis as 
well as periodontitis, suggesting that any infectious agent, especially multiple chronic 
infections, could result in accelerated atherosclerosis [6].
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1.4.1. Oxidised LDL: a key antigen in atherosclerosis development
Low density lipoprotein (LDL) (Figure 1.1), a spherical particle containing a 
hydrophobic core of cholesteryl esters and triglycerides surrounded by an amphipathic 
monolayer of phospholipid and cholesterol in which a single molecule of 
apolipoprotein B-100 is located, is the major carrier of serum cholesterol [29]. 
Infrared spectroscopy studies have shown that the structure of LDL at 37°C is 24% a- 
helix, 23% p-sheet, 6% P-tums, 24% unordered structure and 24% P-strands [29]. 
Lipid transitions that take place in the lipid core of the particle affect apoB [30], 
which contains a fraction resistant to proteolysis [31].
For more than two decades, evidence suggests that lipid oxidation plays a 
central role in atherogenesis [32], with oxidative modification of LDL considered to 
be one of the earliest events in the initiation of atherogenesis [33, 34]. According to 
Palinski et al, oxLDL is present in aortas of human fetuses of hypercholesterolemic 
mothers [35] even before the formation of macrophage foam cells, in progressing 
atherosclerotic lesions of animal models [36], and within human vulnerable plaques 
[37, 38].
OxLDL is not defined as a single chemical entity, but instead it represents a 
variety of modifications of both the lipid and protein components of LDL after the 
initiation of lipid peroxidation [39]. Therefore, the resulting oxidized lipid and 
oxidized lipid-protein adducts are not only pro-inflammatory [40], but are also 
recognized by the immune system as antigens and are hence highly immunogenic 
[41]. The oxidation hypothesis of atherogenesis focuses on specific proinflammatory
oxidized phospholipids which are a result of the oxidation of LDL phospholipids 
containing arachidonic acid. These oxidized phospholipids are largely generated by 
potent oxidants produced by the lipoxygenase and myeloperoxidase pathways and are 
recognized by the immune system of both animals and humans [32]. In these cases, 
antioxidant vitamins, such as vitamin E, fail to influence or prevent clinical outcomes 
such as the prevention of the formation of oxidized phospholipids and other lipid 
oxidation products [32].
Studies have shown that circulating oxidized LDL is correlated with 
hypercholesterolemia, body mass index, diabetes type 2, and age, with 
hypercholesterolemia and obesity being the strongest predictors of the circulating 
oxidized LDL level [42]. It has also been demonstrated that obese individuals, which 
exhibit no clinical evidence of Coronary Artery Disease (CAD), but display increased 
intima/media thickness of carotid arteries, had increased circulating oxidized LDL 
correlated to intima/media thickness, something which suggests that an increased 
oxidized LDL level is indeed a marker of early atherosclerosis [42].
The levels of specific oxidized lipids in plasma and lipoproteins, the levels of 
antibodies to these lipids, and the inflammatory/anti-inflammatory properties of LDL 
and DDL may be useful markers of susceptibility to atherogenesis [32].
Oxidised low-density lipoprotein (oxLDL) is amongst the number of antigens
linked to atherosclerosis and is known to be a very potent immunogen. Antibodies
generated against oxLDL are able to bind to many other similarly modified
endogenous and exogenous proteins [43]. Low-density lipoprotein oxidation plays a
major role in the initiation and progression of atherosclerosis [44, 45]. In its native
form LDL is not immunogenic, but upon oxidation becomes a neoantigen, a modified
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self-antigen to which the immune system is normally tolerant, but has the potential to 
excerpt autoreactive immune responses upon modification [19]. The peroxidation of 
polyunsaturated fatty acids in phospholipids and cholesteryl esters results in the 
formation of reactive breakdown products, such as malondialdehyde (MDA) and 4- 
hydroxynonenal, which form covalent adducts with amino acids containing free 
amino groups in ApoB-100 [46]. The accumulation and retention of oxLDL 
molecules in the subendothelial space, triggered by interaction with the endothelium, 
initiates atherogenesis and promotes lesion development [47]. This is achieved by the 
induction of macrophage foam cell formation, SMC migration and proliferation by the 
retained oxLDL particles, as well as the stimulation of the secretion of inflammatory 
cytokines and the expression of adhesion molecules which promote endothelial cell 
dysfunction and leukocyte extravasation [19, 48, 49].
Figure 1.1. Low-density-lipoprotein (LDL). LDL is made up of ApoB-100 protein, 
cholesteryl esters, cholesterol, triglycerides and phospholipids. It has an approximate size of 
2x106 kDa and it contains a number of epitopes, such as apoB-100-derived or lipids, 
recognised by antibodies and T lymphocytes (Figure from Encyclopedia Britannica, Inc., 
http://www.britannica.com) [50].
triacylglycerolphosphohd
monolayer
cholesteryl esters
free (unestenfied) 
cholesterol
©  2007 Encyclopaedia Britannica, Inc.
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High levels of oxLDL and of antibodies raised against it have been detected in 
the serum of patients with acute myocardial infarction, and its presence within 
atherosclerotic lesions has been confirmed by immunochemical staining [51].
Initially, LDL interacts with proteoglycans within the extracellular matrix of 
the arterial wall, via their carbohydrate groups known as glycosamynoglycans 
(GAGs), leading to the exposure of GAG-binding sites contributing to retention of 
oxLDL. Apolipoprotein B (ApoB), the main protein component of the LDL particle, 
mediates this interaction facilitating LDL oxidation by oxygen-reactive species 
released by vascular cells or as a result of enzymatic modifications driven by 
endothelial cells, macrophages or smooth muscle cells within the atherosclerotic 
plaques [19, 52, 53]. OxLDL has been demonstrated to act as a chemoattractant for 
monocytes allowing them to infiltrate into the lesion site, as well as inducing 
monocyte adhesion to the endothelium. This is established by the up-regulation of the 
expression of adhesion molecules on their surface via the induction of macrophage 
major histocompatibility class II (MHC-II) and LeuM3 cell surface expression, as 
well as by accelerating the differentiation of monocytes into macrophages [19, 54]. 
Endothelial cells are capable of oxidising LDL contributing to its continuous 
generation within lesion sites. The expression of oxLDL receptor (oxLDL-R) on the 
surface of endothelial cells is also induced by inflammatory mediators such as 
interleukin 1(3 (IL-ip), TNF-a and monocyte colony stimulating factor (M-CSF), also 
contributing to the accumulation of oxLDL [19, 54].
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1.5. Initiation of Atherosclerosis
Inflammation participates in all stages of atherosclerosis, from its onset and 
development to thrombotic complication (Figure 1.2), which is proposed to be the 
endpoint of the disease [43].jln the early 1980s the presence of leukocytes within 
atherosclerotic arteries was reported, when monocyte adhesion to the aortic 
endothelium and the formation of foam cell lesions in areas of enhanced permeability 
of aortic intima during the development of atherosclerosis was reported [55]. [The 
occurrence of these inflammatory cells in the atherosclerotic lesions depends on their 
recruitment rate and the balance of proliferation, survival and apoptosis within the 
arterial wall [56]j
f"~Ih healthy arteries, endothelial cells (ECs) forming the inner-most surface of 
the artery wall resist the adhesion by leukocytes. In the case of atherosclerosis, due to 
factors such as high-saturated-fat diet, hypertension, smoking and hyperglycemia, the 
expression of adhesion molecules by ECs is initiated and leukocytes attach to the 
arterial wall. Vascular cell adhesion molecule-1 (VCAM-1), whose expression is 
initiated by the accumulation of modified lipoprotein particles in the arterial intima, 
through pro-inflammatory cytokines such as interleukin Ip (IL-IP) and tumour 
necrosis factor-a (TNF-a), binds monocytes and T lymphocytes, found in early stages 
of atherosclerotic plaque formation [43]j Studies have shown that experimental LDL 
receptor (LDLr) or Apolipoprotein E (apoE) knockout mice, which are engineered to 
express a poorly functioning form of VCAM-1, have a significant reduction in lesion 
formation compared to VCAM-1 producing littermates [43].
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Figure 1.2. Stages of atherosclerotic plaque development. Alteration of the vascular 
endothelium triggers the recruitment of leukocytes. Cytokines and growth factors are released 
by inflammatory cells and vascular cells, generating a highly mitogenic milieu. Migration and 
proliferation of vascular smooth muscle cells (VSMCs) bring upon the synthesis of 
extracellular matrix components forming the fibrous cap of the atherosclerotic lesion. 
Inflammatory mediators induce the thinning of the fibrous cap by the expression of proteases, 
rendering a weak plaque which is susceptible to rupture and thrombus formation. In advanced 
stages, fibroblasts and VSMCs with extracellular calcification give rise to fibrocalcific lesions 
[57]. Figure from Dzau et.al, 2002.
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Atherosclerotic lesions develop only in specific areas depending on the type of 
blood flow. Shear stress produced by the laminar blood flow elicits atheroprotective 
mechanisms such as the expression of a form of the antioxidant enzyme superoxide 
dismutase and the increase of nitric oxide synthase expression [58]. Areas that 
experience disturbed flow, and lack of laminar flow, are more prone to lesion 
formation due to the reduced activity of those atheroprotective mechanisms [43].
^Endothelial dysfunction has been proposed as the first step in atherosclerosis 
(Figure 6). Possible causes of this endothelial dysfunction include elevated modified 
LDL, free radicals caused from smoking, hypertension and Diabetes mellitus, as well 
as genetic alterations such as elevated plasma homocysteine concentrations, infectious 
microorganisms like Chlamydia pneumoniae or a combination of all these factors [2, 
7, 5 9 ]j
^Endothelial dysfunction leads to compensatory responses that alter the normal 
homeostatic properties of the endothelium, resulting in the increased adhesiveness of 
the endothelium with respect to leukocytes or platelets in addition to permeability. 
This also results in the induction of endothelium having procoagulant properties, 
instead of anticoagulant, and the formation of vasoactive molecules, cytokines and 
growth factors. Such inflammatory responses stimulate the migration and proliferation 
of smooth muscle cells, which become intermixed with the area of infla.mmat.inn to 
form an intermediate lesion, leading to the thickening of the artery wall [2, 60}. j
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1.5.1. Development of the fatty streak
(^Most of the responses in atherogenesis are mediated by monocyte-derived 
macrophages, as well as specific subtypes of T lymphocytes at every stage of the 
disease [61, 62]. Once adhered to the arterial endothelium, monocytes penetrate the 
endothelial lining and enter the intima of the vessels wall via the chemoattractant 
gradient established, among others, by the secretion of monocyte chemoattractant 
protein-1 (MCP-1), which is over-expressed in human and experimental atheromas 
and has the ability to recruit monocytes in early atheromas^ Studies in ApoE knockout 
mice lacking the ability to express CCR2, the receptor for MCP-1, have demonstrated 
a reduced lesion development, when compared to mice with a normal CCR2 gene [43, 
63]. jJThis migration and accumulation within the lesion of macrophages and 
lymphocytes as well as the release of hydrolytic enzymes, cytokines, chemokines and 
growth factors, which further induce damage resulting in focal necrosis [64, 65]^
r
1 Macrophage colony-stimulating factor (M-CSF), expressed in human and 
experimental atherosclerotic plaques, mediates the transformation and proliferation of 
monocytes into macrophages as well as the over-expression of scavenger receptors 
leading to the engulfment of modified lipoproteins. There is also accumulation of 
cholesterol esters in the cytoplasm and transformation of macrophages into foam 
cells. Pro-inflammatory signals are also amplified by the release of growth factors and 
cytokines [43]. T lymphocytes also participate in fatty streak formation. They enter 
the inflamed artery wall after being influenced by IFN-y-inducible protein 10 (y-IP- 
10), monokine induced by IFN-y (MIG) and Interferon-inducible T cell a 
chemoattractant (I-TAC), three interferon-y (IFN-y) inducible chemokines [66]^These
chemokines interact with the CXCR3 receptor expressed by T lymphocytes in the 
atherosclerotic plaque [43].
f rh e  accumulation of mononuclear cells, migration and proliferation of 
smooth-muscle cells and formation of the fibrous tissue leads to the enlargement and 
remodelling of the lesion, which gets covered by a fibrous cap, overlying a core of 
lipid and necrotic tissue, called the complicated lesion [2]. This chronic accumulation 
of foam cells, foam cell death and in situ cholesterol release causes the formation of 
an intermediate lesion called fatty streaks. Fatty streaks are the earliest type of 
atherosclerotic lesions that can be recognised within the artery, can develop from a 
young age and consists of monocyte-derived macrophages and T lymphocytes [67, i
— i
68].
1.5.2. Progression to mature plaque
r
Injury of the arterial wall may also result in pathological remodelling leading 
to atherosclerotic plaque formation, through cellular and molecular events. An 
imbalance between the repair mechanism and the inflammation factors contribute to 
the thickening of the arterial wall and plaque progression through the action of 
inflammatory mediators such as cytokines, chemokines and growth factors [69]. 
Rupture of the plaque results in acute ischemic events due to the release of pro- 
thrombotic factors derived from the atherosclerotic plaques in to the blood circulation 
causing thrombosis [70].
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Atheromas (big mature plaques) are made of a fibrous cap and their rupture 
causes the release of pro-thrombotic agents [71]. The fibrous cap is a protective layer 
formed between the fatty deposits and the intima, due to the proliferation and 
migration of smooth muscle cells (SMCs) from the media to the intima, attracted by 
the cytokines secreted by damaged endothelial cells (ECs). The capped fatty deposits 
produce enzymes that cause the enlargement of the artery over time, hence 
compensating for the thickening of the atheroma and helps in the prevention of lumen 
stenosis [60].
Pro-inflammatory CD40 ligand (CD 154) contributes to this phase of 
atherogenesis, as disruption of CD40/CD154 signalling slows the initiation of 
atherosclerosis [72]. Studies in LDLr deficient mice fed with a high-cholesterol diet 
for 13 weeks, to allow lesion formation, showed significant reduction in disease 
progression after being treated with anti-CD 154, an antibody to CD 154 in order to 
inhibit CD40 signalling when compared to controls [73]. The findings illustrate how 
inflammation influences the progression of atherosclerosis and that the halting of 
inflammatory signalling prevents the formation of new lesions as well as the 
progression of existing atherosclerosis [43].
1.5.3. Plaque Rupture
The main cause of coronary artery thrombosis and subsequent myocardial
infarction is the rupture of unstable atherosclerotic plaques [74, 75]. Predicting which
plaques will rupture is currently not possible and hence studies on helping resolve this
problem are needed [75]. Fragmentation and loss of elastin in the fibrous caps of
relatively small and lipid-rich plaques overlying large complex lesions as well as
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intraplaque haemorrhage are the characteristics of ruptures. The loss of SMCs from 
ruptured caps also occurs [75].
A recent study using ApoE knockout mice fed from 7 weeks of age with high 
fat rodent diet supplemented with 21% lard and 0.15% cholesterol, identified common 
features in lesions that ruptured. Those lesions were associated with luminal thrombus 
formation, intraplaque haemorrhage and presence of erythrocytes. The major site of 
tendency for plaque rupture in the ApoE knockout mice was the brachiocephalic 
artery, a very short vessel emanating from the aortic arch and branching out into the 
right subclavian and right common carotid arteries [75]. The increased occurence of 
these events may be due to the non-laminar blood flow as it enters the brachiocephalic 
artery and the creation of conditions conducive to plaque rupture as it impacts on the 
flow divider at the branch [75].
Plaque rupture is attributed to changes that occur within the atherosclerotic 
plaque. The influx of inflammatory cells, macrophages and T lymphocytes in 
atherosclerotic plaques increases with plaque progression and at sites of plaque 
rupture [2, 74, 76]. Inflammatory mediators such as leukocyte adhesion molecules (P- 
and E-selectins, ICAM-1 and VCAM-1), chemokines (monocyte chemoattractant 
protein-1, IL-8), cytokines (GM-CSF, IL-1, IE-6, IE-8, TNF-a, IFN-y) and C-reactive 
protein (CRP) which are normally expressed in atherosclerotic plaques, have 
increased expression at sites of plaque rupture [2, 74, 77]. The expression of TGF-p, 
an inducer of collagen synthesis expressed in all atherosclerotic lesion types, is 
decreased with lesion progression, inducing a plaque phenotype with increased 
inflammation, thin fibrous caps and intraplaque haemorrhages [78, 79].
1.6. Cellular immunological mechanisms involved in the formation of 
atherosclerotic plaques.
As mentioned, atherogenesis is believed to be initiated by the formation and 
retention of oxLDL within the arterial wall, which induces macrophage accumulation 
and foam cell formation, the proliferation of smooth muscle cells and the production 
of inflammatory mediators, such as cytokines [80]. Dendritic cells (DCs) and 
lymphocytes are found in the adventitia of normal arteries, with their number being 
greatly expanded in atherosclerotic arteries of humans and mice [56].
Following the activation of arterial wall cells, monocytes infiltrate the plaque 
and differentiate into macrophages and engulf oxLDL via scavenger receptors, 
especially CD36, CXCL16 and SR-A, which then develop into foam cells [81]. Lipid 
accumulation also contribute to the synthesis and release of inflammatory factors 
which in turn activate smooth muscle cells causing them to secrete matrix 
metalloproteinases (MMPs) that degrade the elastic lamina between the intima and 
media [49]. SMC migrate from the media to the intima and differentiate into foam 
cells contributing to the lipid core formation.
1.6.1. Adaptive immune responses in atherogenesis
Immune cells such as macrophages, T cells, B cells, DCs, mast cells and 
natural killer cells (NK cells) have been found within atherosclerotic plaques at all 
stages of the disease [20]. Endogenous neoantigens, such as apoptotic cells or oxLDL,
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and exogenous antigens trigger the adaptive immune system which recognises 
specific molecular structures and depends on the generation of antigen receptors, such 
as TCRs and immunoglobulins, by the activation of T cells and B cells [82]. In the 
case of oxLDL, its formation and retention within the arterial wall induces the 
production of inflammatory mediators, such as cytokines [80].
Antigens are processed by antigen presenting cells (APCs) and then presented 
in the context of MHC I and II molecules where they interact with TCRs on the 
surface of T cells, which are then activated or become anergic, depending on co­
stimulatory molecules (B7-1 or B7-2) on APCs interacting with CD28 on T cells [83]. 
The adaptive immune system influences the pathogenesis of atherosclerosis through 
cell-to-cell interactions between APCs and T cells, by the secretion of cytokines from 
activated T cells or by the production of antibodies by B cells in a T cell-dependent or 
independent manner [83]. Therefore, in the process of responding to eliminate a 
foreign particle or microorganisms, T cells are presented with the antigen and an 
adaptive immune response is initiated by cytotoxic T lymphocytes directly attacking 
the antigen-bearing cells or by the production of antibodies from stimulated B cells by 
the antigen and induction of inflammation. Inappropriate expression leads to 
autoimmune diseases and allograft rejection. DCs are strong activating stimuli of 
‘naïve’ T cells as they express MHC class II molecules and other costimulatory 
factors at high density on their surface needed for the activation of these ‘naïve’ T 
cells and the initiation of an adaptive immune response. Once activation has occurred, 
the remaining memory T cells have now a lower activation threshold and hence 
require a lower amount of antigen for stimulation [82]. This lower threshold has been 
proposed as to be the cause of autoimmune diseases [82]. Endogenous molecules that
resemble foreign antigens may be formed, a process called antigen mimicry, leading 
to autoimmunity in the tissues containing such autoantigens, as well as leading to 
inappropriate activation of innate immunity and pathological inflammation by binding 
to pattern recognition receptors on macrophages. In the aspect of B cells, when 
activated by antigens, hypermutations in their immunoglobulin genes occur, which 
together with evolutionary pressure by the antigen, lead to affinity maturation and 
generation of antibodies with high specificity [82].
The majority of T cells in the atherosclerotic plaques are CD4+ T cells (helper 
cells), with smaller numbers of CD8+ T cells (cytotoxic cells) also present. CD4+ T 
helper cells recognise exogenous antigens which are phagocytosed and processed by 
APCs and presented on MHC class II molecules. On the other hand, CD8+ cytotoxic T 
cells recognise antigenic peptides derived from infected cells and are then presented 
on MHC class I molecules. Both CD4+ and CD8+ T cells activate receptors on the cell 
surface causing the secretion of cytokines and chemokines [84], which in turn lead to 
the activation and clonal expansion of T cells [85].
1.6.2. The role of effector CD4+ T cells in atherogenesis
Effector CD4+ T cells give rise to Thl, Th2 or Thl? responses, depending on 
the type of the antigen and the context of the immune response. Thl is a functional 
subset of helper T cells that secretes cytokines such as IFN-y and has as its principal 
function the stimulation of phagocyte-mediated defense against infections [86]. These 
cells are mediators of organ-specific autoimmune diseases, such as thyroditis and
22
gastritis [87]. On the other hand, Th2 is a functional subset of helper T cells that 
secretes cytokines such as IL-4 and IL-5 and has as its main function the stimulation 
of cell mediated immune reactions and to down-regulate Thl responses. These cells 
mediate systemic autoimmune diseases, such as lupus [87].
While T lymphocytes mainly reside within the adventitia of normal non­
inflamed arteries, short-term adoptive transfer experiments suggest that this 
localization of T cells is a consequence of constitutive homing of T cells in the aortic 
wall, which is L-selectin dependent [88, 89]. In atherosclerotic conditions, T cell 
recruitment in the aorta is accelerated [90], with most of those T cells having a 
TCRaP+CD4+ phenotype, while few express CD8 or TCRyô [91, 92]. T cells which 
are specific to oxLDL and HSP are found in atherosclerotic plaques, also suggesting 
local activation and clonal expansion during atherogenesis [93].
Adaptive immune responses depend mainly on T cell receptor (TCR) and B 
cell receptor (BCR) genes, involving clonal selection of T cells, antigen presentation 
and affinity maturation of B cells. Activation depends on specific T cells recognising 
an antigen and then activating B cells inducing effector responses [94, 95]. Naïve T 
cells get activated in secondary lymph nodes and differentiate into effector T cells. 
The function of these effector T cells depends on the environment in which they 
develop. For instance, some CD4+ effector T cells migrate towards the B cell follicle 
in the secondary lymphoid organs in which they were activated in order to help B 
cells in the process of germinal-centre formation. Others, together with CD8+ effector 
T cells, enter the circulation through lymph vessels and the thoracic duct, localise in
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the extralymphoid tissues, helping with the coordination of immune and inflammatory 
responses in the periphery [96].
Clonal selection occurs in the thymus and only T cells that can recognise 
foreign epitopes expressed on the MHC molecule of APCs appear in the periphery 
[97]. Adhesion molecules and chemokines that promote the recruitment of monocytes 
also stimulates T cells to enter atherogenic lesions [82]. Activation of both naïve and 
memory T cells in the periphery results from the presentation of antigens by APCs. 
Activation of CD8+ T cells results in the development of cytotoxic T cells, which 
recognise and kill cells presented in the context of MHC class I molecules. Activation 
of naïve CD4+ T cells leads to the parallel production of effector T cells expressing 
CXC-chemokine receptor 5 (CXCR5), specialised for B cell help and effector T cells 
which express CXCR3 and P-selectin ligands, specialised for tissue-inflammatory 
functions [96, 98]. Moreover, activation of CD4+ T cells results in the development of 
helper T cells, producing cytokines and expressing surface molecules which initiate B 
cell activation, triggering antibody production leading to inflammation. As shown in 
Figure 1.3, T helper cells can be grouped in three effector pathways, Thl, Th2 and 
Thl 7 responses, depending on the type of cytokines involved [97, 99].
24
Naïve CD4 
T cell
Thl7
Figure 1.3. CD4+ T cell differentiation depending on the cytokine milieu. Antigens 
presented to naïve CD4+ T cells by antigen-presenting cell cause their differentiation into Th1, 
Th2, Th17, Tregs and follicular helper T (Thf) cells. Differentiation depends on cytokines 
produced. Figure from Zhou et al., 2009 [100].
The predominant type of lymphocytes in atherosclerotic lesions is thought to 
be Thl, due to the detection of IFN-y in lesions, promoting inflammation and 
consequently atherogenesis, as well as the abundant expression of the Thl inducer 
cytokine IL-12 [97]. T cells within lesions also secrete IL-2, TNF-a and TNF-(3, 
causing the activation of macrophages and vascular cells, promoting inflammation 
and participating in cellular immunity [84, 97]. As stated above, CD4+ T cells isolated 
from human atherosclerotic plaques express the ap TCR, which recognizes peptide
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antigens presented by MHC class II molecules on the surface of APCs. Activation of 
these lymphocytes is believed to occur in the lymph nodes by DCs and then by 
macrophages within the plaques, through MHC class II molecules, giving rise to 
adaptive immune responses, by the activation of cytotoxic T and B cells for the 
production of antibodies in order to enhance innate responses [101].
I.6.2.I. Regulatory T cells
The production of regulatory cells is one of the mechanisms that the immune 
system develops to suppress the activity of potentially autoreactive cells [102, 103]. 
First described in the early 1970s [104], CD4+CD25+ regulatory T cells, which 
comprise approximately 5-10% of the peripheral CD4+ T cell repertoire in mice and 
humans, are identified by the constitutive expression of the IL-2Ra chain (CD25) and 
have been shown to prevent the development of several autoimmune diseases, also 
modulating immune responses to infections and in transplantation settings [102, 105]. 
Regulatory T cells inhibit naïve CD4+ T cell proliferation and differentiation [102, 
106], prevent cytotoxic activity of CD8+ T cells both in vitro and in vivo [102, 107], 
they suppress the activation and antibody production of B cells [102, 108], they limit 
the activity of cells from the innate immune system (such as NK cells, neutrophils and 
monocytes) [102, 109] and they limit the stimulatory capacity of antigen-presenting 
cells by down-regulating cell surface expression of co-stimulatory molecules such as 
CD80 and CD86 [102, 110].
CD4+CD25+ T cells can also be generated in the periphery from mature 
CD4 CD25" T cells (Figure 1.4). These CD4 CD25" T cells are potentially
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autoreactive and in order to keep them from becoming pathogenic in response to 
antigen re-encounter they are induced into CD4+CD25+ regulatory T cell phenotype 
and function [102, 111]. Thus, the population of naturally arising regulatory CD25+ T 
cells in the periphery may also contain adaptive CD25+ T cells produced upon 
interactions with foreign antigens [102]. In such cases, TGF-p is shown to play an 
essential role in this ‘peripheral conversion’ of CD25" T cells into CD25+ T cells with 
regulatory properties [102, 112].
Whilst little is known in regards to the lifespan and turnover of CD4+CD25+ 
regulatory T cells compared to that of naïve CD4+ T cells, studies have shown that in 
order to expand in the periphery, CD4+CD25+ regulatory T cells require stimulation 
with specific peptide : MHC complexes, with a possible role for cytokine signals for 
their relative survival. Signals mediated from IL-2/IL-2R and through CD28/B7 
signalling appear to be necessary for the maintenance and survival of CD4+CD25+ 
regulatory T cells, as well as the interactions between the TCR and self-peptide : 
MHC [113]. Regulatory T cells exert their suppressive activity, after activation via 
their TCRs, in a cell-cell contact-dependent and cytokine-soluble factor-independent 
manner [114].
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Figure 1.4. CD25+ Regulatory T cell development. Potential TCR-ligand interactions result 
in the generation of CD25+ T cells with regulatory properties in the thymus (left) and in the 
periphery (right) [102, 115].
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Mechanisms involving immunosuppressive cytokines, IL-10 and TGF-p have 
been shown to regulate immune responses by regulatory T cells in vivo. This 
important role of IL-10 was first demonstrated in the adoptive transfer colitis model 
and in models of transplantation tolerance, graft-versus-host disease, chronic parasite 
infection and other autoimmune models [116, 117]. Due to the numerous cellular 
sources of TGF-p (effector T cells, nonlymphoid tissues such as epithelium and 
regulatory T cells), its role in CD4+CD25+ mediated suppression is controversial
[118]. Studies carried out by Nakamura and his group have shown expressed TGF-P 
bound to the surface of CD4+CD25+ regulatory T cells, but not CD4+CD25* T cells
[119]. Regulatory T cells in mice also express Cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4), another molecule thought to be involved in the function of these 
CD4+CD25+ cells. Several studies have demonstrated that signals through CTLA-4 
may activate CD4+CD25+ regulatory T cells, with blockage of that signal leading to 
failure of the activation and attenuation of the regulatory T cell mediated suppression 
[102, 120]. In vitro killing of antigen-presenting B cells by CD4+CD25+ regulatory T 
cells in a Fas/FasL-dependent manner has also been reported recently [121].
I.6.2.2. Types of Regulatory T cells
One of the most characteristic features of regulatory T cells is the constitutive 
expression of CD25, with the regulation activity being enriched in CD4+ T cells with 
the highest levels of CD25 expression (CD4+CD25hl cells). Regulatory T cells express 
intra-cytoplasmic and cell-surface CTLA-4 (CD 152), which is a negative regulator of 
cell-mediated immunity and Glucocorticoid-induced Tumour necrosis (TNF) receptor
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family-Related (GITR), a member of the TNF receptor superfamily. Expression of 
CD25, GITR and CD 152 on activated non-regulatory T cells suggests that expression 
of these molecules does not functionally define regulatory T cells and hence not all 
regulatory T cells express these molecules [122, 123].
The transcription factor forkhead box P3 (FoxP3) is documented as the most 
definite marker for the identification of regulatory T cells [124]. FoxP3 is a functional 
regulator of Treg cell development and function [125]. Mouse and human genetic 
studies demonstrated that mutations in the FoxP3 gene are linked to autoimmune 
manifestations observed in scurfy mice and immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) disease in humans 
[126]. FoxP3-deficient mice were found to lack TregS, whereas over-expression of the 
FoxP3 leads to immune suppression [127]. According to flow cytometric and 
immunohistochemical analyses, FoxP3 is expressed on CD25+, CD25low and CD25" 
CD4+ T cells, as well as some CD8+ T cells [128, 129].
Being an intracellular protein, FoxP3 cannot be used to separate Tregs for 
functional studies or for in vivo expansion in the context of cellular therapy, hence 
limiting its use and hence making the search for new biomarkers of Tregs more intense 
[130]. Recent studies have demonstrated that CD 127 expression is down-modulated 
on regulatory T cells, making it a possible marker associated with regulatory T cell 
[130]. CD 127 is part of the heterodimeric IE-7 receptor that is composed of CD 127 
and the y chain shared by other cytokine receptors, such as IL-2R, IL-4R, IL-9R, IL- 
15R and IL-21R, expressed on thymocytes, T and B cell progenitors, mature T cells, 
monocytes and some other lymphoid and myeloid cells. Studies have shown that the
IL-7R plays an important role in the proliferation and differentiation of mature T cells 
and that the expression of CD 127 is down-regulated following T cell activation [122, 
131, 132].
There are five types of regulatory T cells described so far, out of which four 
have been studied in the context of atherosclerosis, namely CD4+ TregS, Trl cells, Th3 
cells and CD8+ Tregs (Table IV, CD8+ Tregs not studied in atherosclerosis).
Table IV. Regulatory T cell subsets.
Naturally occurring C D 4 ^ D 2 5 ® ^ T o x P 3 ^ ^ ^ ^ ^ Direct contact
Tr1 CD4+CD25'FoxP3" IL-10 secretion
Th3 CD4+CD25+m9nFoxP3+ TGF-p secretion
CDS CD8+CD25+n,9nFoxP3+ Direct contact
CD31 CD4+CD31 +FoxP3+ Direct contact
Naturally occurring regulatory T cells develop in the thymus from positively
selected thymocytes and represent approximately 5-10% of total CD4+ T cells. They
express CD4, intermediate to high levels of CD25 and the transcription factor FoxP3
(CD4+CD25+int/hlghFoxP3+). The signal for the production of this regulatory T cells
subset comes from interactions between TCR and MHC class II complex. They act by
inhibition of the immune response by direct cell-to-cell contact [133]. Trl regulatory
T cells develop in the periphery and have a CD4+CD25"FoxP3" phenotype. They are
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induced by IL-10 stimulation and regulate the immune response by secretion of high 
levels of IL-10 and moderate levels of IFN-y [134]. The Th3 subset, like Thl, 
develops in the periphery and originally has a CD4+CD25*FoxP3" phenotype, but after 
stimulation by TGF-P they become CD4+CD25+hlghFoxP3+. Th3 regulatory T cells act 
by secreting TGF-p [135]. CD8+ regulatory T cells, which have not yet been studied 
in the context of atherosclerosis, are less characterised and induce an inhibitory effect 
on CD4+ T cell proliferation. They have a CD8+CD25+hlghFoxP3+ phenotype and act 
by a direct cell-to-cell contact mechanism [136].
I.6.2.3. Differences between natural and adaptive Treg cells
Even though nTregs develop in a highly controlled environment [137], iTreg 
cells have the capacity to differentiate under more varied conditions (Table V) [138]. 
For instance, iTreg cells that appear in the mesenteric lymph nodes during oral 
tolerance [139] continuously differentiate in the lamina propria of the gut in response 
to food antigens [140] and they are generated in inflamed tissues [141], tumor [142] 
as well as in transplanted tissues [143].
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Table V. Differences between nTreg and iTreg cells [138].
Generation: Tissue Thymus GALT, spleen, 
lymph node, inflamed 
tissue
Co-stimulation
requirement
CD28 CTLA-4
Cytokine
requirement
TGF-p, IL-2 or IL-15 TGF-p, IL-2
Specificity: Self
-
Allergens,
commensal microbiota, 
neoantigens (tumor), 
alloantigens, 
self (inflammation)
Differences are not only present between nTreg and iTreg cells, but also 
amongst iTreg cells which are generated in different ways (e.g. in vitro and in vivo 
generated iTreg cells) [138]. In mice, FoxP3+ iTreg cells generated in vitro are believed 
to be as effective suppressors as natural Treg cells [111, 141], whereas it is doubtful if 
this is also the case for iTreg cells generated in vivo [112, 144].
FoxP3+ iTreg cells have the TCR repertoire of naïve T cells, something that
differs from the TCR of naive FoxP3+ Treg cells [145, 146]. The similarity of the
repertoires has been classified from 10% to 42% [146, 147], something that may be
due to the analysis of nTreg cells being present in the FoxP3+ population analysed
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[138]. From this, it can be observed that the number of iTreg cells in the total 
population of Treg cells may be small, as if the frequency of iTreg cells in the total Treg 
pool was higher, then the repertoires would be more overlapping [138].
Complete de-methylation within the Treg cell-specific demethylated region 
(TSDR) was identified by different studies on méthylation of CpG motifs in the 
FoxP3 locus of natural FoxP3+ Treg cells [138]. This TSDR de-methylation is unique 
to FoxP3+ regulatory T cells, but unlike nTreg cells, iTreg cells which are generated in 
vitro only display partial déméthylation, also loosing FoxP3 expression and 
suppressive activity when restimulated in the absence of TGF-P [148, 149]. On the 
other hand, iTreg cells generated in vivo after the administration of antigen coupled 
with DEC205 antibodies display efficient TSDR de-methylation [150].
In the case of gene profiling, a subset of genes expressed in natural FoxP3+ 
Treg cells has been identified and is defined as the ‘Treg cell signature’ [138]. Part of 
this also corresponds to genes which are induced or repressed in Treg cells 
independently of FoxP3 expression [138]. When this Treg signature was compared for 
Tregs generated in different conditions, it was observed that in vitro generated FoxP3+ 
Tregs lack part of the Treg cell signature genes, despite FoxP3 being expressed in high 
levels [151]. This results in the poor suppression activity displayed by iTregs in vitro 
and in vivo [138].
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1.6.3. T-lymphocytes and regulatory T-cells in Atherosclerosis
Activated T lymphocytes are present at all stages of atherosclerosis. CD4+ T 
cells are the major class of T lymphocytes identified within atherosclerotic lesions, 
and a small proportion of CD8+ T lymphocytes [97].
CD4+ cells isolated from human plaques express the ap T cell receptor (ap 
TCR), which recognises antigens, such as oxLDL components, heat shock proteins 
and microbial antigens, presented in the context of HLA-DR on the surface of antigen 
presenting cells (APCs) [62]. These lymphocytes are involved in recognition of the 
antigen and in antigen-specific proliferation in the shoulder regions of atherosclerotic 
lesions [49]. CD4+ cells get attracted to the tissue by chemokines and adhesion 
molecules which are expressed on the endothelial cell surface. Their involvement in 
affinity maturation and isotype class switching of B cell clones specific to atherogenic 
antigens is also demonstrated due to the presence of IgG antibodies specific to oxLDL 
epitopes in the serum, in addition to the already present IgM natural auto-antibodies, 
which are believed to be predominant in atherosclerosis [19, 152].
The dynamic synthesis and secretion of cytokines within human 
atherosclerotic lesions suggests a local regulation of Thl versus Th2 subtypes [97] 
(Figure 1.5). An unbalance between pro- and anti-inflammatory immune responses 
appears to be responsible for the development of atherosclerosis. Naïve CD4+ T cells 
generate one of the two major types of functionally different effector T cells, the T- 
helper 1 (Thl) or the Th2.
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An anti-inflammatory, Th2 immune response is triggered by epitope-specific 
stimulation or by the induction of natural antibodies involved in the clearance of 
lipoprotein particles [153]. A correlation between the concentrations of auto­
antibodies against oxLDL in plasma and lesion size is present [154], in contrast to the 
correlation of plaque size with the number of Thl cells present within the lesions
[155]. While Thl is the predominant T cell subset found in atherosclerotic lesions, 
Th2 responses are also recognised in advanced stages of atherosclerosis, indicating 
that in late stages the immune system is trying to overcome the pro-inflammatory 
damage by a shift towards a Th2 type immune response [46]. By expressing IL-10, 
the anti-inflammatory cytokine which suppresses the effect of pro-inflammatory 
cytokines IL-12 and IFN-y, switching to a Th2 immune response can be achieved
[156].
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Figure 1.5. T lymphocyte regulatory mechanisms. Naïve CD4+ T-lymphocytes differentiate 
into the Th1, Th2 or Th17 lineage, depending on local cytokines. Th1 is related to intracellular 
pathogens, acts via a cell-mediated response and results in more inflammation. On the other 
hand, Th2 is related to parasitic infections, acts via an antibody-mediated response and 
results in less inflammation.
A possible role of T h l7 cells in cardiovascular disease has been recently 
reported [157]. Thl7 cells are characterised by the expression of IL-17, IL-6, IL-22
and TNF-a. They have been proposed to play a key role in inflammation and
autoimmunity, with a recent study suggesting that Thl7/Treg balance may play a key 
role in controlling inflammation, plaque destabilisation and the onset of acute 
coronary syndrome [157]. This hypothesis is investigated by assessing Thl7/Treg 
functions through the analysis of T cell frequencies, the secretion of specific
cytokines and the production of key transcription factors in acute myocardial
infarction, unstable and stable angina patients. T h l7 cell numbers as well as cytokines
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IL-17, IL-6 and IL-23 and transcription factor levels were found to be significantly 
higher in patients with acute coronary syndrome when compared to controls. A 
significant decrease in the number of regulatory T cells, regulatory T cell-related 
cytokines (IL-10 and TGF-P) and FoxP3 levels were also observed in these patients, 
suggesting a role for Thl7/Treg imbalance in plaque destabilisation [19, 157].
I.6.3.I. Regulatory T cells in Thl vs. Th2 balance in atherosclerosis
A balance between athero-protective and atherogenic immune responses 
(Thl vs. Th2 balance) may be controlled by a specific type of T lymphocytes, 
regulatory T cells, which may also modulate inflammation leading to atherosclerosis. 
Regulatory T cells, also known as suppressor cells, have immunoregulatory properties 
involved in control of autoimmune reactions in the periphery by inactivation of self­
reactive T-lymphocytes that have escaped negative selection in the thymus and that 
can recognise self-antigens inducing autoimmunity, a process known as ‘dominant 
tolerance’ [158].
Despite the extensive attention on regulatory T cells and their involvement in 
diseases, such as cancer, their potential role in atherosclerosis development has not 
been intensively studied. The first evidence of regulatory T cells participation in 
atherogenesis came from a study that showed T-cell clones with unique cytokine 
profile distinct from that of ThO, Thl or Th2 cells was generated after continuous 
stimulation of naïve T cells from ovalbumin-(0VA)-T-cell-receptor transgenic mice 
with OVA and IL-10. The cells were classified to be Trl, producing IL-10, IL-5 and
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IFN-y, with low or no levels of IL-2 or IL-4 and proliferating poorly after polyclonal 
T cell receptor-mediated activation. The development of atherosclerosis was 
significantly reduced when these Trl cells were transferred into low density 
lipoprotein receptor deficient (LDLr"A) mice [159]. Another study, recently described 
another group of lymphocytes with regulatory functions, bearing a CD4+CD25'CD31+ 
phenotype. This subset may play a role in thrombotic events in atherosclerosis, as 
atherosclerotic plaques from mice were shown to contain CD4+CD31" pro-atherogenic 
activity [160].
The significant anti-atherogenic effect of naturally occurring CD4+CD25+ 
regulatory T cells was recently demonstrated using LDLr'7' mice, with deficient 
expression of CD80, CD86 and CD28 co-stimulatory molecules, known to participate 
in the generation and functional activation of CD4+CD25+ regulatory T cells [161]. 
Irradiated LDLr'7' mice reconstituted with bone marrow derived from CD80'7'86'7' or 
CD28"7" mice showed more than double the size of atherosclerotic plaques than 
control animals. It was also shown that adoptively transferred CD4+CD25+ regulatory 
T cells significantly reduce the size of atherosclerotic plaques in ApoE"7"Rag2"7" 
deficient mice compared with animals that received CD4+CD25' regulatory T cells. A 
reduction in lymphocyte and macrophage intra-plaque infiltration and increased 
collagen content was also observed in animals that received CD4+CD25+ regulatory T 
cells [161].
Other studies have provided evidence for the role of naturally occurring 
CD4+CD25+ regulatory T cells populations in atherogenesis, although a deeper study 
and understanding is needed. Also, based on current treatments (i.e. vaccines), it will
39
be possible to investigate a possible atheroprotective mechanism and to formulate 
new and/or improved therapeutic strategies to combat cardiovascular disease. 
Evidently, the therapeutic correction of the balance between Thl and Th2 responses 
has been pivotal for the development of vaccines against the development of the 
vaccine [19].
1.7. Dendritic cells and the induction of regulatory T cells
Dendritic cells (DCs) were originally characterised by their strong 
immunostimulatory properties and expression of large amounts of MHC class II 
molecules and T cell co-stimulatory molecules of the B7 family on their surface 
[162]. Despite the capacity of DCs to induce immune responses, they have been also 
shown to participate in the induction of tolerance [102, 162]. This is believed to be 
carried out by different subsets of DCs, at different DC developmental stages. The 
ability of DCs to act in a tolerogenic fashion depends on the maturation status, with 
immature DCs being prone in inducing regulatory T cells and promoting tolerance, 
while mature DCs stimulate effector T cells, facilitating immunity [162]. Tolerance is 
achieved by DCs via the secretion of suppressive cytokines, such as IL-10 and the 
induction of regulatory T lymphocytes (Figure 1.6).
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Figure 1.6. Tolerance induction by DCs. DCs residing in peripheral tissues take up self­
antigens via apoptotic vesicles or cellular debris. In the absence of inflammation, steady-state 
DCs migrate towards lymphoid organs and induce CD4+CD25+ Tregs by direct contact or 
develop into IL-10-producing DCs that anergise T cells. These DC-induced Tregs are able to 
curb proliferation of effector T cells and contribute in the maintenance of peripheral tolerance 
[102].
In search for the origin of such tolerogenic DCs, Wakkach et a l [163] isolated
C D llc low, CD45hlgh DCs from the lymph nodes and spleen of mice secreting high
levels of IL-10 and inducing Trl regulatory T cells in vitro and in vivo. Compared to
other DCs, they expressed low CD11c, expressed CD45, which is normally expressed
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by T cells, as well as other non-classical DC markers such as B220 and CDS, and they 
had plasmacytoid morphology [102, 164]. In addition to these thymic DCs, Lu et al 
identified the B220+ DC subset which may also take part in peripheral tolerance. The 
B220+, CD 19', DEC-205+ subset of DC was isolated, which even after activation with 
IL-3 and CD40, it induces Trl cells [165]. This proves the notion that the anatomical 
site might have an impact on whether regulatory T cells or T effector cells are induced 
by the DCs. In the lung and in the gut DCs are constantly exposed to numerous 
innocuous antigens and thus regulatory T cells that control overboarding immune 
reactions have to be present. Lung and Peyer’s patch DCs produce large amounts of 
IL-10, which promote differentiation of Trl cells by either keeping incoming DCs in 
an immature status or by direct effects on Trl differentiation [102, 166-168].
1.7.1. Immature Dendritic cells as inducers of regulatory T cells
The ability of activated DCs to stimulate T cell proliferation and to induce T
effector functions is widely known and experimentally proven. Recent studies have
demonstrated that immature DCs, previously considered as inactive, are able to
induce tolerance. After repeated in vitro stimulation of peripheral CD4+ T cells with
immature DCs, regulatory properties were acquired [102, 169]. Jonuleit et al.
generated DCs from peripheral blood monocytes by incubation with GM-CSF and
IL-4. CD4+ T cells were repeatedly incubated with the in vitro generated immature
DCs and after three periods of co-incubation the T cells were co-cultured with freshly
isolated CD4+ T cells and stimulated with anti-CD3 and anti-CD28 antibodies.
Despite the fact that incubation of T cells with CD3/CD28 triggers T cell
proliferation, this was not observed in the presence of immature DCs, as the pre-
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cultivated T cells blocked the proliferation of effector T cells by cell-cell contact. Due 
to the anti-CD3/CD28 stimulation, pre-cultured T cells did not produce IL-2, but 
expressed the surface molecule CD25, fulfilling the criteria for regulatory T cells 
[102].
The maturation status of DCs determines whether immunity or tolerance is 
induced [170]. In the absence of pathogens and inflammation, peripheral DCs pick up 
self-peptides and cell detritus (i.e. apoptotic bodies) without being activated. These 
DCs remain immature and induce tolerance upon antigen presentation to T cells. 
Conversely, during inflammation, DCs become activated via their pattern recognition 
receptors and toll-like receptors (TLR), which are engaged by the pathogens. This 
leads to up-regulation of T cell stimulatory molecules, such as B7-1, B7-2, MHC-II 
and CD40, resulting in T cell activation [102, 171].
1.7.2. Factors affecting the ability of Dendritic cells to induce regulatory T cells
The term ‘immature’ DCs may not be completely accurate as studies have 
reported that lung-derived migratory DCs, which are hence partly activated, account 
for the induction of regulatory T cells, leading to the observation that tolerogenic DCs 
in the lymph nodes may be differentially activated or semi-mature [102, 166].
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1. TNFa
Experiments have demonstrated that DCs cultivated in the presence of TNFa act in a 
tolerogenic fashion, as they were able to halt the development of autoimmunity in a 
murine model of multiple sclerosis [172]. Suppression of the disease was mediated by 
IL-10-producing regulatory T cells. These DCs expressed regular amounts of MHC 
class II and T cell co-stimulatory molecules, but failed to secrete IL-ip, IL-6, TNFa 
and particularly IL-12, which is important for the full maturation of DCs. This can 
actually be due to IL-10 which has been shown to cause resistance to terminal 
maturation of DCs and induces T cell unresponsiveness in vitro [173]. This goes to 
show that the maturation state of DCs does not depend on the surface markers 
expressed, but instead the cytokine expression has to be taken into consideration 
[102].
2. IL-10
Due to the effects exerted upon IFNy production by Thl cells and suppressive effects 
on a wide range of different populations of lymphocytes, IL-10 was originally 
described as a cytokine-synthesis-inhibiting factor (CSIF). Exposure of human or 
murine DCs to IL-10 in vitro results in reduced surface expression of MHC class I 
and MHC class II molecules and reduced expression of T cell co-stimulatory 
molecules of the B7 family. The release of pro-inflammatory cytokines, such as IL- 
ip, IL-6, TNFa and most importantly IL-12 is eliminated after treatment with IL-10 
[174, 175]. In the case of mature DCs, a stable phenotype is displayed in the presence 
of IL-10 [176]. These reports implied the production of regulatory T cells after IL-10
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injection, due to CD25+ up-regulation and cell-cell contact which is required for their 
suppressive activity [102, 163].
3. Pharmacological interference
The concept of inducing regulatory T cells by affecting the maturation status of DCs 
has been tested by the use of several pharmaceuticals, such as vitamin D3 metabolite 
la, 25-(OH)2D3, N-acethyl-L-cysteine and other common immunosuppressive drugs, 
such as corticosteroids, cyclosporine A, rapamycin and aspirin [102, 177-180]. 
Exposure of DCs to N-acethyl-L-cysteine directly induces regulatory T cells in vitro, 
whereas injected DCs exposed to a mixture of vitamin D3 and mycophenolate mofetil 
were found to induce full tolerance in a murine allograft model [181]. Adoptive 
transfer of T cells from those tolerant mice into untreated mice also prevented the 
rejection of respective allografts, indicating the induction of regulatory T cells from 
vitamin D3 treated DCs in vivo [102]. In the case of rapamycin, its administration 
prevented the full maturation of DCs and down-regulated IL-12 secretion and their 
capacity to induce T cell proliferation in vitro. Adoptive transfer of the rapamycin- 
treated DCs resulted in an allo-antigen specific T cell hyporesponsiveness [102, 182].
1.7.3. Subsets of Dendritic cells that induce regulatory T cells
Presentation of self-antigens, by steady-state DCs, induces regulatory T cells 
and provides the maintenance of peripheral tolerance (Figure 8). Other than the
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maturity state of DCs, different subsets of DCs that are intrinsically programmed to 
induce regulatory T cells, regardless of the activation status, also exist [102].
1.7.3.1. CD8+ Dendritic Cells
CDS was one of the first molecules used to define the DC subsets with 
tolerogenic effects. A subset of CD8a+ DCs was identified in the thymus and the 
spleen of experimental mice, suggesting a lymphoid origin, as opposed to the 
conventional CDS' DCs that are thought to be derived from myeloid precursors. These 
lymphoid DCs were also identified in humans [102, 183, 184].
CD8a+ DCs were found to be less effective than other DCs in regards to 
inducing T cell proliferation and they were able to inhibit IL-2 production [185]. 
Studies also showed enhanced FasL expression by these cells, something that allows 
the killing of potentially autoreactive lymphocytes by apoptosis [102, 186]. Although 
not all CD8+ DCs are assigned to a tolerogenic phenotype, as some are able to 
stimulate T cell responses [187], CD8+ DCs residing in lymphoid tissues are believed 
to be responsible for the induction of self-tolerance to self-associated antigens [102].
1.7.3.2. Plasmacytoid DCs
Plasmacytoid DCs (pDCs) is a novel subset of DCs that has been recently 
characterised and is documented as the main source of IFN type I secretion, priming 
naïve T cells to produce IFN-y and IL-10 upon viral infection. They also have the 
ability to induce T cells anergy, as experiments have shown that freshly isolated pDCs
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induce antigen-specific anergy in CD4+ T cells [188]. It has also been reported that 
pDCs induce naïve human CD8+ T cells into IL-IO^IFN70 producing T cells able to 
suppress proliferation of conventional CD8+ T cells. Immaturity of pDCs is not 
required in order for them to induce regulatory T cells, as they have to be activated 
through CD40L ligation [102, 189].
1.7.4. Feedback mechanisms between regulatory T cells and dendritic cells
Under certain conditions, DCs may be inducers of regulatory T cells (Tregs), 
but at the same time, Tregs may also affect DC functions [190]. DCs cultured in the 
presence of Tregs remain in the immature state, are less effective in inducing T cell 
proliferation and produce significant amounts of IL-10 [191]. A study carried out by 
Min et al. [192] in a murine cardiac transplantation model showed increased numbers 
of splenic CD4+CD25+ regulatory T cells and immature DCs after treatment with 15- 
deoxyspergualin, a common anti-rejection drug [193]. These immature DCs purified 
from tolerant recipients induced CD4+CD25+ regulatory T cells after incubation with 
naïve T cells, whereas tolerogenic DCs were generated after these regulatory T cells, 
from tolerant recipients, where incubated with DC progenitors, indicating a lesser T 
cell stimulatory capacity and IL-10 production [102]. The results demonstrate the 
critical role of IL-10 in a 'self-maintaining feedback loop’, where IL-10 from 
regulatory T cells plays a role in maintaining immature DCs in a tolerogenic state, 
which in turn induces further regulatory T cells that contribute to the production of 
IL-10 [102, 194]. This positive feedback loop ensures prolonged immunosuppression
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and does not merely rely on cell-cell contact which is normally required by genuine 
regulatory T cells (Figure 1.7) [102].
Induction of IL-10 producing Treg by ‘non­
activated’ and/or subsets of DCs
Direct suppression 
of effector T cells
Immature DC reg
Inhibition of DC 
maturation by IL-10 IL-10 mediated suppression 
of effector T cells
Figure 1.7. Self-maintaining regulatory loop. DCs induce regulatory T cells by cell-cell 
contact or by IL-10 cytokine secretion, while at the same time, regulatory T cells produce IL- 
10 and TGF-p keeping DCs in an immature and tolerogenic state, which further promotes the 
induction of regulatory T cells [102].
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1.7.5. Dendritic cells in Atherosclerosis
Dendritic cells were firstly identified in atherosclerosis after studies described 
their presence within the intima of arteries of humans and laboratory animals [195]. 
These arterial DCs have a CDla+S-100+lag+CD31‘CD83'CD86' phenotype and are 
similar to Langerhans cells of the skin [56]. CD1 lc+CD68+ DCs have been located in 
the intima layers of the lesion-susceptible lesser curvature of the aortic arch [196]. 
While the function of vascular DCs in healthy and atherosclerosis-prone arteries is 
poorly understood, DCs have been seen to be in contact with T cells in the 
atherosclerotic plaques within the zones of neovascularisation and near the zones of 
vasa vasorum within the adventitia [56]. In the shoulder regions of the human 
unstable plaques CD83+ DCs have been found in close proximity to CD40L+ T cells, 
producing CCL19 and CCL21 chemokines which might accelerate the recruitment of 
naïve lymphocytes in atherosclerotic vessels [197]. DCs within vessels that are prone 
to atherosclerosis are IFNa+ plasmacytoid DCs and respond to pathogen derived 
motifs [198] which may lead to accelerated apoptosis of CD4+ T cells [56].
Blood monocytes entering different tissues differentiate into tissue-resident 
macrophages or DCs, which leave nonlymphoid tissue within few days migrating 
back to lymphoid organs through lymphatic vessels [56]. Due to accelerated migration 
into the aorta, reduced emigration out of the vessel wall, increased local proliferation 
and decreased apoptosis, significantly increases the number of DCs in arteries which 
are prone to atherosclerosis [56].
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DCs can present atherogenic antigens to transgenic T cells in the context of 
costimulatory molecules like CD40, OX40L, CD80 and CD86, inducing the 
differentiation and proliferation of T cells [56].
1.8. Immunomodulation of Atherosclerosis
Based on recent observations that activation of immune responses promotes 
atherosclerosis, while selective activation of certain immune functions may actually 
inhibit the process, it is thought to be possible that selective suppression of pro- 
atherogenic immune responses or selective activation of anti-atherogenic immune 
responses may provide new approaches in the prevention and treatment of 
atherosclerosis [46]. Atheroprotection has been demonstrated using oxLDL related 
antigens, through the activation of adaptive immune responses, as well as for heat 
shock protein 65/60 and (32 glycoprotein 1, with the induction of immune tolerance 
through the activation of mucosal immunity [199]. Specific immunoreactive antigenic 
epitopes in the apolipoprotein B-100 (ApoB-100) component of LDL has also 
demonstrated the potential use of specific ApoB-100-related antigens in a novel 
immunomodulating atheroprotective strategy [199].
1.8.1. oxLDL-associated antigens and immunomodulation of atherosclerosis
As described above, oxLDL is a neoantigen with a key role in atherosclerosis 
development, as degradation of apolipoprotein B-100 into numerous peptide
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fragments is targeted by the immune system [46, 154]. Autoantibodies against oxLDL 
are common in healthy as well as patients suffering with cardiovascular disease [46, 
200]. Studies have shown that animals immunised with oxLDL resulted in a 40-70% 
reduction in plaque development in mice and rabbits [46, 201, 202]. Hence, oxLDL is 
known to be a complex and poorly characterised particle with numerous epitopes 
potentially inducing atheroprotective and atherogenic immune responses. Two major 
subclasses of oxLDL have been identified: specific MDA-modified peptide sequences 
in apoB-100 and oxidised phospholipids containing a phosphorylcholine head group, 
present as an isolated lipid or covalently bound to an apoB-100 peptide sequence [46].
Studies in ApoE7' mice immunised with apoB-100 demonstrated a reduction 
of up to 70% in atherosclerosis, as well as a decrease in macrophage and increase in 
collagen content of the remaining plaques [46, 203]. A change from IgG2a to IgGl 
expression also suggested a shift towards a Th2 response [46]. Based on these 
findings, the existence of potential T-cell mediated regulatory mechanisms capable of 
controlling pro-inflammatory (pro-atherogenic) responses that can significantly 
reduce atherosclerotic lesions and also induce plaque stability is possible.
1.8.2. ApoE7' mice as a model for Atherosclerosis
Throughout the years, many animal species have been used in order to study 
the pathogenesis and the potential treatment of atherosclerosis; from relatively large 
animals, such as nonhuman primates [204-206], swine [207-209] and rabbits [210- 
212], to hamsters [213] and pigeons [214]. The ApoE-deficient mouse, created by 
homologous recombination in embryonic stem cells, is a small, genetically
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reproducible model of atherosclerosis [215]. ApoE is a 34 KDa protein which 
maintains plasma cholesterol homeostasis, as it mediates the binding of lipoproteins to 
the LDL receptor and to its related proteins. It is required for the clearance of 
chylomicron remnants, VLDL, intermediate density lipoproteins and a subclass of 
DDL from the plasma [216, 217]. The majority of ApoE is derived from the liver 
[218], where it is synthesised by hepatocytes [216], whereas some is also synthesised 
by macrophages in various other tissues [219]. In atherosclerosis, ApoE is abundant in 
regions where it is produced by macrophages [220, 221]. The uptake of lipoproteins 
mediated by ApoE promotes cholesterol efflux from cells of the arterial wall and 
hence prevents atherosclerosis [222].
ApoE" " mice are now widely used as a model for atherosclerosis as they 
develop severe hypercholesterolemia due to delayed clearance of large atherogenic 
particles from the circulation [215]. These mice, unlike other models, are a good 
model of plaque development [223] as they demonstrate the entire spectrum of lesions 
(from fatty streaks to fibrous plaques) observed during atherogenesis and is said to be 
the first mouse model to develop lesions similar to those developed in humans, both 
in appearance and distribution [215]. Studies have shown that they demonstrate foam 
cell accumulation in the aortic root and pulmonary arteries by 10 weeks of age, as 
well as monocytes attached to the endothelium in the thoracic aorta and in other 
arteries before the development of foam cell-rich fatty streaks at those sites [215]. 
Fatty streaks consist of lipid-laden and monocyte-derived macrophages with SMCs 
[215]. Foam cell lesions develop as early as 8 weeks and after 15 weeks advanced 
lesions and fibrous plaques are observed, consisting of a fibrous cap containing SMCs
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surrounded by connective tissue matrix that covered a necrotid core with 
macrophages [215].
ApoE'7' C57BL/6 strain mouse model is hence now extensively used for the study of 
the pathogenesis as well as the therapy of atherosclerosis, as it portrays the 
progressive series of atherogenic events in humans [215, 224, 225]. Atherosclerosis 
may be induced by the introduction of a high fat diet, which increases cholesterol 
levels and particularly LDL and VLDL cholesterol [226]. Due to the high fat diet, 
mice develop more advanced atherosclerotic lesions in a shorter period of time, which 
also contain more lipids than mice on a normal diet [215]. Therefore, it is observed 
that the high fat diet aggravates and accelerates atherosclerosis, something that is also 
seen in humans [215]. These many similarities of the mouse model with the human 
lesion formation suggest that this particular model may provide a fertile source for 
further investigations of atherosclerosis [215]. Further genetic recombinations, 
including models of diabetes, hypertension, and other factors that can be genetically 
studied in the mouse, offer an opportunity to examine the multiple interactions of 
factors associated with the pathogenesis of atherosclerosis [215].
1.9. Study outline
The study looks at immune responses against atherosclerosis-related antigens. 
The properties of ApoB-100-derived peptides, P2, P45 and P210, and their effect on T 
lymphocytes, as well as on the activation and expression of Toll-like receptors on 
DCs are examined. The effect of these peptides on the humoral and T cell mediated
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immune responses when administered alone or loaded on to DCs, in an environment 
which is prone to atherosclerosis, as well as their effect on the compartmentalisation 
of the immune response is also studied. Based on the observations and the properties 
of the ApoB-100-derived peptides to induce regulatory T cells, the effect of these 
cells on atherosclerosis and atherosclerotic plaque development is studied. This is 
assessed by depletion of CD4+CD25+ and CD8+CD25+ Treg cells by PC61. The levels 
of IFN-y, IL-4 and IL-10, as well as the lipid profile of ApoE'7' mice treated with 
PC61 are examined. The effect of such depletion on the formation of atherosclerotic 
plaques in the aortic sinus of the ApoE'7' mice was also observed in order to further 
assess the role of Treg cells in atherosclerosis.
Finally, patients with Coronary Heart Disease from Trinidad and Tobago were 
evaluated for their plasma levels of pro-atherogenic auto-antibodies to these peptides. 
Assuming that the ApoB-100-derived peptides are related to the severity of Coronary 
Heart Disease and/or diabetes disease state, ethnicity, age and/or gender, such 
understanding could further enhance the understanding of differences in CHD 
susceptibility between racial groups and help in future therapeutic development for 
treatment and prevention of atherosclerosis.
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CHAPTER 2.
GENERAL MATERIALS AND METHODS
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2.1. Materials
2.1.1. General Reagents
2.1.1..1 Chemicals
General laboratory chemicals and reagents were obtained from Sigma-Aldrich 
(U.K.) unless otherwise stated.
2.1.1.2. Health and safety
Use and handling of all reagents was carried out according to the safety 
regulations provided by the suppliers of each product, COSHH regulations and local 
college regulations. Biological waste was disposed according to University 
regulations.
2.1.1.3. Instruments and software
All centrifugations were performed using the Heraeus Megafuge LOR, from 
Thermo Fisher Scientific Inc, U.K., unless otherwise stated. Incubations at 37°C were 
carried out in a Heraeus Dry Incubator also from Thermo Fisher Scientific Inc, U.K. 
Flow Cytometry studies were performed using the BD FACSDiva™ flow cytometer 
(BD Biosciences, U.K.). A Bio-Tek ELxSOO plate reader from Bio-Tek Instruments, 
Inc., Ontario, Canada and supportive software (KC4 Programme, Bio-Tek Version 
3.4, Bio-Tek Instruments, Inc., Ontario, Canada) were used to analyse the absorbance 
in Enzyme-linked immunosorbent assays (ELISA).
2.1.2. C57BL/6 ApoE'7" mice
C57BL/6 mice are used in the study, as the particular strain is highly 
susceptible to diet-induced atherosclerosis. The C57BL/6 mice are classified as 
inbred, resulting from a crossing of no less than 20 consecutive generations of 
brother-sister siblings, allowing both genetic and phenotypic uniformity. ApoE*7' 
(B6.129P2-Apoe?m/to7J) mice were purchased from Charles Rivers (UK) and bred at 
the Faculty of Health and Medical Sciences’ Experimental Biology unit (EBU), of the 
University of Surrey and housed under standard conditions. ApoE'7" mice develop 
advanced atherosclerotic plaques with features characteristic to those seen in human 
[227].
The mouse has been an excellent model for experimental atherosclerosis since 
the early 1990s. Despite being used before then, the mouse model of diet-induced 
atherosclerosis demonstrated lesions that were too small and limited to early fatty 
streak stage [228]. In 1992, apolipoprotein E knockout mice, the first line of gene 
targeted animals, were developed. This model is the only one that develops extensive 
atherosclerotic lesion on a high fat diet and its lesions have been thoroughly 
characterised. The lesions develop into fibrous plaques, but there is still no evidence 
of plaque rupture in the model. This mouse model is preferred over the LDL receptor 
deficient model, as the later has elevated LDL levels, but very small lesions formed 
on the high fat diet [228, 229].
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2.1.3 Cell Culture
2.1.3.1 Mammalian cell culture reagents
All cell culture reagents were supplied from Gibco Life Technologies 
(Invitrogen, U.K.) unless otherwise stated. RPMI 1640 media were certified L- 
Glutamine free and the Advanced RPMI 1640 media were also L-glutamine free, with 
110 mg/L sodium pyruvate and non-essential amino acids (Invitrogen, GIBCO, U.K.). 
Plasticware were obtained from the University of Surrey chemistry stores. Disposable 
plasticware, such as syringes, needles and tubes were obtained from BD Plastipak 
(U.K.), Terumo Europe (Belgium) and Barloworld Scientific (U.K.), respectively. 
Tissue culture hoods (BioMAT, Class II Microbiological Safety Cabinet, Medical Air 
Technology Ltd, U.K.) were always treated with a solution of 70% (v/v) ethanol 
before use and regularly cleaned with Virkon disinfectant (Antek International, A- 
DuPont Company, U.K.) or fumigated with vaporised formaldehyde for several hours. 
All cells were cultured in a humidified incubator at 37°C in the presence of 5% CO2 
(Heraeus, HERA Cell 240, Thermo Electron Corporation, Thermo Fisher Scientific 
Inc, U.K.).
2.1.4 General Solutions
2.1.4.1 Composition of general buffers, solutions and reagents
A list of the general buffers, solutions and reagents, as well as their 
composition is given in Table I.
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Table I. General Buffers, Solutions and Reagents.
3,3’,5,5’ tetramethylbenzidine dihydrochloride 
Substrate
one TMB tablet in 10ml of 0.05M Phosphate- 
Citrate buffer; pH 5.0
10% neutral phosphate buffered formalin 100ml Formalin (40% formaldehyde solution) 
4.5g Sodium dihydrogen orthophosphate 
(NaH2P0 4 .2 H20 ), 6.5g Anhydrous disodium 
hydrogen orthophosphate (Na^HPG^) and up 
to 1 litre with distilled water
Complete advanced RPMI 1640 media 500ml 1x RPMI 1640, 25ml 5% PCS and 5ml 
Pen/Strep/Glut 100U/ml, 100pg/ml and 2mM, 
respectively
Coomassie® blue staining solution Methanol (50%, v/v), Acetic acid (10%, v/v), 
Coomassie® Blue R-250 (0.25%, w/v)
Cy-Quant® cell-lysis buffer Prepare 1x from 20x stock (Component B 
from CyQuant® kit) in nuclease-free dH20
Cy-Quanf GR dye 550 pi of a 400x concentrate in DMSO
Cy-Quant® GR solution Prepare 1x from 400x stock (Component A 
from CyQuant® kit) into the 1x Cy-Quant® 
cell-lysis buffer.
Destaining solution Methanol (10%, v/v), Acetic acid (5%, v/v)
EDTA 0.5M stock solution was made from 
ethylenediaminetetraacetic acid disodium 
dehydrate solid, adjusted to pH 7.5 at RT
ELISA Block buffer 1% BSA in PBS
ELISA Coating buffer 0.05M carbon-bicarbonate buffer
ELISA Diluent 0.05% Tween-20, 0.1% BSA in PBS
ELISA Substrate 1p-NPP tablet/4ml ultrapure water/1 ml of 
diethanolamine (Pierce, U.K.)
ELISA Wash buffer 0.05% Tween-20 in PBS
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FACS Labelling buffer 1% BSA/0.05% NaN3 in PBS
Fixative (cells) 1% Formaldehyde in PBS
Fixative (organs) 10% Formalin
Intracellular Permeabilisation buffer 5ml 10% Saponin in PBS
Intracellular Staining buffer 
(PBS/BSA/Azide buffer)
50ml 10xPBS, pH 7.4 with 450ml cell culture 
grade H20, 0.5ml 1M Azide and 2.5g BSA, 
allowing the BSA to dissolve at RT without 
stirring
PBS Na2HP04  (0.01 M), KCI (0.0027M) and NaCI 
(0.137M); pH 7.4
Phosphate-Citrate buffer (0.05M) One Phosphate-Citrate buffer tablet (Sigma) 
dissolved in 100ml of deionised water with 
stirring
RIPA buffer 1x PBS, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS
SDS-PAGE running buffer (10X) Glycine (0.5M), Tris (250mM), SDS (1% w/v)
SDS-PAGE sample buffer (10X) Glycerol (40%, w/v), SDS (4%, v/v), 
bromopherol blue (0.05%, w/v), stacking gel 
buffer (50%, v/v). Deionised water to a final 
volume of 19ml. The (3-mercaptoethanol was 
added just before use to 1 % (v/v).
SDS-PAGE separating gel buffer Tris (1.5M) SDS (0.4%, w/v); pH 8.8
SDS-PAGE stacking buffer Tris (0.5M) SDS (0.4%, w/v); pH 6.8
TBS-T 150mM NaCI, 10mM Tris; pH8.O and 0.05% 
Tween-20 (v/v)
Transfer buffer Glycine (195mM), Tris (25mM), methanol 
(20% v/v); pH 8.3
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2.2. General Methodology
2.2.1. Isolation of murine bone marrow
Male mice aged 6-8 weeks old were used to isolate bone marrow progenitor 
cells, using a modification of the classical protocol by Inaba et al [230]. Bone 
marrow was extracted from the femur and the tibia of the animals by flushing with 
10ml RPMI 1640 (Invitrogen, GLBCO, Cat. No. 11879-020) with a syringe and 25- 
gauge needle. After washing the cells twice with RPMI 1640 media by centrifugation 
(Heraeus Megafuge 1.0R, Thermo Fisher Scientific Inc, U.K.) at 200 x g for 5 
minutes, the contaminant erythrocytes were eliminated using a Mouse Erythrocyte 
Lysing kit (R&D Systems, UK, Cat. No. WL2000), where the cell pellet was 
disrupted by ‘racking’ the tube and re-suspending the cells in Ix M-lyse buffer (1ml 
of Ix M-lyse buffer/processed bone marrow of 1 animal). The cells were vortexed and 
incubated at room temperature for 10 minutes, until red cell lysis was complete 
(longer incubation periods would reduce cellular viability and decrease the total yield 
of mononuclear cells). At this stage, a darkening in colour of the fluid and clearing 
turbidity also occurred. The cells were washed twice with RPMI 1640 + 10% foetal 
calf serum (500ml RPMI 1640 + 50ml PCS) by centrifugation at 200 x g for 5 
minutes.
Progenitor cells were obtained by negative selection following a protocol in 
which 107 cells were prepared in sterile culture medium and the appropriate amount 
of rat anti-mouse antibodies against CD4, CD8 and CD 19 markers (AbD Serotec, UK, 
Cat. Nos. MCA1767, MCA1108G and MCA1439, respectively) was added to the 
cells (Ipg primary antibody per 107 target cells) and incubated for 20-30 minutes at
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4°C. Unbound primary antibodies were removed from the cells by centrifugation (at 
200 x g for 5 minutes) and resuspended in 1ml sterile medium and added to 9ml 
washed BioMag® Goat anti-Rat IgG 1 mg/ml particles (Qiagen, UK, Cat. No. 310107) 
to remove the sodium azide preservative (1ml BioMag per 107 cells, washed 2-3 times 
in RPMI 1640 + 10% PCS [500ml RPMI 1640 + 50ml PCS] using a magnetic 
separator, >20 megaoersted, to pull the magnetic particles to the side of the tube). The 
cells were then incubated at 4°C for 15-30 minutes, occasionally swirling the vessel. 
The vessel was then applied to a magnetic separator for 5-10 minutes and once 
separation was complete (a clear supernatant indicating that separation is complete), 
the supernatant was carefully removed without disturbing the pellet. The supernatant 
was applied again to the magnetic separator for an additional 5 minutes in order to 
remove any remaining BioMag particles and then it was centrifuged at 200 x g for 5 
minutes to pellet the cells and cells were re-suspended in l-2ml of fresh complete 
advance medium (500ml Ix RPMI 1640, 25ml 5% PCS and 5ml Pen/Strep/Glut 
lOOU/ml, 100pg/ml and 2mM, respectively), purchased from Invitrogen, GIBCO, 
Cat. No. 12633-012. The final cell concentration was adjusted to the IxlO6 cells/ml in 
complete advanced RPMI 1640 medium supplemented with 50gM 2-(3ME, 25mM 
HEPES, lOng/ml rmGM-CSF and 2ng/ml rmIL-4 and plated 1 ml/well in 24-well 
plates (NUNC, Thermo Fisher Scientific Inc., U.K.).
Bone marrow derived cells were cultured at a concentration of IxlO6 
cells/well in 24-well plates (NUNC) for 7 days, with advanced RPMI 1640 and 
supplements (Table II) for differentiation factors into immature dendritic cells (DCs). 
Cultures were supplied with fresh media every 2 days and on day 7 the cells were 
further purified (enriched) by density gradient, using Histopaque®-1077 (SIGMA-
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ALDRICH, Inc., St. Louis, MO, USA, Cat. No. 10771-500ML) at 1:2 ratio of 
Histopaque to cells, in order to remove contaminants and dead cells. The cells were 
detached from the plates using a 1ml syringe plunge and passed to a 50ml tube for 
washing by centrifugation at 200 x g for 5 minutes. The cells were then re-suspended 
to a final volume of 10.5ml with complete RPMI 1640 and slowly added to 4ml of 
Histopaque®-1077, previously warmed at room temperature (RT), then span at 200 x 
g for 30 minutes at RT. The inter-phase layer of mononuclear cells was collected and 
washed twice with PBS at 4°C by centrifugation at 200 x g for 5 minutes.
Table II. Recipe for Advanced RPMI and supplements. All purchased from Gibco- 
Invitrogen, UK.
1x RPMI 1640 Basic cell culture medium [231]. 500ml 1x
100% PCS A rich source of nutrients, which are needed for cells 
to grow and proliferate. Derived from the fetuses of 
cows found pregnant at slaughter. Blood without any 
cells, platelets or clotting factors [232].
25ml 5%
100x
Pen/Strep/Glut
Antibiotics added to help eliminate or control cell 
culture contamination [233].
5ml 100U/ml, 100pg/ml 
& 2mM respectively
1M HEPES A good buffering agent due to its nutritional benefits. 
Provides supplemental buffering to cell culture 
medium. No nutritional benefit to cells. Added solely 
for extra buffering capacity when cell culture requires 
extended periods of manipulation outside of the C02 
incubator [234].
25mM
50mM 2-0ME A hybrid of ethylene glycol used to reduce disulfide 
bonds. Acts as a biological anti-oxidant by 
scavenging hydroxyl radicals. The hydroxyl group 
confers solubility in water and lowers instability [235].
50pM
10pg/ml
mrGM-CSF
Bioactive protein involved in growth promoting 
activities, such as growth and development of 
granulocyte and macrophage progenitor cells, 
stimulation and the initiation of differentiation of 
myeloblasts and monoblasts, and chemotaxis of 
eosinophils [236].
10ng/ml
2pg/ml IL-4 Bioactive protein which promotes the proliferation 
and differentiation of activated B cells. Up-regulates 
MHC II antigen expression and IgE receptors [237].
2ng/ml
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The cell concentration was adjusted to 3-5xl05 cells/ml with cRPMI 1640 and 
supplements (50pM 2-pME, 25mM HEPES and cytokines 10ng/ml rmGM-CSF and 
2ng/ml rmIL-4) and plated 1 ml/well in 24-well plates (NUNC, Thermo Fisher 
Scientific Inc., UK). The cells were cultured for another 2 days in the incubator at 
37°C, 5% CO2 (Heraeus, HERA Cell 240, Thermo Electron Corporation, Thermo 
Fisher Scientific Inc, U.K.).
2.2.2. Isolation of T lymphocytes
ApoE'7' mice were euthanized with the use of CO2, their spleens were 
extracted and the tissue was dissociated using a homogeniser to generate a cell 
suspension in RPMI 1640 + 10% PCS. The cells were washed twice with RPMI 1640 
+ 10% FCS by centrifugation at 200 x g for 5 minutes and the Mouse Erythrocyte 
Lysing kit (R&D Systems, U.K., Cat. No. WL2000) was used to remove contaminant 
erythrocytes. The cells were disrupted by racking the tube, re-suspended in Ix M-lyse 
buffer and vortexed. 2ml of Ix M-lyse solution was used per processed spleen. The 
cells were incubated at RT for 10 minutes, until the red lysis was completed and then 
washed with RPMI 1640 + 10% FCS by centrifugation at 200 x g for 5 minutes. The 
supernatant was discarded and the cells were re-suspended at a concentration of 5x l07 
cells/ml with RPMI 1640 + 10% FCS. The cell suspension was then incubated in 
tissue culture flasks for 2 hours, at 37°C and 5% CO2 (Heraeus Dry Incubator, Thermo 
Fisher Scientific Inc, U.K.) to deplete samples from macrophages, monocytes and 
other tissue adhering cells. Non-adherent cells were collected in 50ml centrifuge tubes 
and centrifuged at 200 x g for 5 minutes, decanting the supernatant and resuspending
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the pellet in RPMI 1640 + 10% FCS. CD4+ or CD8+ lymphocytes were then isolated 
by negative selection using 1 mg/ml BioMag® Goat anti-Rat IgG (Qiagen, U.K., Cat. 
No. 310107), containing IxlO8 magnetic particles per milligram.
2.2.2.I. Cell viability analysis and quantification
Trypan blue, one of several stains recommended for use in dye exclusion 
procedures, was used for viable cell counting. The method is based on the principle 
that viable cells do not take up certain dyes, whereas non-viable cells do. Such 
staining facilitated the visualisation of cell morphology. The cells were prepared in 
1ml of RPMI 1640 medium. Trypan blue solution was prepared by mixing the trypan 
blue with PBS at a 1:1 ratio. A small number of cells (dilution factor =10) was added 
to the trypan blue solution and then transferred to both chambers of a haemocytometer 
for counting. The concentration of cells, total cells and cell viability per ml were 
calculated as,
Cells per ml = the average of counts per square x dilution factor x 104
Total cells = cells per ml x the original volume of cell suspension from which the cell
sample was removed
Cell viability (%) = total viable cells (unstained) / total cells (stained and unstained) 
x 100
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2.2.2.2. Purification of T lymphocytes
Cells were isolated by the BioMag® negative selection method (Figure 2.1). 
They were prepared in the sterile culture medium and incubated for 20-30 minutes at 
4°C with the appropriate amount of Rat anti-Mouse antibodies against CD4 or CDS, 
CD 11b and CD19 markers (AbD Serotec, U.K., Cat. Nos. MCA1767, MCA1108G, 
MCA711G and MCA1439, respectively), at a volume of Ipg per 107 target cells. 
Unbound primary antibody was removed from the cells by centrifugation at 200 x g 
for 5 minutes and cells were re-suspended in the appropriate amount of washed 
BioMag particles in sterile culture medium (RPMI 1640 + 10% FCS). Cells and 
BioMag particles were incubated together at 4°C for 15-30 minutes, with the vessel 
being occasionally swirled during incubation. The vessel was then applied to a 
magnetic separator for 5-10 minutes, until a clear supernatant was observed indicating 
that the separation was complete. Separation was performed with the vessel held 
vertically so that the pellet would form on the side of the tube ensuring that unselected 
cells do not contaminate the magnetic pellet. Once the separation was competed, the 
supernatant was carefully removed, without disturbing the pellet, and centrifuged at 
200 x g for 5 minutes to pellet the cells and re-suspended in complete RPMI 1640.
The final cell concentration was adjusted to IxlO6 cells/ml and plated 1ml per 
well in 24-well plates (NUNC, Thermo Fisher Scientific Inc., UK) at 37°C, 5% CO2 
for 3 days.
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Splenocytes and CD11b+, CD19+, Antibodies bind on the cells
CD4+ or CD8+ Abs in solution
Labelled cells are added in Particles + labelled cells attach
solution with charged particles on the magnetic separator
Figure 2.1. Isolation of T lymphocytes using the BioMag® negative selection method.
Splenocytes labelled with Rat anti-Mouse CD4+ or CD8+, CD11b+ and CD19+ bind to the 
BioMag particles which are IgG Goat anti-Rat coated. Finally, the particles and the cells bind 
to the magnetic separator, while all other cells are removed. Labelled cells stay in solution.
2.2.5. Flow Cytometry
Flow Cytometry is widely used for the characterisation and analysis of cell 
particles as they move in a fluid stream through a beam of light. The flow cytometer 
measures the properties of individual particles, which vary between 0.2 and 50 pm.
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2.2.5.I. Analysis of triple stained cell populations
In order to obtain the number of events for a triple stained population the 
following steps were taken (Figure 2.2):
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Figure 2.2. Analysis of triple stained populations. Displayed above is an unstained 
population analysed for CD4+CD25+FoxP3+. The same was done for CD4+CD25+CD127+. 
The T cell population was chosen and depending on the non-stained cells, the CD4+ 
population was gated. The gated CD4+ population was plotted against the other two 
fluorochrome channels (PE and Alexa Fluor 647) in order to display in four quadrants the 
combinations of staining.
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2.2.S.2. Permeabilisation and labelling of Regulatory T cells
Flow Cytometry was performed to study the effects of peptide treatment on 
the phenotype and activation of regulatory T cells. T lymphocytes were isolated from 
the spleens, washed with 1% Bovine Serum Albumin (BSA, Fluka, Sigma-Aldrich, 
Germany, Cat.No. 05477) and 0.05% sodium azide in PBS by centrifugation at 200 x 
g for 5 minutes and incubated with 2pl of Rat anti-Mouse antibody CD25-RPE (AbD 
Serotec, UK, Cat. No. MCA1260PE) and combinations of Rat anti-Mouse CD4-FITC 
(AbD Serotec, UK, Cat. No. MCA1107F) or CD8-FITC (AbD Serotec, UK, Cat. No. 
MCA609F) antibodies and Mouse anti-Mouse/Rat/Human FoxPS-Alexa 647 
(BioLegend, San Diego, Cat. No. 320011) or Rat anti-Mouse CD127-Alexa 647 
antibodies (AbD Serotec, U.K., Cat. No. MCA2306A647T). T lymphocytes were 
triple labelled as followed: CD4+CD25+FoxP3+, CD4+CD25+CD127+,
CD8+CD25+FoxP3+ and CD8+CD25+CD127+.
Labelling of T lymphocytes with markers CD4, CDS, CD25 and CD 127 was 
done by incubation of the T lymphocytes with the antibodies for 30 minutes on ice 
and then washed with 0.5% BSA in PBS by centrifugation at 200 x g for 5 minutes 
and fixed by re-suspension of the cell pellet with 1% Formaldehyde in PBS (obtained 
by diluting the appropriate amount of Formaldehyde solution, 36% [Sigma-Aldrich, 
USA, Cat. No. F1635-500ML] in PBS). Samples were stored at 4°C in the dark.
Cells had to be permeabilized in order to perform intracellular staining for 
FoxP3. After the cells were labelled for CD4 or CDS, CD25 and CD 127, the cells 
were fixed (1% Formaldehyde in PBS) and let to stand for 20 minutes at RT, washed
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twice with PBS/BSA/Azide buffer (50ml lOxPBS, pH 7.4 with 450ml cell culture 
grade H2O, 0.5ml 1M Azide and 2.5g BSA, allowing the BSA to dissolve at RT 
without stirring) by centrifugation at 200 x g for 5 minutes and incubated for 10 
minutes at RT with 500 ml permeabilization buffer (5ml 10% Saponin in PBS [5g 
Saponin (Riedel-de Haen, Sigma-Aldrich, Germany, Cat. No. 16109) and 50ml PBS, 
pH 7.4, at 37°C until Saponin dissolves completely, filter sterile] and 95ml 
PBS/BSA/Azide buffer). Cells were then pelleted and re-suspended for incubation 
with the permeabilization buffer and 2pl of Alexa Fluor 647 anti Mouse/Rat/Human 
FoxP3 antibody, for 30 minutes at RT. The cells were then washed with 
permeabilization buffer, by centrifugation at 200 x g for 5 minutes, then washed again 
with PBS/BSA/Azide buffer, by centrifugation at 200 x g for 5 minutes, and then re­
suspended in 1% Formaldehyde/PBS and stored at 4°C in the dark.
Unlabelled cells (-/-) and isotype combinations were used as negative controls. 
Isotype controls are antibodies with no specificity for the cells in question, but with 
all the non-specific characteristics of the antibodies used in the experiment. The 
isotype control used here were: Rat IgG2a-FITC + Rat IgG2b-RPE + Mouse IgGl- 
Alexa 647. Isotype control was prepared twice. One tube was prepared and stored at 
4°C in the dark following the standard extracellular staining protocol, where the other 
was prepared and stored at 4°C in the dark following the intracellular staining 
protocol. Flow Cytometry studies were performed using the BD FACSDiva™ flow 
cytometer (BD Biosciences, U.K.).
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2.2.6. IL-4, IL-10 and IFN-y Enzyme-Linked ImmunoSorbent Assay
Serum samples were tested by Enzyme-Linked Immunosorbent Assay 
(ELISA) for cytokine levels of IL-4 (PeproTech Inc., Cat. No. 900-K49), IL-10 
(PeproTech Inc., Cat. No. 900-K53) and IFN-y (PeproTech Inc., Cat. No. 900-K98).
For a quantitative measurement of the IL-4, IL-10 and IFN-y serum levels, a 
commercial kit in a sandwich ELISA format was used and the manufacturer’s 
(PeproTech Inc.) protocol was followed. The capture antibody (200pg of purified 
rabbit anti-mIL-10 + 2.5mg D-mannitol and lOOpg of antigen-affinity purified rabbit 
anti-IL-4, anti-IL-10 and anti-IFN-y (depending on the cytokine assay) + 2.5mg D- 
mannitol, reconstituted in 1ml sterile water for a concentration of 100jig/ml, 200pg/ml 
and 100jjg/ml for IL-4, IL-10 and IFN-y respectively) was diluted with PBS to a 
concentration of 2pg/ml for the IL-10 and Ipg/ml for the IL-4 and IFN-y ELISA 
development kits and lOOpl were immediately added to each ELISA microplate 
(Microplate Nunc Immuno MaxiSorp 96 well flat bottom, Fisher, Cat. No. DIS-971- 
030J). The plates were sealed and incubated overnight at RT. After aspirating the 
wells to remove liquid, the plates were washed 4 times using 300pl of wash buffer 
(0.05% Tween-20 in PBS) per well and 300pl of block buffer (1% BSA in PBS) were 
added to each well and the plates were incubated for 1 hour at RT. Samples were 
diluted at a ratio of 1:50 in diluent (0.05% Tween-20, 0.1% BSA in PBS), lOOpl of 
sample were added to each well in duplicate and incubated overnight at 4°C. 
Standards were also diluted in diluent from 3ng/ml to zero for IL-10 and 2ng/ml to 
zero for IL-4 and IFN-y respectively and lOOpl of standard per well were added in 
duplicate. After washing the plate 4 times with 300pl of wash buffer per well, lOOpl
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of detection antibody (50jig of biotinylated antigen-affinity purified rabbit anti-mlL- 
10 + 2.5mg D-mannitol and 50pg of biotinylated antigen-affinity purified rabbit anti- 
mEL-4, anti-IL-10 and anti-mIFN-y (depending on the cytokine assay) + 2.5mg D- 
mannitol, reconstituted in 0.5ml sterile water for a concentration of 100pg/ml for IL- 
4, IL-10 and IFN-y) diluted in diluent to a concentration of 0.5pg/ml were added per 
well and incubated at room temperature for 30 minutes. The plates were washed 4 
times with 300pl/well of wash buffer and lOOpl of 3,3’,5,5’-tetramethylbenzidine 
dihydrochloride Substrate solution (one TMB tablet in 10ml of 0.05M Phosphate- 
Citrate buffer [one Phospate-Citrate buffer tablet, Sigma, Cat. No. P 4809, dissolved 
in 100ml of deionised water with stirring], pH 5.0 and 2pl of fresh 30% hydrogen 
peroxide (Sigma, Cat. No. H 1009) were added per well and incubated at RT for 
colour development. The reaction was stopped by adding 50pl of 2M H2SO4 per 
200pl of reaction mixture and the colour development was monitored with an ELISA 
plate reader at a wavelength of 405nm.
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CHAPTER 3.
THE EFFECT OF APOB-IOO-DERIVED PEPTIDES ON THE 
PROLIFERATION AND FUNCTIONAL PROPERTIES OF
T CELLS IN VITRO.
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3.1. Introduction
3.1.1. ApoB-100-derived peptides
ApoB-100 is the major protein component in LDL and also the ligand that 
binds to the LDL receptor [238]. It has a vital role in the metabolism of LDL, with 
increased levels of LDL-ApoB in plasma being strongly associated with a high risk of 
coronary artery disease [239]. ApoB-100 is a very large, insoluble particle with a 
tendency to aggregate, hence making it very hard to study, despite its great clinical 
and biological importance [240]. The complete amino acid sequence of human ApoB- 
100 was first reported by Yang et al. in 1986, who deducted it by sequence analysis of 
complementary DNA [239]. Direct sequencing of ApoB-100 tryptic peptides also 
confirmed 2,366 of the 4,536 residues [239]. Trypsin-accessible and -inaccessible 
peptides of the protein on LDL are non-randomly distributed and are grouped in 5 
hypothetical domains [239]. Twenty potential N-glycosylation sites were identified, 
out of which 13 display glycosylated direct peptide sequencing and 4 unglycosylated 
[239]. The primary structure of ApoB-100 is made up of a large number of long (>70 
residues) internal repeats and even more shorter ones, something that suggests that the 
ApoB-100 sequence is mainly derived from internal duplication [239].
MDA-modified ApoB-100-derived peptides (Table I) were used by Jan 
Nilsson (Lund University, Mahno) and Prediman Shah (Atherosclerosis Research 
Centre, Cedars-Sinai Medical Center, Los Angeles) whilst searching which antigens 
and epitopes of LDL could be responsible for athero-protective immune responses. A 
library of 302 overlapping peptides, each being around 20 amino acids long, with a 5 
amino acid overlap, was constructed, scanning the full polypeptide sequence of
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ApoB-100 [241]. Using ELISA, the reactivity of both native and MDA-modified 
peptides was tested against serum from CVD patients and healthy individuals. Only 
102 peptides cross-reacted with the serum samples. Both native and MDA-modified 
peptide sequences were recognised by human IgG and IgM plasma-derived 
antibodies. The peptides that cross-reacted were then used to immunise ApoE'7' 
hyperlipidémie mice, and they showed that this reduced atherosclerosis by 60% with 
an increased collagen content of atherosclerotic plaques [241]. Immunisation with the 
peptides also resulted in increased titres of peptide-specific IgG antibodies suggesting 
T-cell-dependent antibody class switching [241].
Subsequently, a study was performed by Fredrikson et al. in order to examine 
if immunization with these MDA-modified human ApoB-100 peptides is associated 
with a shift in the Thl/Th2 balance [242]. ApoE"7' mice were immunized with 
peptides P45 (amino acids 688-707) or P74 (amino acids 1123-1142) or P240 (amino 
acids 3613-3632) at 6, 9 and 11 weeks of age [242]. Compared to controls, 
immunization with P45 and P74 reduced atherosclerosis in the aorta of 25-week-old 
mice by 48% and 31%, and macrophage content in atherosclerotic plaques by 33% 
and 39%, respectively [242]. The levels of Th2-specific IgGl against each peptide 
were increased more than 50-fold after the immunization, whereas the levels of 
specific IgM and Thl-associated IgG2a were slightly affected [242]. Immunization 
with P240, a non-homologous peptide which was used as a control, induced a 10-fold 
increase of specific IgGl [242]. In conclusion, they observed an association between 
the reduction of atherosclerosis and the production of significant levels of peptide- 
specific Th2 IgGl in response to immunization, in contrast to lower levels of peptide- 
specific IgM and Thl-associated IgG2a [242].
Table I. MDA-modified ApoB-100-derived human peptides. The peptides used in 
the project, provided by Prof. Jan Nilsson.
P2 ATRFK HLRKY TYNYE AESSS 16-35 95
P45 IEIGL EG KG F EPILE ALFGK 661-680 95
P210 KTTKQ SFDLS VKAQY KKNKH 3136-3155 90
The change from IgG2a to IgGl expression suggested a shift towards Th2 
immune responses [46]. Based on these findings, it is possible to hypothesise that 
potential T-cell mediated regulatory mechanisms capable of controlling pro- 
inflammatory (pro-atherogenic) responses exist and could significantly reduce 
atherosclerotic lesions and induce plaque stability.
3.1.3. Toll-like Receptors and Treg cells
Inflammatory reactions against bacteria and pathogen are controlled by 
regulatory T cells, which are activated by host-derived pro-inflammatory molecules or 
by bacterial products directly [243]. Studies have shown that in the absence of Treg 
cells alymphoid animals which were reconstituted with CD4+ T cells from normal 
mice develop severe inflammatory bowel disease when colonized by enteric bacteria 
[244], or pneumonia if infected by Pneumocystis carinii [245], whereas co-transfers 
of Treg cells protect them from disease [244, 245]. These also suggest the involvement
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of Treg cells at early stages on infection and inflammation [243]. The expression of 
chemokine receptors drives Treg cells at the inflammatory sites, where they get 
activated. While the actual mechanism of activation is still unclear (i.e. triggered by 
components of host inflammatory response or by direct recognition of microbial 
products), the engagement of germline-encoded receptors is a possibility [243].
Between innate and adaptive immunity, the two immune responses in 
vertebrates, innate immunity is characterized as the first line of defense, as it 
discriminates between pathogens and self via Toll-like receptors (TLRs) and destroy 
them, by engulfing and digesting them [246]. In the innate immune system, cells are 
activated by pathogens via the toll-like receptors family [247, 248]. Phagocytes, such 
as neutrophils, macrophages and dendritic cells, are the main players in innate 
immunity [249]. They differentiate between pathogens and self by utilising signals 
from Toll-like receptors (TLRs) [250]. Toll-like receptors recognise pathogen- 
associated molecular patterns (PAMPs) which are shared by large groups of 
microorganisms and play an essential role in the identification of microbial 
components [251]. TLRs recognise endogenous ligands induced during the 
inflammatory response [251] and upon stimulation they immediately trigger a 
defensive response, such as the production of an array of antimicrobial peptides and 
cytokines [249], inducing immunity [246]. Antigen presenting cells (APCs), such as 
DCs, process the pathogens and present them on the cell surface together with major 
histocompatibility antigens, they travel from the infected tissue to the lymph nodes 
and present the antigens to naïve T cells. In order for those naïve T cells to be 
activated, DCs are also activated by stimulation of TLRs which are expressed on their
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surface. Hence, TRLs seem to play important roles in inducing adaptive immunity as 
well as innate immunity [252].
It has been recently demonstrated that regulatory T cells can sense pathogens 
directly through TLRs [253]. There are ten members in the TLR family, comprising a 
subfamily of interleukin receptors [246]. They are type 1 transmembrane receptors 
that possess an extracellular leucine-rich repeat domain and cytoplasmic domain 
homologous with that of IL-1 receptor (IL-1R) family, which upon stimulation 
recruits the IL-lR-associated kinase (IRAK) via the MyD88 adapter, leading to the 
activation of nuclear factor-kB [246].
TLR expression is mainly restricted to endothelial cells and macrophages 
indicating that these cells are the primary responders to microbial challenge in the 
plaque [254]. Studies based on semi-quantitative polymerase chain reaction and 
immunohistochemical analysis have demonstrated that the expression of TLR1, TLR2 
and TLR4 is enhanced in human atherosclerotic plaques [254]. In the case of TLR2, it 
has been proven that TLR2 ligation stimulates the differentiation of macrophages into 
antigen-presenting cells [255]. These findings may provide a link between local innate 
and adaptive immunity and enhance the cellular immune response in the plaque to 
local antigens [254]. Hence, the detection of microbial infection and the initiation of 
the innate immune response are mediated via germline-encoded, pattem-recognition 
receptors, including TLRs, which recognise highly conserved pathogen-associated 
molecular patterns [256-259]. Ligation of TLR2 and TLR4, amongst others, results in 
the recruitment of the adaptor protein myeloid differentiation factor 88 (MyD88) 
followed by the subsequent activation of nuclear factor-kB (NF-kB) and the mitogen-
activated protein kinases (MAPKs) [260]. As a result, a cascade of cytokines, 
chemokines and other pro-inflammatory molecules are produced, which contribute to 
the inflammatory response [256-259].
3.I.3.I. Role of Toll-like receptors in modulating Thl, Th2 and Treg cells
Several studies have established the importance of TLRs in inducing Thl 
responses. For example, the TLR4 ligand LPS [261] and TLR7 ligands induce IL- 
12p70 and IFN-a from DCs and stimulate Thl responses [262-266]. There is 
increasing evidence that certain TLR ligands may mediate Th2 responses. While 
E.coli LPS (a TLR4 ligand) induces a Thl response, highly purified LPS preparations 
from P.gingivalis LPS, a putative TLR2 ligand [267], favors a Th2 response [268]. 
Although E. coli LPS induces strong Thl responses, Pam-3-cys and schistosome egg 
antigens (SEA) favour a Th2 bias [264]. Similarly, in the mouse system, Pam-3-cys 
induces very little IL-12p70 in splenic CD8a+ DCs compared to E. Coli LPS, with the 
induction of IL-10 being largely abrogated in DCs from MyD88'A mice [265]. 
Consistent with their differential cytokine induction in DCs, Pam-3-cys and E. coli 
LPS induced Th2- and Thl-biased responses, respectively [264, 265]. These results 
suggest that signalling via TLR2 may result in Th2 or T regulatory responses [269- 
271].
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3.I.3.2. TLR2 in atherosclerosis
Whilst Treg cells play a central role in the suppression of immune reactions and 
prevention of autoimmune responses, TLRs have pathogen recognition receptors 
expressed by innate immune cells, which are crucial for the generation of effective 
immunity [272]. In addition, TLRs have been recently associated with atherosclerosis, 
with Edfeldt et al demonstrating elevated levels of TLR2 and TLR4 in human 
atherosclerotic lesions [273].
Scientists have shown that CD4+CD25+ Treg are significantly reduced in 
TLR2"/" mice compared to WT control mice, hence indicating a link between Treg cells 
and TLR2 [272]. Additionally, TLR2 triggers the expansion of Treg proliferation in 
vitro and in vivo, resulting in a temporal loss of the suppressive Treg phenotype in 
vitro by directly affecting Treg cells [272]. WT Treg cells adoptively transferred into 
TLR27' mice were neutralised by systemic administration of TLR2 ligand, 
demonstrating that in vivo TLR2 also controls the function of Treg cells and 
establishes a direct link between TLRs and the control of immune responses through 
Treg cells [272]. Liu et al reported that TLR2 is functionally expressed on human and 
mouse CD4+ and also CD8+ T cells [274] and also demonstrated that TLR2 signalling 
in T cells has distinct effects on effectors and Treg cells, representing a unique 
mechanism for regulating the host’s immune response against pathogens [275].
TRL2 mRNA and surface expression, as well as the ability of TLR2 ligands to 
activate endothelial cells are reduced under laminar flow conditions, but increased
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under ‘disturbed flow’, as would occur at atherosclerosis-prone arterial branches 
[276].
3.I.3.3. TLR4 in atherosclerosis
TLR4 is a key regulator of both innate and adaptive immune responses [277]. 
It recognises PAMPs and activates inflammatory cells [277]. TLR4 is the receptor for 
bacterial lipopolysaccharides (LPS) and also recognises cellular flbronectin and heat 
shock protein 60, endogenous peptides that are produced in response to tissue injury 
[278].
Unlike TLR2, TLR4 is not functionally expressed on T cells, based on the 
findings that T cells are generally not responsive to LPS [261, 279-281]. This also 
occurs in the presence of CD 14, which acts as a co-receptor [282]. Despite the fact 
that activated human CD4+ T cells express cell surface TLR4, they fail to respond to 
LPS [274]. Based on the finding of Higgins et a l, upon interplay between the LPS- 
binding protein, CD14 and the TLR4-MD2 complex [283], TLR4 signalling activates 
innate IL-10 production, both directly and by promoting the induction of IL-10- 
secreting type 1 Treg cells, inhibiting Thl responses and hence limiting inflammation 
[284].
TLR4, although not required for the full maturation of DCs [285], plays a 
crucial role in activation of DCs and macrophages by LPS [284]. It has been reported 
that LPS stimulates pro-inflammatory cytokine and chemokine production from DCs 
and macrophages and maturation of DCs through TLR4 [284]. Higgins et al.
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demonstrated that IL-10 is produced by cells of the innate immune system through 
TLR4 and as a consequence Treg cells are activated, something that can be observed as 
a protective strategy by the host in order to limit collateral damage mediated by 
pathogen-stimulated inflammatory responses [284]. Despite observations that IL-10 
secretion is involved by TLR4 activation [284], in atherosclerosis, it has been shown 
that TLR4 is pro-inflammatory and affects the initiation and progression of 
atherosclerosis [277]. TLR4 has been suggested as a link between 
infection/inflammation and atherosclerosis [286]. TLR4 recognises LPS, a part of the 
outer membrane of gram-negative bacteria [287], is activated by HSP60 [288], which 
is associated with atherosclerosis, and it recognises an alternatively spliced fragment 
of cellular flbronectin produced in response to tissue injury [289]. Therefore, TLR4 
serves as a receptor by which both bacterial particles and arterial injury can induce an 
inflammatory reaction [278].
Functional TLR4 is expressed in human adventitial fibroblasts and 
macrophages, with adventitial TLR4 activation augmenting neointima formation in 
mice [278]. Based on these results, Vink et al. provided evidence for a link between 
the immune receptor TLR4 and intimai lesion formation [278]. It was demonstrated 
that activation of TLR4 in adventitial fibroblasts induced activation of NF-kB and the 
production of cytokines, suggesting that this cell type has TLR4-dependent 
immunoregulatory functions [278]. At the same time, adventitial stimulation of TLR4 
augmented neointima formation, an effect which was reduced in TLR4-defective mice 
[278].
82
3.1.4. Preliminary observations that lead to the study of the immunomodulatory 
properties of ApoB-100 peptides on T cell-related responses
Peptide sequences in ApoB-100 (Table I, page 76), the protein component of 
LDL particles, have been identified as capable of inducing immune responses which 
inhibit atherosclerosis development [241, 242]. Both native and malondialdehyde 
(MDA)-modified peptide sequences are recognised by human IgG and IgM plasma- 
derived antibodies [241]. Preliminary data show that ApoB-100-derived peptides, 
especially P45 and P210, significantly inhibit the expression of important co­
stimulatory markers such as CD86 and CD40 in peptide-loaded DCs with no effect on 
the expression of MHC class II molecules as compared with control cells. An increase 
in secretion of IL-2, but no changes in IL-10 were also observed. Interestingly, P45- 
loaded DCs down-regulated IL-2 secretion and also the proliferation of naïve CD4+ T 
lymphocytes in co-culture experiments, but without significantly altering the 
expression of CD25 on these cells. None of the peptides had significant effects in the 
morphology of DCs as compared with the dramatic changes observed when the cells 
were treated with ox-LDL or LPS used as controls. The effect of the ApoB-100- 
derived peptides on the pattern of DCs membrane metalloproteinase (MMP) synthesis 
was also examined by RT-PCR. Results showed that all peptides significantly induce 
DCs secretion athero-protective MMP-9 [290], but not MMP-2, as compared with 
non-treated cells.
83
P r o f i le  d i s p l a y e d  b y  D C s  l o a d e d  w ith
A p o B - 1  O O -d e r iv e d  p e p t i d e s
• } CD40 and CD86
• —► MHC-II Key
• Î IL-12 With respect to controls:
• —- IL-1 0 — ► No change 4 Decreased 
Î Increased• | IL-2
• | CD4+ T cell proliferation
• —-CD25
• —►Morphology
• Î MMP-9
• —► MMP-2
Figure 3.1. Profile displayed by DCs loaded with ApoB-100-derived peptides.
These preliminary results, as observed by Dr. Oviedo-Orta’s group at the 
University of Surrey, U.K., show that ApoB-100-derived peptides help immature DCs 
(iDCs) to retain some of their characteristic tolerogenic features which in turn may 
induce the differentiation of naïve CD4+ T lymphocytes into Treg cells (Figure 3.1).
We have shown that these tolerogenic peptide-induced DCs can migrate into 
lymphoid organs where they can potentially elicit the differentiation of Treg cells. 
Also, by directly migrating into the vascular wall these DCs could also directly 
modulate atherosclerotic plaque development by playing down in situ T cell-mediated 
pro-inflammatory reactions.
These hypotheses are supported by recent evidence suggesting that:
a) Regulatory T cell proliferation, mobilisation, peripheral maintenance and 
suppressive functions are dependent on Ag specificity [291-295] in addition to non­
specific/naturally occurring regulatory T cell-mediated mechanisms.
b) Organ-specific regulatory T cells acquire a more specific suppressive activity 
through activation by DCs expressing organ-derived antigens [293].
In this chapter we hypothesise that (a) the ApoB-100-derived peptides, P2, 
P45 and P210, have the ability to inhibit T lymphocyte proliferation in cultures 
stimulated with oxLDL or Staphylococcal Enterotoxin B (SEB), (b) peptide-specific 
Treg cells can inhibit the proliferation of T lymphocytes in cultures stimulated with 
oxLDL, (c) FoxP3 is transiently expressed in CD4+ Treg cells and (d) ApoB-100- 
derived peptides affect the activation and expression of Toll-like receptors TLR2 and 
TLR4 on DCs.
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3.2. Experimental Procedures
3.2.1. Isolation of Splenocytes
Isolation of splenocytes was carried out as described in Chapter 2, Section 
2.2.2., using ApoE'7' mice.
3.2.2. Isolation and purification of T lymphocytes
As described in Chapter 2, Section 2.2.2, the cell suspension generated from 
spleens of ApoE'7' mice was lysed using a Mouse Erythrocyte Lysing kit (R&D 
Systems, U.K., Cat. No. WL2000) to remove contaminant erythrocytes and then 
incubated in tissue culture flasks for 2 hours, at 37°C and 5% CO2 (Heraeus Dry 
Incubator, Thermo Fisher Scientific Inc, U.K.) for further depletion of the sample 
from macrophages, monocytes and other tissue adhering cells. Non-adherent cells 
were collected and CD4+ or CD8+ lymphocytes were isolated by negative selection 
using 1 mg/ml BioMag® Goat anti-Rat IgG (Qiagen, U.K., Cat. No. 310107) as 
follows. Non-adherent cells were incubated with rat anti-Mouse antibodies against 
CD4 or CDS, CD lib  and CD19 markers (AbD Serotec, U.K., Cat. Nos. MCA1767, 
MCA1108G, MCA711G and MCA1439, respectively), at a concentration of Ipg per 
107 target cells. The cells were incubated with BioMag particles and then the tube was 
applied to a magnetic separator until a clear supernatant was observed. Once the 
separation was completed, the supernatant was carefully removed by pipetting, 
without disturbing the pellet. The final cell concentration was adjusted to IxlO6
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cells/ml and 1ml was plated per well in 24-well plates (NUNC, Thermo Fisher 
Scientific Inc., UK) and incubated at 37°C, 5% COz for 3 days.
3.2.3. Isolation of murine bone marrow progenitor cells
Bone marrow was extracted from the femur and the tibia of male ApoE'7' mice 
and cultured at a concentration of 1x106 cells/well in 24-well plates (NUNC) for 7 
days, with advanced RPMI 1640, 2-pME and HEPES, and supplements for 
differentiation factors (e.g., mrGM-CSF and IE-4) into immature dendritic cells 
(DCs), as described in Chapter 2, Section 2.2.1.
3.2.4. In vitro loading of dendritic cells
Bone marrow-derived DCs were incubated with each of the peptides, P2, P45 
and P210 at a concentration of 2.5pg/ml for 2 hours at 37°C. After incubation, the 
DCs were collected and washed by centrifugation at 200 x g for 5 minutes. The 
supernatant was discarded and the pellet was resuspended in sterile PBS. Cell 
concentrations were adjusted to 1x106 cells/ml (200ml) of peptide-loaded DCs before 
being adoptively transfered by intraperitoneal injection into ApoE"7" mice.
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3.2.5. Induction of Treg cells in vitro
Splenocytes were isolated, as described in Chapter 2, Section 2.2.2, from 
ApoE' " mice spleens. After lysis of the red blood cells the cells were re-suspended at 
a concentration of 5xl07 cells/ml with RPMI 1640 + 10% PCS in 24 well plates (1ml 
per well in triplicates) and treated every 24 hours with 2.5pg/ml of apoB-100-derived 
peptides P2, P45 or P210 and 10pg/ml oxLDL for 72 hours. Treatment with 10pg/ml 
of oxLDL for 72 hours was used as positive control for T cell proliferation, whereas 
naive untreated splenocytes were used as negative control. Cells were then labelled 
with CD4, CD25 and FoxP3 and analysed by flow cytometry, as described in Chapter 
2, Section 2.2.5.1.
3.2.6. Isolation of CD4+CD25+ Treg cells
Mouse CD4+CD25+ Treg cells were isolated in a two-step procedure using a 
commercial kit from Miltenyi Biotec, Germany (Miltenyi Biotec, Germany, Cat. No. 
130-091-041). Following the established protocol, CD4+ T cells were pre-enriched by 
depletion of unwanted cells and then CD25+ cells were positively selected from that 
enriched CD4+ T cell fraction.
A single-cell suspension was prepared in RPMI 1640 media containing 10% 
PCS by gently tearing apart the mouse spleen. The cells were washed with 30ml 
RPMI 1640 media containing 10% PCS by centrifugation at 200 x g for 5 minutes and 
then the cell pellet was resuspended in 40pl of working buffer (PBS, pH 7.2,
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supplemented with 0.5% BSA and 2mM EDTA) per 107 total cells. Biotin-Antibody 
cocktail, at lOpl per 107 total cells was added and the cells were incubated for 10 
minutes at 4°C. The cocktail contained biotin-conjugated monoclonal anti-mouse 
antibodies against CD8a, CD1 lb, CD45R, CD49b and Ter-119. Following 10 minutes 
incubation with the biotin-antibody cocktail, 30pi of working buffer, 20pl of anti- 
Biotin MicroBeads (MicroBeads conjugated to monoclonal anti-biotin antibody) and 
lOpl of CD25-PE antibody (monoclonal anti-mouse CD25 antibody conjugated to R- 
Phycoerythrin) were added per 107 total cells. The cells were mixed well and 
incubated for additional 15 minutes in the dark at 4°C and then washed by 
centrifugation with 1ml of working buffer per 107 total cells at 300 x g for 10 minutes. 
The supernatant was pipetted off completely, the cells were re-suspended in 500pl of 
working buffer and then applied onto an LD column placed in a magnetic field of a 
MidiMACS™ Separator (Miltenyi Biotec, Germany, Cat. No. 130-042-302) and 
prepared by rinsing with 2ml of working buffer. The unlabelled cells which passed 
through the column were collected and the column was washed twice with 1ml of 
working buffer. The total effluent collected was the unlabelled CD4+ T cell fraction.
The isolated CD4+ T cells were centrifuged at 300 x g for 10 minutes and the 
supernatant was completely pipetted off before the cell pellet was re-suspended in 
90pl of working buffer, per initial starting cell number of up to 107 leukocytes. lOpl 
of anti-PE MicroBeads (MicroBeads conjugated to monoclonal anti-PE antibodies) 
were added and after mixing well the cells were incubated for 15 minutes in the dark 
at 4°C. The cells were then washed with 1ml of working buffer by centrifugation (at 
300 x g for 10 minutes and re-suspended in 500pl of working buffer before being 
applied onto an MS column which was placed in the magnetic stand of a
MiniMACS™ Separator (Miltenyi Biotec, Germany, Cat. No. 130-042-102) and 
prepared by rinsing with 500pl of working buffer. The cells were let to pass through 
the column and the column was then washed three times with 500pl of working 
buffer. The column was then removed from the separator and 1ml of working buffer 
was pipetted onto the column. The fraction with the magnetically labelled cells 
(CD4+CD25+ cells) was immediately flushed out by firmly applying the plunger 
supplied into another column. Another column run was performed in order to achieve 
higher purity. The CD4+CD25+ labelled cells were then flushed out in a collection 
tube.
3.2.7. Inhibition of T cell Proliferation Assay
An Inhibition of Proliferation assay was performed in order to confirm the 
ability of peptide-induced Treg cells to inhibit the proliferation of T cells in vitro 
(Figure 3.2). Splenocytes from C57BL/6 mice were incubated with peptides P2, P45 
and P210 at a concentration of 2.5pg/ml, for 72 hours. Untreated splenocytes were 
used as negative controls. After 72 hours, the cells were collected and the 
CD4+CD25+ T cells were isolated using the commercial kit from Miltenyi Biotec, as 
described in Section 3.2.6. In the mean time, splenocytes from untreated C57BL/6 
mice were incubated with oxLDL for 72 hours, in order to induce the proliferation of 
T cells. The isolated CD4+CD25+ T cells from apoB-100 peptide-treated cultures were 
added to the oxLDL-induced proliferating splenocytes and T cell proliferation of the 
lymphocyte mixture was assessed after 72 hours both by flow cytometry as well as
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CyQuant® T cell proliferation assay (Invitrogen, Cat. No. C-7026). Figure 3.2 
illustrates the experimental set up for the analysis.
Culture 72 hrs
+/- Peptide
Splenocytes
(C57BL/6)
Treg isolation
Culture 72 hrs
+ oxLDL
Splenocytes
(C57BL/6)
Assess Proliferation
in lymphocyte reaction after 
72 hrs in culture
Figure 3.2. Inhibition of proliferation assay. Functional assay to confirm the ability of 
peptide-induced regulatory T cells to inhibit proliferation of oxLDL-induced T cells. Regulatory 
T cells induced by treatment of mice with peptides were isolated and their potential inhibitory 
effect on the proliferation of T cells induced by oxLDL was assessed using CyQuant® 
Proliferation Assay Kits (Invitrogen).
3.2.8. Transient induction of Treg cells in vitro
Splenocytes were isolated, as described in Chapter 2, Section 2.2.2, from 
spleens of ApoE" " mice. After lysis of red blood cells the cells were re-suspended at a
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concentration of 5xl07 cells/ml with RPMI 1640 + 10% PCS in 24 well plates (1ml 
per well in triplicates) and treated every 24 hours with 2.5pg/ml of apoB-100 peptides 
P2, P45 or P210, lOpg/ml oxLDL or 5pg/ml SEB (Sigma, Cat. No. S 4881) for a time 
course of 6, 12, 24, 48 or 72 hours. Cells induced to proliferate with oxLDL and SEB 
were used as positive controls. SEB is a single polypeptide chain protein containing 
239 amino acids with a protein content of approximately 25% [296] and it has been 
described as a super antigen due to its massive impact on the host’s immune system 
[297]. Super antigens combine with MHC class II molecules to form the ligands that 
stimulate T cells via the V/? element of the TCR [298]. They are highly potent 
immunostimulatory molecules, capable of activating virtually all cells that express the 
particular TCR variable regions [299]. Two groups of super antigens are described so 
far: the endogenous murine products, that include the minor lymphocyte stimulating 
(Mis) determinants, and the bacterial products, such as SEB [298]. Untreated 
splenocytes were used as negative controls. At each time point the supernatants were 
collected, washed by centrifugation at 200 x g for 5 minutes with RPMI 1640 media 
and then with PBS. The peletted cells were re-suspended in 1ml of FACS labelling 
buffer (1% BSA/0.05% NaNg in PBS) and the cell viability was determined by trypan 
blue staining. The concentration of cells was then adjusted to lx l07/ml and lOOpl of 
each sample was transferred into a 5ml polystyrene round-bottom tube, achieving a 
final concentration of lx l06/ml cells. Cell surface staining was performed using 
fluorescently labelled antibodies against CD4, CD25 and CD 127, as well as 
intracellular staining for FoxP3, as previously described in Chapter 2, Section 2.2.5.2. 
The cells were re-suspended in 300pl of fixation buffer and stored at 4°C in the dark 
until flow cytometry analysis.
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3.2.9. CyQuant® T Cell Proliferation Assay
The CyQuant® Cell Proliferation Assay kit was used to determine the number 
of cells that proliferate in culture. Using a single dye concentration, the assay has a 
detection range from 50 to at least 50,000 cells in 200pl volumes (Figure 3.3). A 
green fluorescent dye, CyQuant GR dye, is used, which exhibits strong fluorescence 
enhancement when bound to cellular nucleic acids. The maximum excitation of 
CyQuant GR is around 480 nm and the emission maximum is around 520 nm. Frozen 
cells (at -80°C) were thawed and lysed by the addition of a buffer (eell-lysis buffer) 
containing the CyQuant GR dye and the fluorescence was measured directly [300].
Ex = -485 nm
I
I
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Figure 3.3. Reference standard curve for the quantification of cells using CyQuant Cell 
Proliferation Assay Kit. Fluorescence measurement taken using a microplate reader. 
Fluorescence is directly proportional to the number of cells in solution.
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In order to obtain a reference standard curve, a concentrated cell suspension in 
medium was prepared at a concentration of IxlO6 cells/ml (Figure 3.4). 1ml of the cell 
suspension (at a concentration of IxlO6 cells/ml) was centrifuged for 5 minutes at 200 
x g and the supernatant was carefully removed without disturbing the pellet and then 
frozen at -70°C. Before analysis, the cell pellet was thawed at RT and 1ml of CyQuant 
GR dye/cell-lysis buffer was used to re-suspend the cells by vortexing. lOOpl of 
CyQuant GR dye was added to each well to create the standard curve and 90pl of 
CyQuant GR dye was added to each well for the samples. Standards were prepared by 
using a serial dilution, using the CyQuant GR dye/cell-lysis buffer to make dilutions 
corresponding to cell numbers ranging from 3100 -  200 000 in 200pl (Figure 3.4). A 
200pl sample with no cells was also included as a control. lOpl of sample were added 
to the appropriate wells followed by lOOpl of CyQuant GR solution, completing each 
sample well volume to 200pl The samples were incubated for 5 to 10 minutes in the 
dark at RT. The fluorescence of the samples was measured using a fluorescent 
microplate reader set up with appropriate excitation and emission filters.
[# cells] Vol. (pi) Cells Vol. (pi) CyQUANT GR sol.
20.00x104 200 0
10.00x104 100 100
5.00x104 100 100
2.50x104 100 100
1.2ÔX104 100 100
0.62x104 100 100
0.31x104 100 100
0.00x104 0 100
From pure
Discard 100pl
Figure 3.4. Serial dilutions for the generation of a standard curve. Serial dilutions in the 
microplate corresponding to cell numbers ranging from 3100-200 000 in 200pl volumes.
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3.2.10. Analysis of the expression of FoxP3 in activated T cells
CD4+ T cells which were activated using plates coated with anti-CD3 and anti- 
CD28 antibodies in the presence of 2.5pg/ml of apoB-100-derived peptides P2, P45 
or P210 were analysed in order to study the expression of FoxP3 in these cells. 
Splenocytes treated with oxLDL and SEB were used as positive controls, whereas 
resting CD4+ cells were used as a negative control. After the indicated times, cells 
were collected at different time intervals of treatment (6, 12, 24, 48 and 72 hrs) and 
the intracellular expression of FoxP3 was assessed by flow cytometry, as previously 
described in Chapter 2, Section 2.2.5.1.
3.2.11. Expression of Toll-like receptors by DCs after peptide stimulation in vitro
Cells obtained from the isolation of murine bone marrow as described in 
Chapter 2, Section 2.2.1 were incubated with each of the peptides, P2, P45 and P210 
at a concentration of 2.5pg/ml. Untreated DCs were used as negative controls. After 
48 hours of treatment, DCs were collected and fluorescently labelled using Hamster 
anti-Mouse CDllc-RPE (Serotec, Cat. No. MCA1369PE), Mouse anti-Mouse/Human 
TLR2-Alexa 647 (CD282) (BioLegend, Cat. No. 121809) and Mouse anti-Mouse 
TLR4-Alexa 488 (CD284) (eBiosciences, Cat. No. 53-9041-80). DCs were then 
analysed by flow cytometry, as previously described in Chapter 2, Section 2.2.5.1.
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3.3. Results
3.3.1. ApoB-100-derived peptides reduce the numbers of T cells
The tolerogenic effect of peptide-loaded DCs was assessed using a T cell 
proliferation assay in vitro. The use of this model allowed us to assess the effect of 
peptide-induced Treg cells on T cell immune responses triggered by athero-related 
stimuli such as ox-LDL.
P2, P45 and P210-induced Treg cells significantly reduced the numbers of T 
lymphocytes primed to proliferate with oxLDL or SEB for 48 hrs, compared to 
cultures of untreated DCs (**/? < 0.05) (Figure 3.5). As no irrelevane peptide was 
used, comparisons were made with untreated DCs only. In the absence of any 
stimulation only P2 and P45 were able to significantly decrease the numbers of naïve 
T cells (Figure 3.5A) (**p < 0.05 for both). The number of T cells driven by DCs 
which were incubated with oxLDL were reduced by P45 and P210 (Figure 3.5B) (**p 
< 0.05 for both), while the number of T cells induced after incubation with SEB were 
only reduced by P210 (Figure 3.5C) (**/? < 0.05).
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Figure 3.5. Assessment of the inhibitory effect of the apoB-100-derived peptides on T 
cell numbers in vitro. DCs were first incubated in the presence of ox-LDL or SEB for 48 
hours before naive CD4+ T lymphocytes, isolated from the spleen of ApoE'7' mice, were 
added. T lymphocytes were allowed to proliferate for 24 hours before 25pg/ml of peptides P2, 
P45 or P210 were added to the culture. Lymphocytes were collected after 48 hours and T cell 
numbers were assessed using CyQuant Cell Proliferation assay. Numbers of cells (x 103) are 
graphically represented as mean ± SD. DCs incubated with lymphocytes, ox-LDL or SEB 
alone were used as controls (**p < 0.05).
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3.3.2. Peptide-specific Treg cells reduce the numbers of T cells
After assessing the effect of the ApoB-100-derived peptides on the number of 
T cells, an inhibition of proliferation assay was then performed in order to confirm the 
ability of peptide-induced Treg cells to affect this number of T cells. Splenocytes were 
first treated with 2.5pg/ml of P2, P45 or P210 every 24 hours for a total of 72 hours. 
Peptide-induced Treg cells were then isolated, as described in Section 3.2.6 of this 
Chapter, and added to the ox-LDL induced proliferating splenocytes, as described in 
Section 3.2.7 of this Chapter. The T cell numbers of the lymphocyte mixture was 
assessed after 72 hours. Two sorts of analyses were performed for this experiment. 
Plots for representative examples of the gating and the quadrant analysis for flow 
cytometry are displayed in Figure 3.7. These results are also presented as cell 
percentages in Figure 3.6 (see overleaf).
The number of T cells observed in proliferating cultures incubated with IxlO6 
and 0.5xl06 P2 iTreg cells (**p < 0.005; *p < 0.05), IxlO6 and 0.25xl06 P45 iTreg cells 
(**p < 0.005 for both) and IxlO6 P210 iTreg cells (***p < 0.001) was significantly 
higher than the corresponding cultures incubated with naturally occurring Treg cells 
(Figure 3.6). On the other hand, in the case of O.SxlO6 P210 iTreg cells, the number of 
T cells observed was significantly lower than that in the corresponding culture of 
naturally occurring Treg cells (**p < 0.005) (Figure 3.6).
When comparing within the different groups, there was a higher number of T 
cells in cultures incubated with IxlO6 than when incubated with 0.25x106 P2 iTreg 
cells (*p < 0.05), IxlO6 than when incubated with 0.25xl06 or 0.125xl06 P45 iTreg
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cells (**p < 0.005 for both) and when incubated with IxlO6 than when incubated with 
0.5xl06 or 0.25xl06P210 iT^g cells (***p < 0.001; < 0.005) (Figure 3.6).
Figure 3.6. The effect of peptide-induced regulatory T cells on T cell numbers in vitro.
The inhibitory effect of peptide-induced regulatory T cells on a proliferating culture of 
splenocytes incubated with oxLDL was assessed using flow cytometry. The results are plotted 
here as percentages of CD4+CD25+FoxP3+ cells acquired by flow cytometry. (Here, nTreg cells 
refer to naturally occurring Treg cells, not induced after peptide treatment.)
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Figure 3.7. Flow cytometry plots for the analysis of the reduction in T cell numbers by 
peptide-induced Treg cells in vitro. Representative examples of gating and quadrant 
analysis for each of the treatments, including isotype and un-stained (-/-) controls. Cells were 
identified and displayed as percentages, as previously described in Chapter 2, Section 
2.2.5.1.
100
A CyQuant® proliferation assay was also performed and the results are shown 
in Figure 3.8. The number of T cells observed in proliferating cultures incubated with 
0.125x10* P2 1 ^  cells < 0.05), 0.25x10* P45 iTreg cells (**p < 0.005) and 
0.25x10* or 0.125x10* P210 iTreg cells (*p < 0.05; **/? < 0.005) was significantly 
lower than that of the corresponding culture incubated with nTreg cells (Figure 3.8).
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Figure 3.8. CyQuant® T cell proliferation assay for the reduction on T cell numbers by 
peptide-induced Treg cells in vitro. The inhibitory effect of peptide-induced Treg cells on a 
proliferating culture of splenocytes pre-treated with oxLDL was also assessed by CyQuant® T 
cell proliferation assay.
When comparing within the different groups, there was a higher number o f T 
cells in cultures incubated with 1x10* than when incubated with 0.25x10* or 
0.125x10* P45 iTreg cells (**/? < 0.05; *p < 0.05) and with 0.5x10* than when
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incubated with 0.25xl06 P45 iTreg cells (**/? < 0.005) (Figure 3.8). In the case of P210 
iTreg cells, there was a higher number of T cells in cultures incubated with IxlO6 than 
when incubated with O.SxlO6, 0.25xl06 or 0.125xl06 P210 iTreg cells (*p < 0.05; **p
< 0.05; *p < 0.05) (Figure 3.8).
Interestingly, 0.25x106 P45 iTreg cells induced significantly higher reduction in 
T cell numbers compared to cultures incubated with 0.25x106 P2 or P210 iTreg cells 
(**p < 0.005 for both) (Figure 3.8).
3.3.3. CD4+ Treg cells show a transient expression of FoxP3
CD4+ T cells were activated using coated plates with anti-CD3 and anti-CD28 
antibodies in the presence of 2.5pg/ml of the apoB-100-derived peptides P2 (Figure 
3.9), P45 (Figure 3.10) or P210 (Figure 3.11). Trend lines are also used to 
demonstrate the drift of FoxP3 expression at the different time points. The flow 
cytometry graphs are also displayed in Figure 3.12.
As displayed in Figure 3.9A, the expression of FoxP3 was significantly 
increased after treatment for 12 hours {*p < 0.05), but significantly lower after 24 
hours (*p < 0.05), compared to the 6 hours treatment with P2. The expression at 12 
hours was also significantly higher compared to the 24, 48 and 72 hours treatment (*/?
< 0.05 for all) (Figure 3.9A). The trend line for P2 demonstrates that FoxP3 is 
expressed more at 12 hours of treatment, followed by the 6 hours treatment, then by
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the 72 hours, then the 48 hours and finally the 24 hours treatment (12 hours > 6 hours 
> 72 hours > 48 hours > 24 hours) (Figure 3.9B).
After incubation with P210, the expression of FoxP3 was significantly higher 
after 72 hours of treatment compared to 24 and 48 hours (*p < 0.05 for both) (Figure 
3.11 A). The trend line of FoxP3 expression after P210 treatment was as follows: 72 
hours > 6 hours > 12 hours > 48 hours > 24 hours (Figure 3.1 IB).
Although there was no significant difference between on expression of FoxP3 
in any of the treatment hours with P45, a trend of transient expression is observed at 
the different time intervals (Figure 3.10A). The trend line observed of FoxP3 
expression after P45 treatment was as follows: 12 hours > 6 hours > 72 hours > 48 
hours > 24 hours (Figure 3.1 OB). These results demonstrate that FoxP3 follows a 
transient mode of expression.
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Figure 3.9. Expression of FoxP3 in resting and activated CD4+ T cells after P2 peptide 
treatment. CD4+ T cells were activated in plates coated with anti-CD3 and anti-CD28 
antibodies in the presence of 2.5pg/ml of the apoB-100-derived peptide P2. oxLDL was used 
as a positive control, whereas resting, naive CD4+ T cells were used as a negative control. 
After the indicated times, cells were collected and processed for analysis of FoxP3 
expression, using flow cytometry. Results are shown here as percentage of cells (A), and in a 
trend line (B) in order to show the drift of expression. n=3, with experiments done in triplicates 
(3 well for each treatment each time) and then cultures were pooled together for flow 
cytometry analysis, (*p < 0.05).
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Figure 3.10. Expression of FoxP3 in resting and activated CD4+ T cells after P45 
peptide treatment. CD4+ T cells were activated in plates coated with anti-CD3 and anti-CD28 
antibodies in the presence of 2.5pg/ml of the apoB-100-derived peptide P45. Results are 
shown here as percentage of cells (A), and in a trend line (B) in order to show the drift of 
expression. n=3, with experiments done in triplicates (3 well for each treatment each time) 
and then cultures were pooled together for flow cytometry analysis. No significant differences 
were observed here, but a trend of expression can be seen.
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Figure 3.11. Expression of FoxP3 in resting and activated CD4+ T cells after P210 
peptide treatment. CD4+ T cells were activated in plates coated with anti-CD3 and anti-CD28 
antibodies in the presence of 2.5pg/ml of the apoB-100-derived peptide P210. oxLDL was 
used as a positive control, whereas resting CD4+ T cells were used as a negative control. 
After the indicated times, cells were collected and processed for analysis of FoxP3 
expression, using flow cytometry. Results are shown here as percentage of cells (A), and in a 
trend line (B) in order to show the drift of expression. n=3, with experiments done in triplicates 
(3 well for each treatment each time) and then cultures were pooled together for flow 
cytometry analysis, (*p < 0.05).
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hours). Cells were selected as per Chapter 2, Section 2.2.5.1.
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3.3.4. Activation and expression of Toll-like receptors on DCs after peptide 
stimulation
Regulatory T cells can sense pathogens directly through TLRs [253], which 
have a significant role in the detection of pathogens and in driving an immune 
response against them [246]. Based on evidence indicating that TLRs, and particularly 
TLR4, are important players in the initiation and progression of atherosclerotic 
disease [301], it would be of great interest to see the effect of the apoB-100 derived 
peptides on the levels of TLR2 and TLR4.
DCs incubated with each of the peptides, P2, P45 or P210, at a concentration 
of 2.5jxg/mL, for 48 hours, were assessed for the expression of TLR2 and TLR4, by 
flow cytometry analysis (Figures 3.13 and 3.14).
As observed in Figure 3.13, P45 induced the higher percentage of TLR2+ DCs 
(28.6%), compared to the untreated control (4.7%). In the case of TLR4+ DCs (Figure 
3.14), the higher percentage of cells was induced after treatment with peptide P2 
(14.3%), always compared to the untreated control (12%). The experiment was only 
performed once, hence the results are displayed as percentages.
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Figure 3.13. Expression of TLR2 on DCs after peptide stimulation. Flow cytometry 
analysis of peptide treated DCs labelled for CD11c+, TLR2 shows a 6-fold increase in the 
expression of TLR2 after P45 peptide treatment, compared to the untreated DCs control.
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Figure 3.14. Expression of TLR4 on DCs after peptide stimulation. Flow cytometry 
analysis of peptide treated DCs labelled for CD11c\ TLR4 shows similar results for all 
peptide treatments compared to the untreated DCs control, with a small increase in 
expression after P2 treatment.
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3.4. Discussion
The immunosuppressive nature of the apoB-100-derived peptides was 
demonstrated by a proliferation model in vitro (Figure 3.5). ox-LDL and SEB induced 
the proliferation of T lymphocytes and in both cases treatment with apoB-100-derived 
peptides was capable to significantly reduce the numbers of T cells compared to the 
untreated controls. In the presence of oxLDL, P45 and P210 significantly reduced T 
cell numbers when compared to the no-peptide control (**/?< 0.05), whereas in the 
presence of SEB, P210 was shown to significantly reduce T cell numbers, also when 
compared to the un-treated control (**/?< 0.05).The fact that the peptides reduce the 
number of T cells of both ox-LDL and SEB proliferating cultures indicates that this 
capacity of the peptides is independent to their relation with ox-LDL.
Additionally, the ability of peptide-induced Treg cells to reduce the number of 
T cells in proliferating cultures was confirmed by a proliferation assay (Figure 3.6). 
The number of T cells observed in proliferating cultures incubated with IxlO6 and 
0.5x10* P2 ilreg cells (**p < 0.005; *p < 0.05), 1x10* and 0.25x10* P45 iTreg cells 
(**p < 0.005 for both) and 1x10* P210 iTreg cells (***p < 0.001) was significantly 
higher than the corresponding cultures incubated with nTreg cells (Figure 3.6). On the 
other hand, in the case of 0.5x106 P210 iTreg cells, the number of T cells observed was 
significantly lower than that in the corresponding culture of nTreg cells (**p < 0.005) 
(Figure 3.6). Amongst the different groups, there was a higher number of T cells in 
cultures incubated with IxlO6 than when incubated with 0.25x106 P2 iTreg cells (*p < 
0.05), IxlO6 than when incubated with 0.25x106 or 0.125xl06 P45 iTreg cells (**/>< 
0.005 for both) and when incubated with IxlO6 than when incubated with 0.5xl06 or
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0.25xl06 P210 iTreg cells (* * ^  < 0.001; **p < 0.005) (Figure 3.6). These results may 
indicate that these peptide-induced regulatory T cells are able to significantly reduce 
the number of T cells in oxLDL proliferating cultures.
From the CyQuant® proliferation assay performed it was also observed that 
the number of T cells observed in proliferating cultures incubated with 0.125xl06 P2 
iTreg cells (*p < 0.05), 0.25xl06 P45 iTreg cells (**p < 0.005) and 0.25xl06 or 
0.125xl06 P210 iTreg cells (*/? < 0.05; **j9 < 0.005) was significantly lower than that 
of the corresponding culture incubated with nTreg cells (Figure 3.8). Comparisons 
within the different groups also showed that there was a higher number of T cells in 
cultures incubated with IxlO6 than when incubated with 0.25xl06 or 0.125xl06 P45 
iTreg cells (**/?< 0.05; *p < 0.05) and with 0.5x106 than when incubated with 
0.25xl06 P45 iTreg cells (**/? < 0.005) (Figure 3.8). In the case of P210 iTreg cells, 
there was a higher number of T cells in cultures incubated with IxlO6 than when 
incubated with 0.5xl06, 0.25xl06 or 0.125xl06 P210 iTreg cells {*p < 0.05; **/7 < 
0.05; *p < 0.05) (Figure 3.8). Interestingly, 0.25xl06 P45 iTreg cells induced 
significantly higher inhibition of proliferation compared to cultures incubated with 
0.25xl06 P2 or P210 iTreg cells (**p < 0.005 for both) (Figure 3.8). These 
observations indicate that at an optimal concentration these peptide induced 
regulatory T cells are able to significantly reduce the numbers of T cells by oxLDL in 
culture.
Based on these findings, it can be concluded that these apoB-100-derived 
peptides, as well as the Treg cells induced after incubation with the peptides, have the 
ability to reduce the number of T cells in proliferation cultures. The peptides increase
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the number of Treg cells, however the mechanism is unknown. More importantly, 
these results may suggest that peptide-induced Treg cells reduce the number of T 
lymphocytes in an atherosclerosis-related environment. Further studies are needed in 
order to identify the optimal concentration of peptide-induced Treg cells needed to 
inhibit the proliferation of IxlO6 cell/ml T cells. Also, in order to further confirm the 
significance and the validity of those results, the functionality of the cells should be 
assessed, as apoptosis may be occurring in the cultures. In addition, it should be taken 
into consideration that the purity of the Treg cell was only 50%, something that may 
have affected the result, as under normal conditions, the purity should vary around 70- 
90%. Hence, in order to have a non-biased result, the same number of Treg cells 
(depending on experimental condition) should be added to the cultures before 
assessing the effect on T cell numbers.
Experimental studies have shown that the expression of FoxPS in T cell 
populations is transient, indicating that endogenous FoxPS expression in humans may 
not be sufficient in inducing regulatory T cell activity or to even identify this subset of 
T cells [302]. It is demonstrated here that FoxPS is transiently expressed by 
CD4+CD25+ Treg cells with the three ApoB-100-derived peptides P2, P45 and P210 
demonstrating different trends of FoxPS expression and reaching the maximum 
expression at different time points after stimulation by anti-CDS and anti-CD28 Abs.
When incubated with P2, the trend lines demonstrates that FoxPS is expressed 
more at 12 hours of treatment, followed by the 6 hours treatment, then by the 72 
hours, then the 48 hours and finally the 24 hours treatment (12 hours > 6 hours > 72 
hours > 48 hours > 24 hours) (Figure 3.9B). Significant differences were also
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observed, with the expression of FoxPS being significantly higher after 12 hours of 
treatment (*/? < 0.05), but significantly lower after 24 hours of treatment (*p < 0.05), 
compared to the 6 hours treatment (Figure 3.9A). The trend line observed of FoxPS 
expression after P45 treatment was as follows: 12 hours > 6 hours > 72 hours > 48 
hours > 24 hours (Figure 3.1 OB). No significant differences were observed for the P45 
treatment. After incubation with P210, the trend line of FoxPS expression was as 
follows: 72 hours > 6 hours > 12 hours > 48 hours > 24 hours (Figure 3.1 IB). The 
expression of FoxPS was significantly higher after 72 hours of treatment compared to 
24 and 48 hours (*p < 0.05 for both) (Figure 3.11 A).
Although not always significant, a trend of transient expression was observed 
at the different time intervals. These results come to add to recent findings about the 
transient expression of FoxPS and suggest that this trend starts from as early as 6 to 12 
hours after stimulation. This may also suggest that there is need of identification of 
other Treg markers as FoxPS alone may not be sufficient for the generation of genuine 
Treg cells [303, 304].
TLR’s are known to mediate cell activation by microbial products and can also 
be used to determine the nature of pathogens based on the cytokines and chemokines 
produced by DCs and also contribute to the polarisation of an immune response [270]. 
A TLR4 agonist promotes the production of IL-12 p70 and chemokine interferon-y 
inducible protein (IP)-10, both of which are associated with Thl responses. On the 
other hand, TLR2 does not induce IL-12 or chemokine interferon-y inducible protein 
(IP)-10, but releases IL-12 inhibitory p40 homodimer producing conditions which are 
favouring a Th2 development [270]. Here, DCs were incubated with each of the
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peptides and their effect on the expression of TLR2 and TLR4 was assessed (Figure 
3.13 and 3.14, respectively). Results demonstrate that P45 peptide treatment induces a 
6-fold increase in the expression of TLR2 on DCs, compared to the control of 
untreated DCs (Figure 3.13), whereas TLR4 expression remained at the same levels 
after peptide treatment (Figure 3.14). From these, it can be concluded that P45 peptide 
treatment favours a Th2 immune response.
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CHAPTER 4.
THE EFFECT OF IMMUNISATION WITH 
APOB-100-DERIVED PEPTIDES ON THE PROLIFERATION 
AND FUNCTIONAL STATUS OF REGULATORY T CELLS.
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4.1. Introduction
CD4+CD25+ Treg cells are regulatory components of the adaptive immune 
system that limit autoreactive T cell responses in various models of autoimmunity 
[305], including atherosclerosis. This type of natural, thymus derived [306] 
CD4+CD25+ Treg cell has as its function to limit the activation, trafficking and/or 
effector function of both CD4+ and CD8+ T cells [307]. Originally described as CD4+ 
T cells, Treg cells co-express CD25 and FoxP3 [308] and contribute to the protective 
processes that govern the susceptibility and the progression of various autoimmune 
diseases [305].
The transcription factor FoxP3 is characterized as essential for the 
establishment of a functional regulatory T cell lineage [308-310]. FoxP3+ Treg cells 
derived in the thymus are known as ‘natural Treg cells’ (nTregs), whereas FoxP3+ Treg 
cells which are generated in the periphery are known as ‘induced Treg cells’ (iTregs) 
[138].
In the thymus, nTregs are generated through MHC class II-dependent T cell 
receptor (TCR) interactions, which result in high avidity selection [311, 312]. 
Different conditions may cause FoxP3+ TregS to be generated outside the thymus 
(Figure 4.1). In 2002, it was proposed that CD25" cells convert to CD25+ in the 
presence of IT-2 produced by effector T cells and in the process they gain Treg cell 
function [313]. Studies in the early 2000s, gave evidence on peripheral conversion of 
naïve CD4+ T cells into FoxP3+ T cells. This was done by the adoptive transfer of 
polyclonal CD4+CD25" naïve T cells into lymphopénie mice, causing part of the
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donor population to become CD25+CTLA-4+GITR+, acquiring the expression of 
FoxPS as well as the suppressive activity [314]. It is thought that CD25+FoxP3+ TregS 
originated from the CD25"FoxP3+ cells that were present in the original population 
[314]. In the case where the adoptive transfer was done in mice containing a 
monoclonal T cell repertoire devoid of nTreg cells, FoxP3+ Tregs were derived from 
FoxPS" cells [313].
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Figure 4.1. Generation of FoxP3+ regulatory T cells outside the thymus. The generation 
of FoxP3+ regulatory T cells is driven by a number of different factors outside the thymus.
Foreign antigens have also been demonstrated to induce iTreg cells. FoxP3+ 
iTregs were generated in mice treated with small antigen doses cross-linked to DEC- 
205 (CD205) antibody in the presence of co-stimulatory signals [111, 315]. Naïve 
CD4+ T cells were also converted into FoxP3’r Treg cells after treatment with CD4 
antibodies [143]. Mice administered with the antigen chicken ovalbumin (OVA) by
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the oral route, exhibit OVA-specific FoxP3+ Tregs in their lymph nodes [316]. It is 
clear that naïve CD4+FoxP3" in the thymus have full prospective in becoming FoxP3+ 
in vivo and in vitro [138].
4.1.1. Antigen-specific Treg cells
Despite the low number of Treg cells, they are a challenging and potent 
tolerogenic population which is a major challenge in the treatment of autoimmunity 
and transplant rejection [317]. Their anergic phenotype and diverse antigen specificity 
are some of the reasons that make them such an interesting cell type [317].
It is currently believed that TCR ligation enables Treg cells to non-specifically 
inhibit T cell proliferation both in vitro and in vivo [318]. However, other functional 
measures, such as cytokine production and cellular differentiation, also affect Treg 
cells [319]. Antigen-specific T cells possess a unique combination of cell surface 
markers and array of cytokines and are able to inhibit the function of T cells carrying 
the same T cell receptor specificity, preventing skin allograft rejection in an antigen- 
specific, dose dependent manner [320]. These Treg cells are able to acquire alloantigen 
from APCs, present the alloantigen to activated syngeneic T cells and then send death 
signals to T cells, hence demonstrating a novel mechanism of regulatory T cell- 
mediated antigen-specific suppression [320]. Antigen-specificity is a hallmark of 
adaptive T cell-mediated immune responses [321]. Although these Treg cells require 
antigen-specific activation, they are able to suppress bystander T cell responses once 
activated, implying that antigen-specific Treg cells may be used therapeutically by
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localizing generalized suppressive activity to tissues expressing select target antigens 
[321].
Adoptive transfer of antigen-specific Treg cells, by Klein et a l, demonstrated 
that the Treg cells maintain their phenotype in the absence of an antigen, are not 
anergic in vivo and they proliferate as extensively as naïve CD4+ T cells after 
immunisation without losing their suppressive function in vivo and in vitro [322]. 
Kohm et al demonstrated that a co-culture of MOG antigen-specific T cells with Treg 
cells inhibits the level of both Ag-specific proliferation and IFN-y production [319]. 
These findings suggest that Treg cells may block the initiation of autoimmune 
responses and inhibit the function of established autoreactive effector cells [319]. 
Another study, by Tang et al., demonstrated that antigen-specific Treg cells from 
autoimmune non-obese diabetic (NOD) mice effectively suppressed the development 
of diabetes in Treg-deficient CD28"/" mice and blocked syngeneic islet graft rejection is 
chronically diabetic animals [317]. This small population of antigen-specific Treg cells 
was capable of reversing diabetes after disease onset, suggesting a novel approach to 
cellular immunotherapy for autoimmunity [317]. Tang et al also suggested that the 
efficacy of Treg-based immune therapy, at least in autoimmune diabetes, is critically 
dependent on the antigen specificity of the Treg cells [317]. Therefore, it is important 
to develop a procedure of selectively expanding antigen-specific Treg cells from 
polyclonal populations for therapeutic use [317].
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4.1.2. ApoB-100 peptide immunisation in atherosclerosis
In order to identify the nature of the athero-protective antigenic epitopes 
identified by Nilson in LDL, Chyu et al. investigated the effect of immunisation with 
two of those epitopes on atherosclerosis in hypercholesterolemic ApoE"7" mice [323]. 
Peptide P2 with alum as an adjuvant reduced aortic atherosclerosis by 40% and 
plaque inflammation by 80% when compared to untreated controls [323]. A reduced 
progression of aortic lesions was also observed in mice immunised with P2, 
suggesting a possible peptide-based immunomodulating therapy for atherosclerosis 
[323].
ApoB-100 peptide autoantibodies, which are present in human plasma, are 
associated with a decreased cardiovascular risk [324]. A more recent study by 
Fredrikson et al in 2008 proved that immunisation with ApoB-100 peptide-based 
vaccines inhibit atherosclerosis in mice [324]. Such a protective effect was 
independent of pre-existing apoB-100 peptide autoantibody levels and occurred 
without an increase in peptide-specific antibodies suggesting that this protection 
against atherosclerosis is mediated by cellular immune responses [324].
4.1.3. Modulation of the immune response by dentritic cells
Dendritic cells capture and process antigens in the periphery and express 
lymphocyte co-stimulatory molecules, while migrating to lymphoid organs secreting 
cytokines and initiating immune responses [325]. Besides activating lymphocytes,
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DCs also tolerise T cells to self-antigens (antigens that are innate to the body) and 
hence minimize autoimmune reactions [325]. These APCs, which are the initiators 
and modulators of the immune response, were first visualized in 1868 as Langerhans 
cells (LCs) in the skin and the characterization of DCs began 25 years ago, when their 
distinct function as APCs became obvious, after they were identified and purified 
from contaminating lymphocytes and macrophages [326].
DCs efficiently stimulate T lymphocytes by processing antigens and 
presenting them to T lymphocytes, where antigens fragments bound to major 
histocompatibility complex (MHC) molecules get recognized by TCRs on the surface 
of an APC [327]. There are two types of peptide-binding proteins, MHC class I and 
MHC class II, stimulating cytotoxic T cells (CTLs) and helper T cells respectively 
[325]. Intracellular antigens are cut into peptides in the cytosol of the APCs, bind to 
MHC class I molecules and are then recognized by CTLs, which get activated and kill 
target cells. In the case of extracellular antigens, once they enter the endocytic 
pathway of the APC, they are processed and presented to T helper cells by MHC class 
II, which when turned on they have intense immune-regulatory effects [325].
T cell immunity is initiated once peptides from infected cells are recognized 
by T cells that circulate in the blood stream. There is typically a small amount of 
specific antigen-MHC complexes on tumors and infected cells (one hundred or less 
per cell) and should be recognized by rare T cell clones (usually at a frequency of 
1/100.000 or less) through a TCR with low affinity (IpM or less) [325]. Furthermore, 
infected cells and tumors frequently lack co-stimulatory molecules that drive the 
clonal expansion of the T cells, the production of cytokines and the development into
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killer cells. DCs provide a means of solving these, by capturing and processing 
antigens, and displaying large amounts of MHC-peptide complexes at their surface 
[325]. Hence they up-regulate co-stimulatory molecules and migrate to lymphoid 
organs, the spleen and lymph nodes, where they activate antigen-specific T cells 
[325]. These properties of DCs can be induced by infectious agents and inflammatory 
products[325]. DCs present antigens to T cells and express co-stimulators for the 
induction of immunity [325].
Additionally, DCs play a vital role in avoiding autoimmunity. Under normal 
circumstances, mature T cells would not respond to self-peptides, as only T cells with 
no or low affinity to those peptide antigens are allowed to leave the thymus and enter 
the circulation during maturation [325]. Some self-antigens however are not 
represented in the thymus. The same system that initiates immunity to foreign 
antigens also has the ability to tolerise the T cell repertoire to self-antigens, both in the 
thymus and the periphery [325]. DCs can capture and present self-antigens that are 
exclusive to specialized peptides. They present many self-antigens, derived from the 
normal turnover of somatic cells, to T cells and hence induce tolerance to self-proteins 
that have no access to the thymus [325].
DCs express high levels of MHC-self peptide complexes and this is maybe 
what makes T cells become anergic or cause them to die in response to abundant and 
persistent antigens [230]. All these support the notion that DCs are a powerful tool for 
manipulating the immune system [325].
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This Chapter hypothesises that (a) ApoB-100-derived peptides P2, P45 and 
P210 exert a differential effect on humoral and T cell mediated immune responses 
when administered alone or loaded on to DCs and (b) ApoB-100-derived peptides P2, 
P45 and P210 have an effect on the compartmentalisation of the immune response.
4.2. Experimental Procedures
4.2.1. Isolation of DCs
Bone marrow dendritic cells were isolated from the femur and the tibia of 
ApoE'7' mice and cultured at a concentration of IxlO6 cells/well in 24-well plates 
(NUNC) for 7 days, with advanced RPMI 1640 and supplements for differentiation 
factors into immature dendritic cells (DCs). Cultures were further purified by density 
gradient, using Histopaque®-1077 (SIGMA-ALDRICH, U.S.A.), as described in 
Chapter 2, Section 2.2.1.
4.2.2. Labelling of DCs for flow cytometry
Cells obtained from the isolation of murine bone marrow as described above 
were collected and fluorescently labelled using Rat anti-Mouse CD4-Alexa647 
(Serotec, Cat. No. MCA1767A647), Rat anti-Mouse CD8-PerCP (BD Pharmingen, 
Cat. No. 553036), Rat anti-Mouse CDllb-RPE (Serotec, Cat. No. MCA74PE) and 
Hamster anti-Mouse CDllc-FITC (Serotec, Cat. No. MCA1369F). Un-stained cells 
and a combination of isotype controls (1. Rat IgG2b-Alexa647 (Serotec, Cat. No. 
MCA1125A647) + Rat IgG2a-PerCP (BD Pahrmingen, Cat. No. 553933) + Rat
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IgG2b-PE (Serotec, Cat. No. MCA1125PE) + Hamster IgG-FITC (Serotec, Cat. No. 
MCA2356F), 2. Rat IgG2b-Alexa647 + CD8-PerCP + CDllb-PE + CDllc-FITC, 3. 
CD4-Alexa647 + CD8-PerCP + CDllb-PE + CDllc-FITC, 4. CD4-Alexa647 + 
CD8-PerCP + Rat IgG2b-PE + CDllc-FITC, 5. CD4-Alexa647 + CD8-PerCP + 
CDllb-PE + Hamster IgG-FITC) were used as controls. DCs were then analysed by 
flow cytometry, as previously described in Chapter 2, Section 2.2.5.
4.2.3. Assessment of tissue distribution of DCs
4.2.3.I. DiICi8(3)
DiICig(3), 1,1$ -dioctadecyl-3,3,3 </: ,3# -tetramethylindocarbocyanine
perchlorate, is a carbocyanine membrane dye that labels cell membranes by inserting 
its two long hydrocarbon chains into the lipid bilayers. It is a part of the group of 
long-chain carbocyanine fluorescent lipophilic traces [328]. Cell membranes provide 
a convenient conduit for loading live and fixed cells with lipophilic dyes as cells can 
tolerate a high concentration of lipophilic dye and the lateral diffusion of the dye 
within the membrane can serve to stain the entire cell, even if the dye is applied 
locally [328]. Lipophilic tracers have been used to label cells, liposomes, viruses and 
lipoproteins for a variety of long-term tracing applications, including cell 
transplantation, migration, adhension and fusion studies [328].
The lipophilic carbocyanines are weakly fluorescent in water, but highly 
fluorescent and quite photostable when incorporated into membranes. They have 
extremely high extinction coefficients (>125,000 cm^M"1 at either longest-
125
wavelength absorption maximum) through modest quantum yields, and short excited- 
state lifetime (~1 nanosecond) in lipid environments [328]. Once applied to cells, dyes 
diffuse laterally within the plasma membrane, resulting in the staining of the entire 
cell. Transfer of these probes between intact membranes is negligible [328]. Dil and 
its analogues exhibit very low cell toxicity, however, inhibition of electron transport 
chain activity has been reported with some analogues [329].
4.2.3.2. Labelling Dendritic Cells with DiICig(3)
DiICig(3) was used to label peptide-loaded DCs in order to identify the tissues 
they are localised after 48 hours of immunisation. DCs in culture (IxlO6 per well) 
were first incubated with the peptides (2.5pg/mL) for 2 hours at 37°C. DCs were then 
dye-loaded for 30 min at 37°C with lOOpl of 0.5pM DiICig(3), prepared in 1% 
Glucose in PBS, obtaining a 0.05jliM final concentration of dye per well. The cells 
were incubated further for 30 minutes at 37°C, 5% CO2. The cells were then 
harvested, collected by centrifugation at 200 x g for 5 minutes and washed twice by 
sterile PBS to remove excess dye. 2.5x106 cells (0.2ml) were adoptively transfered by 
intraperitoneal injection into ApoE7' mice.
4.2.3.3. Tissue processing and flow cytometry analysis
After 48 hours from the adoptive transfer of DCs loaded with peptides and 
labelled with DiICig(3), the ApoE7' mice were euthanized by CO2. The spleen, the 
thymus, the lymph nodes, the heart and the aorta were collected and processed as 
described below. The aortas were fixed in 10% Formalin (Sigma-Aldrich, U.K.) and
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stored in the dark and visualised for DiICig(3) fluorescence under UV light (Appendix 
Figure Al).
Each tissue was separately tomed apart in a small volume of RPMI 1640 
media and the superantant of the cells suspension was collected passed into a clean 
50ml centrifuge tubes (Barloworld Scientific, U.K., Cat. No. 36050NPG ). Red cell 
lysis was performed on the spleens using the Mouse Erythrocyte Lysing kit (R&D 
Systems, UK, Cat. No. WL2000). The cell suspension for each tissue was separately 
washed with 25ml RPMI 1640 media by centrifugation at 200 x g for 5 minutes and 
again with 25ml PBS. The cells were re-suspended in 0.5ml of 1% Formaldehyde and 
0.5% BSA in PBS and the cell suspension was transferred into 5ml polystyrene 
round-bottom tubes (BD Falcon™, U.K., Cat. No. 322003).
Unlabelled DCs and tissue from naïve-unimmunised animals were processed 
in a similar manner. Samples were analysed for DiICig(3) by flow cytometry. Data 
was acquired from 5 x 104 cells from each sample and results were expressed as the 
mean fluoresce intensity as a result of dye transfer above an arbitary value set of the 
negative cells.
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4.2.4. Immunisation with peptide-coupled carriers and peptide-loaded dendritic 
cells.
4.2.4.1 Coupling peptides with carrier proteins
Peptides P2, P45 and P210 were added to a Img/ml solution of carrier protein 
Bovine Serum Albumin (BSA) in PBS at a molar ratio of protein/peptide ranging 
1/10, as shown in Table I, in Chapter 3.
L5mg/ml of peptide at 0.68 IpM added to 4.54mg/ml BSA at 0.068 IpM. To 
achieve a molar ratio protein/peptide of 1/10, 132pl of 0.68 IpM peptide in 600pl final 
volume solution giving final concentration of 0.15pM added to 132pl of 0.068 IpM 
BSA in 600pl final volume solution giving final concentration of 0.015pM.
Glutaraldehyde solution diluted in double-distilled water, acting as an 
antiseptic, was added drop-wise to the peptide-protein mixture with constant stirring 
at 4°C and incubated for 1 hour. The reaction was then stopped by adding 25pi of 5M 
glycine to the protein-peptide mixture with continuous stirring for 1 hour at 4°C, 
which stops the reaction by pH modification. The final peptide-protein mixture was 
then dialysed against PBS to remove uncoupled peptides and then stored in aliquots at 
-20°C.
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4.2.4.2. In vitro loading of Dendritic Cells
Bone marrow dendritic cells were produced as described before (Chapter 2, 
Section 2.2.1) and incubated with each of the peptides, P2, P45 and P210 at a 
concentration of 2.5pg/ml for 2 hours at 37°C. After the incubation, the DCs were 
collected and washed by centrifugation at 200 x g for 5 minutes. The supernatant was 
discarded and the pellet was re-suspended in sterile PBS.
4.2.4.3. Immunisation Scheme
Coupled peptides as well as peptide-loaded DCs were used to immunize 
ApoE"' mice. IxlO6 of DCs in 200pl total volume were adoptively transfered by 
intraperitoneal injection into ApoE'7' mice. Mice were also immunised with BSA and 
PBS as controls. Naïve splenocytes or DCs from non-immunized mice were also 
isolated and served as negative controls. Five mice were used for each peptide and 
each control group.
A 30 day immunisation protocol was followed (Figure 4.2). Pre-immunization 
plasma was collected and before the booster after day 15. On day 30, mice were 
terminated, plasma was collected from the aorta and also spleens were extracted. 
Plasma was collected to measure levels of IL-10, IFN-y, IgGl and IgG2a by ELISA. 
Splenocytes were labelled with CD4, CDS, CD25, FoxP3 and CD 127 for flow 
cytometry analysis.
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Figure 4.2. Peptide immunization protocol. ApoE'7' mice at 6-8 weeks old were used in this 
study (n=5). Pre-immunisation plasma was collected from the tail and then the mice were 
immunised with BSA coupled peptides (P2, P45 or P210) or peptide loaded DCs, as well as 
BSA, PBS and DCs alone as controls. A booster dose was given on day 15, where pre- 
booster plasma was also collected. Upon termination on day 30, plasma was collected from 
the aorta and the spleen of every animal was isolated.
4.2.4.4. Enzyme-Linked ImmunoSorbent Assay for the detection of cytokine and
antibody levels in plasma
4.2.4.4.I. Detection of cytokine levels in plasma
Plasma samples were tested by ELISA for cytokine levels of IL-10 and IFN-y 
using a commercial kit from PeproTech Inc. and following the manufacturer’s 
protocol was followed, as previously described in Chapter 2, Section 2.2.6.1. Samples 
were diluted at a ratio of 1:50 in diluent (0.05% Tween-20, 0.1% BSA in PBS) and 
lOOgl of sample were added to each well in duplicate and incubated overnight at 4°C. 
A detection antibody was added to each well and incubated at room temperature for 
30 minutes. 3,3 ’,5,5’-tetramethylbenzidine dihydrochloride Substrate solution was 
added per well and incubated at RT for colour development. The reaction was stopped
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by adding 50gl of 2M H2SO4 and the colour development was monitored with an 
ELISA plate reader at a wavelength of 405nm.
4.2.4.4.2. Detection of antibody levels in plasma
A standard ELISA protocol was used to test for plasma levels of IgGl and 
IgG2a antibodies. 96-well flat bottom microtiter plates (Microplate Nunc Immuno 
MaxiSorp 96 well flat bottom, Fisher, Cat. No. DIS-971-03OJ) were washed with 
200pl of Carbonate-bicarbonate buffer, pH 9.0 (Sigma, Cat. No. C3041-50CAP) and 
coated with 50pl per well of 20pg/ml of antigen in 0.05M carbon-bicarbonate buffer, 
and incubated overnight at 4°C, tightly wrapped to avoid evaporation. The plates were 
washed with 200pl per well of Ix TBS (150mM NaCl, IQmM Tris pH8.0)-0.05% 
Tween-20, blocked with 200pl per well of Superblock blocking buffer in TBS (Pierce, 
Cat. No. 37535) and immediately emptied by inversion, repeated twice. Serum 
samples were diluted 1:50 in Superblock 1:10 in TBS, 0.1% Tween-20 and lOOpl 
were applied per well and incubated at 4°C overnight, tightly wrapped to avoid 
evaporation. After washing the plates with 200pl per well of Ix TBS-0.05% Tween- 
20, lOOpl of the detection antibody, rat anti-mouse IgGl (Serotec, Cat. No. 
MCA336B) or rat anti-mouse IgG2a (Serotec, Cat. No. MCA421B), diluted in 
Superblock 1:10 in TBS, 0.1% Tween-20 were added and the plates were incubated 
for 2 hours at 37°C. The plates were then washed with 200pl per well of Ix TBS- 
0.05% Tween-20 and incubated with lOOpl per well of conjugated Streptavidin- 
Alkaline Phosphate (Sigma-Aldrich, U.K., Cat. No. E2636-5ML) diluted 1:2000 in 
Superblock 1:10 in TBS, 0.1% Tween-20 at room temperature for 1 hour. Following a 
final wash with 200pl per well of Ix TBS-0.05% Tween-20, lOOpl per well of
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substrate (lp-NPP tablet/4ml ultrapure water/lml of diethanolamine, Pierce, Cat. No. 
37620) were applied and the plates were incubated for 1 hour in the dark and the 
reaction was stopped by adding 50pl per well of 2M NaOH. Absorbance was read at a 
wavelength of 405 nm, using a plate reader (Bio-Tek Instruments, Inc., Ontario, 
Canada, Model No. Bio-Tek ELx800) and supportive software (KC4 Programme, 
Bio-Tek V3.4, Bio-Tek Instruments, Inc., Ontario, Canada).
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4.3. Results
4.3.1. Determ ination of the phenotype of DCs
Fluorescently labelled DCs were analysed using flow cytometry in order to 
determine their phenotype. A representative example of the results, including un­
stained cells and isotype controls, are displayed in Figure 4.3.
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Figure 4.3. Flow Cytometry plots for the determination of the phenotype of isolated DCs.
Representative examples of the results, including isotype and un-stained (-/-) controls.
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Based on the results, 98.5% of the CD llb+ labelled cells were of a 
CD1 lc+CDl lb+CD8"CD4" phenotype, whereas 100% of the CD 11b" labelled cells 
were of a CD1 lc+CDl lb"CD8"CD4" phenotype (Figure 4.3). This experiment was 
performed by Dr. Alexandra Bermudez-Fajardo, from the Immunology group at the 
University of Surrey.
4.3.2. Immunisation with ApoB-100-derived peptides triggers the induction of 
Treg cells in vivo
Immunisation of ApoE"7' mice with BSA-conjugated P2, P45 and P210 
peptides induced a significant increase in the numbers in vivo of CD4+CD25+FoxP3+ 
(***/? < 0.001; ***p < 0.001 and **/? < 0.01 respectively) (Figure 4.6A) of Treg cells. 
A similar effect was also observed on CD8a+CD25+FoxP3+ nTreg cells from P2 and 
P45 (***p < 0.001 and **p < 0.01 respectively) (Figure 4.6B). All treatment groups 
were compared to non-immunised mice and with animals that received PBS or BSA 
alone. In the case of CD8a+CD25+FoxP3+ Treg cells, a significant inhibitory effect was 
observed by P210 (**/? < 0.01) (Figure 4.6B)
The numbers of CD4+CD25"FoxP3+ inducible Treg cells (iTreg cells) was also 
significantly increased after treatment with BSA-conjugated P2, P45 and P210 
peptides (***/? < 0.001; ***p < 0.001; ***p < 0.001 respectively) (Figure 4.6C). The 
number of CD8a+CD25"FoxP3+ iTreg cells was significantly increased only by P2 and 
P45 peptides (***/? < 0.001 and ***p < 0.001 respectively) (Figure 4.6D). Similar to 
the effect noted for the natural Treg cells, P210 showed a significant inhibitory effect 
on the induction of CD8a+CD25"FoxP3+ iTreg cells (**p < 0.01) (Figure 4.6D)
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compared to BSA treated animals. Again, all treatment groups were compared to non­
immunised mice and with animals that received PBS or BSA alone. The flow 
cytometry graphs are displayed in Figure 4.4 and Figure 4.5, for CD4+ and CD8+ Treg 
cells respectively.
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Figure 4.4. Flow Cytometry plots for the analysis of the induction of proliferation of natural 
and inducible CD4+ Treg cells by apoB-100-derived peptides in vivo. Representative examples 
for each of the treatments, including isotype and un-stained (-/-) controls. The percentage of 
CD4+CD25+FoxP3+ T reg cells (number of cells in quadrant Q3) for each treatment was used to 
assess the effect of the peptides on the numbers of T reg cells in vivo.
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Figure 4.5. Flow Cytometry plots for the analysis of the induction of proliferation of natural 
and inducible CD8+ Treg cells by apoB-100-derived peptides in vivo. Representative examples 
for each of the treatments, including isotype and un-stained (-/-) controls. The percentage of 
CD8+CD25+FoxP3+ T reg cells (number of cells in quadrant Q3) for each treatment was used to 
assess the effect of the peptides on the proliferation of T reg cells in vivo.
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Figure 4.6. Induction of natural and inducible regulatory T cells proliferation in vivo by 
ApoB-100-derived peptides. ApoE"z" mice (n=10 for each treatment group) were immunised 
with BSA-conjugated P2, P45 or P210. Upon termination, the spleen was collected and the 
lymphocytes were labelled with anti-mouse CD4 or CDS in combination with anti-mouse 
CD25 and FoxPS fluorescently tagged antibodies. The percentage of CD25+FoxP3+ and 
CD25"FoxP3+ cells, gated on CD4+ and CD8+ populations was analysed by flow cytometry (as 
shown in Figure 4.3). The results are represented as mean ± SD, with the asterisk indicating 
significant differences compared to BSA immunised animals used as a control (**p < 0.01;
* * * p <  0 . 0 0 1 ) .
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4.3.3. Analysis of the effects of peptides on the levels of IFN-y and IL-10 in
plasma samples of immunised ApoE'7' with BSA-conjugated peptides
The levels of IFN-y (Thl-associated cytokine) and IL-10 (Th2-associated 
cytokine) in the plasma of the immunised animals were measured using commercially 
available ELISA kits, in order to assess the pro- vs. anti-inflammatory cytokine 
pattern induced by the immunisation with BSA-conjugated peptides. A significant 
increase in the plasma levels of IL-10 was observed by P45 (*p < 0.05) and P210 
(*p < 0.05) compared to BSA immunised animals and pre-immunised controls (Figure 
4.7A). Conversely, significant differences were not observed in the levels of IFN-y 
when compared to control animals, with P210 giving significantly higher levels 
(*p < 0.05) of the cytokine compared to pre-immunised animals (Figure 4.7B). These 
results indicate the capability of these peptides to selectively induce anti­
inflammatory Th2-mediated immune responses in vivo.
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Figure 4.7. Effect of peptide immunisation on the plasma cytokine profile. Levels of IL- 
10 (A.) and IFN-y (B.) from the plasma of the ApoE"A animals immunised with BSA-conjugated 
P2, P45 and P210 peptides were quantified using commercially available ELISA kits. Levels 
of the cytokines were observed in pg/ml and are represented graphically as mean ± SD, with 
the asterisk indicating the significant differences compared to BSA (*p < 0.05) and to pre­
immunisation plasma.
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4.3.4. Analysis of the effects of peptides on the levels of IgGl and IgG2a in
plasma samples of immunised ApoE " with BSA-conjugated peptides
Immunisations were carried out in the absence of an adjuvant in order to 
assess the effect of BSA-conjugated peptide immunisation on cell-mediated immunity 
(Thl vs. Th2). Plasma from animals immunised with BSA-conjugated P2, P45 and 
P210 was collected before immunisation (pre-immunisation) and at termination. This 
was used to assess the levels of anti-peptide IgG2a (Thl-related) and IgGl (Th2- 
related) synthesis by ELISA.
Significant differences were observed in the levels of anti-P45 (**p < 0.01) 
and anti-P210 (**/? < 0.01) specific for IgGl (indicating a Th2-related response) when 
compared to BSA controls (Figure 4.8), indicating that even in the absence of any 
adjuvant, P45 and P210 can stimulate a peptide-specific T cells response, even at low 
levels. Such a result supports previous studies that have shown the induction of a Th2- 
type immune response from the peptides [330].
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Figure 4.8. Effect of BSA-conjugated peptide immunisation on the humoral immune 
response. Plasma from immunised animals with was used to assess the levels of peptide- 
specific lgG2a (Th1) and lgG1 (Th2) induced by the immunisation. Levels are expressed in 
optic density (OD) units measured at 405 nm and represented as mean ± SD, with the 
asterisk indicating significant differences compared to BSA immunised animals used as 
control (**p < 0.01)
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4.3.5. Immunisation with Dendritic cells loaded with ApoB-100-derived peptides
triggers the induction of Treg cells in vivo
The effect of immunisation using DCs loaded with P2, P45 or P210 peptides 
on the number of CD4+ and CD8+ natural Treg cells was assessed, with the results 
indicating that P210-loaded DCs (DCs-P210) significantly up-regulate the numbers of 
CD4+CD25+FoxP3+ (*p < 0.05) nTreg cells, when compared to control animals which 
were immunised with DCs alone (Figure 4.11 A). On the contrary, the numbers of 
CD4+CD25+FoxP3+ nTreg cells were significantly reduced by DCs-P45 (**/? < 0.001) 
(Figure 4. HA). The expression of CD 127, a marker which is relatively absent on Treg 
cells, was also assessed, with the results showing the same effect as above (Figure 
4.12A).
The number of CD8a+CD25+FoxP3+ nTreg cells was significantly reduced by 
DCs-P2 and DCs-P45 (**p < 0.001 and ***p < 0.001 respectively) when compared to 
the DCs alone immunisation control (Figure 4.1 IB), whereas DCs-P45 significantly 
increased the number of CD8a+CD25+CD127" nTreg cells (**p < 0.01) (Figure 4.12B). 
These results indicate that peptide loaded DCs are capable to increasing the numbers 
of Treg cells. The flow cytometry graphs are displayed in Figure 4.9 and Figure 4.10 
for CD4+ and CD8+ Treg cell respectively.
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Figure 4.9. Flow Cytometry plots for the analysis of the effect of peptide-loaded DCs on the 
numbers of CD4+ Treg cells in vivo. Representative examples for each of the treatments, including 
isotype and un-stained (-/-) controls. The percentage of CD4+CD25+FoxP3+ and 
CD4+CD25+CD127" T reg cells (number of cells in quadrant Q3 and Q4 respectively) for each 
treatment was used to assess the effect of the peptides on the number of T reg cells in vivo.
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Figure 4.10. Flow Cytometry plots for the analysis of the effect of peptide-loaded DCs on the 
numbers of CD8+ Treg cells in vivo. Representative examples for each of the treatments, including 
isotype and un-stained (-/-) controls. The percentage of CD8+CD25+FoxP3+ and 
CD8+CD25+CD127" T reg cells (number of cells in quadrant Q3 and Q4 respectively) for each 
treatment was used to assess the effect of the peptides on the number of T reg cells in vivo.
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Figure 4.11. The effect of peptide-loaded DCs on the numbers of regulatory T cells. DCs
loaded with P2, P45 or P210 in vitro were used to immunise ApoE'7' mice. Upon termination, T 
lymphocytes from the spleen were labelled with anti-CD4, CD8, CD25 and FoxPS 
fluorescently-tagged antibodies. After gating for CD4+ and CD8+ populations, the percentage 
of CD25+FoxP3+ cells was analysed using flow cytometry. Animals immunised with PBS and 
DCs alone were used as negative controls. The results are represented as mean ± SD and 
the asterisk indicates significant differences compared to animals immunised with PBS and 
DCs alone used as a control (*p < 0.05; *** p <0.001 ).
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Figure 4.12. The effect of peptide-loaded DCs on the numbers of CD127" regulatory T 
cells. DCs loaded with P2, P45 or P210 in vitro were used to immunise ApoE"A mice. Upon 
termination, T lymphocytes from the spleen were labelled with anti-CD4, CD8, CD25 and 
CD127 fluorescently-tagged antibodies. After gating for CD4+ and CD8+ populations, the 
percentage of CD25+CD127|0W cells was analysed using flow cytometry. Animals immunised 
with PBS and DCs alone were used as negative controls. The results are represented as 
mean ± SD and the asterisk indicates significant differences compared to animals immunised 
with PBS and DCs alone used as a control (*p < 0.05; ** p <0.01 ).
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4.3.6. Analysis of the effects of peptide-loaded DCs on the levels of IFN-y and IL-
10 in plasma samples of immunised ApoE"7" mice
Plasma levels of IL-10 and IFN-y in animals immunised with peptide-loaded 
DCs were measured by commercially available ELISA kits. After immunisation with 
DCs-P45, the levels of IL-10 were significantly lower when compared to animals 
immunised with DCs alone (p<0.01). On the contrary, the levels of IL-10 were 
significantly higher after immunisation with DCs-P210 (p<0.05) when also compared 
to control (Figure 4.13A).
The plasma levels of IFN-y were not affected after the immunisation of 
animals with peptide-loaded DCs (Figure 4.13B). This result is similar as the one 
noted in animals immunised with BSA-conjugated peptides.
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Figure 4.13. The effect of vaccination using peptide-loaded DCs on plasma levels of IL-
10 and IFN-y. Cytokine levels in plasma of pre-immunised animals and plasma collected 
upon termination were measured by ELISA. Levels are expressed in pg/ml and are 
represented as mean ± SD, with the asterisks indicating significant differences determined by 
a t test compared to animals treated with DCs alone (*p < 0.05). No significant differences 
were found when compared to plasma from pre-immunised animals.
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4.3.7. Analysis of the effects of peptide-loaded DCs on the levels of IgGl and
IgG2a in plasma samples of immunised ApoE "
The effect of peptide-loaded DCs in the generation of peptide-specific 
antibodies was assessed by ELISA, as described above. Plasma levels of IgGl were 
significantly higher after immunisation with DCs-P45 (p<0.05) and DCs-P210 
(p<0.05; p<0.001) when compared to pre-immunised animals or immunised with DCs 
alone, whereas no significant effects were induced after immunisation with any of the 
peptides loaded to DCs (Figure 4.14). The results obtained demonstrate that peptide 
immunisation triggers an antigen-specific immune response which polarises towards a 
Th2 phenotype.
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Figure 4.14. The effect of vaccination with peptide-loaded DCs on plasma levels of 
peptide-specific lgG1 and lgG2a. Plasma from animals treated with peptide-loaded DCs 
was quantified for lgG1 and lgG2a levels by ELISA. Antibody levels were expressed in optic 
density units measured at 405 nm and are represented as mean ± SD, with asterisk indicating 
significant differences between samples and animals treated with DCs alone (***p < 0.001) 
and with pre-immunised plasma (*p < 0.05).
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4.3.8. Tissue localisation of peptide-treated DCs after adoptive transfer
The quantity and the quality of an immune response may be influenced by the 
tissue microenvironment in which it occurs, hence an experiment was carried out to 
study whether treatment with P2, P45 and P210 peptides influences the tissue 
distribution of DCs.
DCs were isolated and treated with P2, P45 and P210 peptides in vitro. They 
were then labelled with DiICig(3). Peptide-treated fluorescently-labelled DCs, as well 
as untreated controls, were adoptively transferred in to ApoE"7" mice and their 
localisation in the spleen, heart, lymph nodes and thymus was quantified 48 hours 
after transfer. Three animals were used per group and labelled, but not peptide-treated 
DCs were used as controls. The analysis was carried out by flow cytometry and the 
effect of migration into different organs is represented in percentage of cells.
The differences observed were not statistically significant compared to non­
treated cells, however it was noted that DCs-P45 have a preferential migration to the 
spleen, while DCs-P2 and DCs-P210 migrate better to the thymus (Figure 4.15).
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Figure 4.15. Tissue localisation of peptide-treated DCs after adoptive transfer. DCs
treated with P2, P45 and P210 peptides in vitro were labelled with DilC18(3) and the injected 
into ApoE'7" mice (n=3 per group). Tissue localisation of fluorescently-labelled DCs was 
carried out 48hrs after transfer. No significant differences were observed between groups.
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4.4. Discussion
The successful use of apoB-100-derived peptides used in vaccine preparations, 
containing alum as adjuvant, to prevent or stop the progression of atherosclerosis 
development has been previously documented [203, 242, 324].
Here, the immune response triggered by the peptides in the absence of alum 
and using BSA as a carrier protein was evaluated. This was decided based on the 
observation that alum itself can enhance antigen presentation, the expression of co­
stimulatory molecules CD80 and CD86, as well as the secretion of IL-lp and IL-18 
cytokines by DCs and macrophages favoring Thl responses in mice [331-333]. In the 
case where alum is administered with the antigen, it has been shown to induce the 
secretion of IT-4, IL-5 and IFN-y by naïve CD4+ T cells [332, 334]. Other studies 
have also shown that alum may affect the compartmentalization of the immune 
response by influencing the migration of antigen presenting cells [334]. Hence, it can 
be concluded here that alum may mask the effect of the antigen or even modulate the 
immune response in the opposite way. Therefore, ApoEv" mice were immunized with 
BSA-conjugated peptides, in the absence of an adjuvant and the results observed were 
entirely due to the effect of the peptides.
Intraperitonial adoptive transfer of BSA-conjugated P2, P45 and P210 
peptides in to ApoE'7' mice induced a significant increase in the numbers of 
CD4+CD25+FoxP3+ of natural Treg cells in the spleen (Figure 4.6A), in vivo. P2 and 
P45 induced a similar effect on CD8a+CD25+FoxP3+ Treg cells (Figure 4.6B), when 
compared to non-immunised mice and with animals that received PBS or BSA alone.
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In the case of CD8a+CD25+FoxP3+ Treg cells, a significant inhibitory effect was 
observed by P210 (Figure 4.6B). Treatment with BSA-conjugated P2, P45 and P210 
peptides significantly increased the numbers of CD4+CD25"FoxP3+ inducible Treg 
cells (iTreg cells) was also significantly induced after (Figure 4.6C), whereas the 
numbers of CD8a+CD25"FoxP3+ iTreg cells were significantly increased only by P2 
and P45 peptides (Figure 4.6D).
While BSA-conjugated peptides did not induce any significant changes in the 
IFN-y levels in the plasma of immunised mice (Figure 4.7B), P210 significantly 
increased the levels of IL-10 cytokine (Figure 4.7A) and IgGl antibody (Figure 4.8), 
both of which are classified to as Th2 anti-inflammatory factors. BSA-conjugated P45 
was also observed to significantly increase the level of the anti-inflammatory antibody 
(Figure 4.8).
The key role of the antigen on cell-mediated immune response is underlined 
here by the differences observed in the number of Treg cells after treatment of ApoE'7' 
mice with peptides alone or peptide-loaded DCs. Based on these results, P210-loaded 
DCs significantly increase the number of CD4+CD25+FoxP3+ (Figure 4.11) and 
CD4+CD25+CD127" (Figure 4.12) Treg cells as well as the plasma levels of IL-10 
(Figure 4.13) when compared to controlled animals which were treated with DCs 
alone. This also suggests that P210-loaded DCs induce the best anti-inflammatory 
response, always when compared to the controls. In the case of P45-loaded DCs, the 
numbers of CD4+CD25+FoxP3+ and CD8+CD25+FoxP3+ regulatory T cells (Figure 
4.11), as well as the IL-10 plasma levels (Figure 4.13) were decreased, suggesting that 
P45 may enhance the maturation of DCs and the enhancement of CD4+ T cell-
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mediated immune responses. In the case of P2-loaded DCs, the numbers observed for 
CD4+CD25+CD127' and CD8+CD25+CD127" regulatory T cells contrasted the 
numbers of CD8+CD25+FoxP3+ regulatory T cells, hence suggesting that a more 
complex mechanism may be involved here (Figures 4.11 and 4.12).
In the case of IFN-y plasma levels, no significant differences were observed 
(Figure 4.13). This may be due to the C57BL/6 background of the ApoE'7' mice which 
is genetically biased to Thl-mediated immunity characterized by high basal levels of 
IFN-y [335, 336]. DCs loaded with peptides P45 or P210 also showed significantly 
increased levels of IgGl antibodies, when compared to plasma levels of animals 
immunised with DCs alone, as well as when compared to pre-immunisation Ab 
plasma levels (Figure 4.14).
Based on the antigens nature and the cytokine environment, DCs produce 
TGF-p that promotes naïve T helper cells to differentiate into IL-10 secreting FoxP3+ 
regulatory T cells [337] and at the same time the suppression of pro-inflammatory 
responses [338, 339]. This is also documented here, by the differential induction of 
regulatory T cells by P45 and P210 and the significant increase in the synthesis of IL- 
10 by P45. Despite the increase in the number of regulatory T cells, P2 did not show 
any effects on the cytokine synthesis, something that may imply that this peptide 
participates in immune regulation through different mechanisms. The time of antigen 
availability, bio-distribution or the direct effect on the immunomodulatory properties 
of DCs may be some of the factors accounting for the differential effect of peptide 
immunization with or without DCs, hence further investigation is needed to explain 
this [340].
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Molecular and functional changes of APCs by antigens while transported to 
effector organs cause the compartmentalization of immune responses [341-345]. The 
effect of the peptides on the compartmentalization of the immune response was 
studied here. Peptide-loaded DCs were detected in the regional lymph nodes, the 
spleen and in peripheral tissues, such as the heart (Figure 4.15). Bearing an immature 
phenotype (iDCs) these cells mostly displayed a CD8a+ phenotype, known for its 
tolerogenic properties [346-348]. ApoB-100-derived peptides P2, P45 and P210 are 
autoantigens that may induce tolerogenic immune responses. Hence, the lack of effect 
on the phenotype and the tissue distribution of DCs supports the tolerogenic effect of 
the peptides, as mature DCs are characterized by a CD4+/CD8a+ phenotype with 
higher levels of MHC class II and co-stimulatory molecules than those displayed by 
the peptide-loaded DC populations here [349].
As demonstrated here, ApoB-100-derived peptides P2, P45 and P210 exert 
differential effects on humoral and T cell mediated immune responses when 
administered alone or loaded on to DCs. This observation comes to highlight the role 
of DCs in immune responses against those antigens both while they are exposed to 
autoantigens released during ox-LDL as well as when used in vaccine preparations. 
Peptide immunisation with P45 and P210 (both alone and loaded onto DCs) showed a 
significant effect on the synthesis of IgGl (Th2-associated immune response) 
something that comes in line with previous findings linking this effect to athero- 
protection [203, 324]. The synthesis of IgGl involves isotype class switching, which 
also requires the participation of CD4+ Th2 cells, known for their anti-inflammatory 
and athero-protective effects [203].
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In conclusion, it is demonstrated here that apoB-100-derived peptides used in 
vaccine preparation may exert anti-inflammatory effects, also contributing to the 
induction of Treg cells in the process of the regulation of atherosclerosis. Also, these 
results suggest for the first time the generation of CD4+ and CD8+ regulatory T cells, 
induced by these peptides.
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CHAPTER 5.
THE EFFECT OF REGULATORY T CELL DEPLETION ON 
ATHEROSCLEROSIS AND ATHEROSCLEROTIC PLAQUE
DEVELOPMENT
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5.1. Introduction
The ‘Immunological Hypothesis’ of atherogenesis was initially based on the 
observation that T lymphocytes accumulate along with macrophages within 
atherosclerotic plaques at all stages [62]. Lesions also contain classic antigen 
presenting cells (APCs) including dendritic cells (DCs), which are clustered at arterial 
branch-points together with T-lymphocytes and macrophages [350, 351]. Other cells 
such as B lymphocytes, Natural Killer (NK) cells and mast cells have been found 
within atherosclerotic plaques and their role in atherogenesis has been already 
proposed [49, 350, 352]. Both self and foreign antigens are involved in triggering the 
inflammatory process in which these different cell types participate, amongst them (a) 
oxidised low density lipoprotein (ox-LDL), (b) neoantigens such as heat shock 
proteins (HSP) and endothelial cell surface antigens, (c) viral and bacterial antigens, 
and (d) p2-glycoprotein I [70, 353].
For several years this Thl vs. Th2 balance theory was the comer stone to 
explain most of the immunopathological changes observed in atherosclerotic plaques 
and a key foundation to propose and develop new therapeutic interventions. However, 
new evidence has recently emerged demonstrating that the balance between athero- 
protective and atherogenic immune responses may be controlled and significantly 
inhibited by Treg cells. The study of the potential role of Treg cells in atherosclerosis 
development has been a neglected area of research as compared with the extensive 
attention received to study their involvement in other diseases.
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The first indirect evidence of Treg cell participation in atherogenesis was 
provided by Mallat and co-workers who showed that repeated stimulation of naïve T 
cells from ovalbumin-(0VA)-T-cell-receptor transgenic mice with OVA and IL-10 
results in the generation of T cell clones with a unique cytokine profile distinct from 
that of ThO, Thl or Th2 cells [159]. These cells were classified as Trl and where 
shown to produce IL-10, some IL-5 and LFN-y, with or without TGF-p secretion. 
They secrete little or no IL-2 or IL-4 and hence, as expected, they proliferate poorly 
after polyclonal T cell receptor-mediated activation [159]. Transfer of these Trl cells 
into low density lipoprotein receptor deficient (LDLf^) mice significantly reduced 
atherosclerosis development. Moreover, neutralisation of IL-10 secretion reversed the 
anti-atherosclerotic effect shown by these cells, implying that immunosuppression by 
Trl cells is a bystander effect mediated by IL-10 secretion [159]. However, these 
results are in somehow questionable due to the MHC incompatibility between the 
transferred Trl cells and the antigen-presenting cells of the recipient mice.
Other groups attempted to study the role of Treg cells in atherosclerosis in 
relation to the expression of important co-stimulatory molecules such as CD40 ligand 
(CD40L) [354] and chemokines, such as CXCL10 (IP-10) [355]. However, these 
studies provide indirect and limited information about the precise role of Treg cells in 
the development of the disease. Mallat and co-workers recently published the first 
demonstration that naturally occurring CD4+CD25+ Treg cells have a significant anti­
atherogenic effect in mice [161]. Due to severe autoimmune phenotype of CD25 (IL-2 
receptor a chain receptor)-deficient (IL2raA) mice, mice used were deficient for the 
expression of important co-stimulatory molecules such as CD80, CD86 and CD28 
that participate in the generation and functional activation of CD4+CD25+ Treg cells.
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Irradiated LD LfA mice reconstituted with bone marrow derived from CD80'/'86'/' or 
CD28'a mice showed more than double the size of atherosclerotic plaques as 
compared with control animals. Also, CD4+CD25+ Treg cells were able to significantly 
reduce atherosclerotic plaque size in ApoR^Ragl'1' deficient mice when adoptively 
transferred as compared with animals that received CD4+CD25" Treg cells. Animals 
that received CD4+CD25+ Treg cells also had a significant reduction in lymphocyte 
and macrophage intra-plaque infiltration and increased collagen content. The 
requirement of TGF-P signalling by CD25+ Treg cells in order to explain their 
protective role in atherosclerosis was also suggested [161].
Although these results only provide evidence for the role of naturally 
occurring CD4+CD25+ Treg cells, they pave the way for a deeper study and 
understanding of the role of other Treg cell populations in atherogenesis. Moreover, 
they provide invaluable evidence to further investigate the possible athero-protective 
mechanisms by which some of the current treatments (i.e. statins, vaccines) may be 
functioning. Knowing how their interplay with the proliferation, mobilisation and 
functional properties of Treg cells during the development of the disease will help us 
formulate new and/or improved therapeutic strategies to combat cardiovascular 
disease.
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5.1.1. Depletion of Treg cells
While investigating mechanisms of immune tolerance and in the process of 
establishing therapeutic methods in various diseases, scientists often focus on Treg 
cells and their role in disease progression. Depletion of Treg cells generally allows the 
study of the significance of the cell subset and indicates their possible use in 
therapeutic techniques. Some examples are mentioned here.
The recombinant IL-2 diptheria toxin conjugate DAB389IL-2 [356], also 
known as immunotoxin denileukin diftitox, ONTAK, and the anti-CD25 monoclonal 
antibody, PC61, are most widely used for the depletion of Treg cells. ONTAK, which 
consists of human IL-2 fused with diptheria toxin [357], selectively targets 
lymphocytes expressing CD25 and may also deplete FoxP3+ Treg cells, due to the high 
expression of CD25 (IL-2R) on Treg cells [357, 358]. This is widely used in cancer- 
related studies, where CD4+CD25+FoxP3+ Treg cells limit antigen-specific immune 
responses and are the cause of suppressed anti-cancer immunity [358]. Hence, 
depletion of Treg cells in cancer leads to immune enhancement [358]. Clay et al. 
demonstrated that FoxP3+ Treg depletion by denileukin diftitox decreases the function 
and number of Treg cells by 74 ± 6% in vitro, enhancing antigen-specific T cell 
responses [358]. The role of CD4+CD25+ Treg depletion by ONTAK was also 
underlined by Hobeika et al. who demonstrated that a 48 - 60% reduction of Treg cells 
(5nM and lOnM ONTAK respectively) enhances in vivo tumor antigen specific 
immunity in response to immunotherapy [357]. In addition to enhanced immune 
functions, ONTAK Treg depletion also results in the substantial development of 
antigen-specific CD8+ T cells in cancer [356, 359].
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Experimental depletion of Treg cells using PC61 improves T cell-based tumor 
clearance in tumor-bearing rodents and enhances the response to DC-based therapy 
[360]. Administration of the Treg-depleting anti-CD25 monoclonal antibody, PC61, 
has been shown, amongst others, to effectively inhibit the further development of 
established murine mesotheliomas [361] and to result in smaller tumors in pancreas 
cancer patients [362]. Comes et al. demonstrated that a cell vaccine that combined the 
anti-CD25 antibody with TS/A mammary adenocarcinoma cells genetically modified 
to secrete IL-21 (TS/A-IL-21), cured > 70% of mice bearing micrometastases [363]. 
This indicates a possible therapeutic activity of IL-21-based anti-CD25 mAb vaccine 
with a strong anti-tumor effect and the induction of long-term protective immunity 
[363].
The granulocyte macrophage colony-stimulating factor-secreting B16BL6-D5 
melanoma cell line has been used as a single vaccine to partially deplete CD4+ cells 
and reduce the number of Treg cells inducing protective anti-tumor immunity [364]. 
Also, a single administration of cyclophosphamide has been shown to deplete 
CD4+CD25+ T cells in colonic carcinoma (PROb) tumor-bearing animals, causing a 
delay in tumor growth and curing established PROb tumors in rats [365]. In general, it 
is shown that low-dose cyclophosphamide improves T cell-based tumor clearance and 
augments the response to DC-based therapy [365, 366], in the same manner as PC61. 
In vitro, anti-CD25 conjugated immunomagnetic beads can also be used to deplete of 
CD25 cells [367-370]. The purity of these T cells can then be assessed by flow 
cytometry, using direct staining for CD4, CDS and CD25 markers [367-370]. 
Similarly, GK1.5 (anti-CD4) and 2.43 (anti-CDS) are antibodies which are purified 
from hybridoma culture supernatants using protein free hybridoma medium and a
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capillary dialyzer [356]. Depletion can then be confirmed by flow cytometry. 
Diptheria toxin injections have also been used for the depletion of FoxP3+ Treg cells, 
while investigating the experimental evidence that the absence of FoxP3+ Treg cells is 
indeed sufficient to induce a scrufy-like phenotype in mice [371]. Such depletion led 
in the development of scurfy-like symptoms with splenomegaly, lymphadenopathy, 
insulitis and severe skin inflammation, confirming the key role of FoxP3 in the 
development of natural Treg cells [371].
Immunosuppressive drugs can also be used for the depletion of Treg and T 
cells. A study by Noris et al. demonstrated that T cell depletion with Campath-1H, 
combined with sirolimus or cyclosporine (CsA) as part of the immunosuppressive 
therapy, caused T cells from treated patients to be anergic and also resulted in 
significantly increased frequency of IFN-y-producing effector cells [372].
5.1.2. The use of PC61 to deplete CD25+ Treg cells
CD25 expression on regulatory T cells has a functional role as the interruption 
of the IL-2R/IL-2 signalling pathway block the effector function of regulatory T cells 
by altering the expression of the glucocorticoid-inducer TNF receptor-family gene 
[373, 374]. CD25, the 55 kDa interleukin-2 receptor a chain (IL-2Ra) which plays a 
role in lymphocyte differentiation, activation and proliferation, is expressed by early 
progenitors of T and B lineage as well as by activated mature T and B lymphocytes. It 
binds IL-2, a T-cell-derived polypeptide hormone of 133 amino acids [375], which 
exerts its growth-promoting activity via a surface receptor [376], with low affinity,
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however, when associated with CD 122 (IL-2 receptor p chain) and CD 132 (common 
y chain) it forms the high affinity IL-2 receptor. This binding of IL-2 to both high and 
low affinity classes of IL-2 receptor is inhibited by PC61 antibody [377-379], a 
monoclonal anti-CD25 antibody. PC61 inhibits the binding of IL-2 to both classes of 
receptor, but IL-2 does not inhibit the binding of PC61, indicating that PC61 
recognises a determinant that is distal to the actual IL-2 binding site of the receptor 
[380]. This was demonstrated by the addition of PC61 causing the accelerated 
dissociation of IL-2 from both high and low affinity IL-2 receptors [380]. As a result, 
PC61 has been observed to cause the reduction in the number of CD25+ cells in 
peripheral blood [381] and the peripheral lymphoid tissues [360].
The IL-2 receptor, a multi-component complex, consists of three subunits 
which are required for high-affinity binding of IL-2, a, p and y. While the a chain 
functions in binding IL-2, the p and y chains contribute to IL-2 binding and are 
essential to IL-2-induced activation of signalling pathways leading to T cell growth 
[127]. PC61 (IgGl clone) and 7D4 (IgM clone) anti-CD25 monoclonal antibodies 
(MoAb) recognise different epitopes of the IL-2 receptor [382]. This blocking of the 
IL-2 receptor modulates the function and the survival of regulatory T cells due to the 
importance of IL-2 in the function and the activation of these cells [374]. This EL-2 
signalling is vital for maintaining homeostasis and the competitive fitness of 
regulatory T cells [383]. Studies have demonstrated that after treatment with either or 
both of these anti-CD25 antibodies there is a clear reduction in the expression of 
CD25, with the kinetics of 7D4 being vaguely delayed compared to PC61, signifying 
internalisation or detaching of the CD25 molecule from the cell surface [384]. The 
different immunoglobulin subclasses of these clones may somehow affect their
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mechanism of action [384], with IgM antibodies mediating their effect through the 
complement pathway, whilst IgG antibodies may also act independently of 
complement and instead utilise Fey receptors [384].
CD4+CD25+ regulatory T cells may not prevent the development of 
autoimmune disease upon immunisation, but they have been shown to modulate the 
severity of disease [385]. The injection of the anti-CD25 monoclonal antibody PC61 
results in the functional inactivation of regulatory T cells and hence in intensified 
autoimmune disease [386]. Such a treatment, with the CD25 MoAb PC61, leads to the 
rapid internalisation or detaching of the IL-2Ra chain on the regulatory T cells, hence 
causing CD25+ cells being undetectable [306]. Several studies have shown that after 
treatment with anti-CD25 MoAb mice have displayed lower numbers of CD4+CD25+ 
regulatory T cells [386]. The injection of lOOpl has been demonstrated to be enough 
to reduce the population of regulatory T cells by a 75.5%, with this effect continuing 
for at least 10 days after the intra-peritoneal administration of PC61 [387]. Studies 
have shown a marked loss of cell-surface IL-2Ra chain expression following the 
administration of PC61, with an elimination of up to 60% of FoxP3+ cells and CD25 
down-regulation in the remaining population of regulatory T cells [306]. The 
remaining population of FoxP3+ regulatory T cells express a lower level of CD25 and 
have a more activated phenotype due to a high expression of CD69 [383]. This is also 
demonstrated by naïve, inactivated regulatory T cells being dependent on IL-2 and 
hence deleted in the absence of IL-2 signalling [306].
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In this Chapter we hypothesise that (a) PC61 triggers the short and long term 
depletion of CD4+CD25+ and CD8+CD25+ Treg cells in vivo, (b) depletion of 
CD4+CD25+ and CD8+CD25+ Treg cells affects the levels of IFN-y, IL-4 and IL-10 in 
plasma samples of immune ApoE'7' mice, (c) depletion of CD4+CD25+ and 
CD8+CD25+ Treg cells exerts an effect on the levels of triglycerides, LDL, HDL and 
total cholesterol in plasma samples of immunised ApoE'7' mice and (d) depletion of 
CD4+CD25+ and CD8+CD25+ Treg cells by PC61 enhances the formation of 
atherosclerotic plaques in the aortic sinus of ApoE'7' mice.
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5.2. Experimental Procedures
To study the effect of Treg cells in the content of atherosclerosis in vivo, 
ApoE"7' mice at 6-8 weeks old were immunised with the anti-CD25 monoclonal 
antibody PC61 following the standard 8 week immunisation protocol. Upon 
termination, the spleen was isolated and the proliferation of Treg cells was analysed by 
flow cytometry. The heart and the aorta were used to analyse atherosclerotic plaques 
and plaque vulnerability.
5.2.1. PC61 production and purification
The B lymphocyte hybridoma from ATCC-LGC Standards U.S.A. (Cat. No. 
TIB-222) was used to produce PC61, a rat monoclonal anti-CD25 antibody, which 
blocks IL-2 binding, IL-2 dependent growth stimulation and immunoprecipitates IL-2 
receptors [388]. This hybridoma was originally produced by immunising mice with 
the cytotoxic T cell line B6.1. Their spleen cells were fused with P3X63Ag8.653 
myeloma cells [389, 390]. The cell line was cultured for 6 days in Dulbecco’s 
Modified Eagle’s Medium (DMEM, ATCC, Cat. No. 30-2002) supplemented with 2- 
mercaptoethanol to a final concentration of 0.05 mM and fetal bovine serum to a final 
concentration of 10%. The supernatant of the cell cultures was used for the isolation 
and purification of the monoclonal antibody, whereas the cells were stored in liquid 
nitrogen.
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5.2.2. Affinity purification of PC61
Melon™ gel monoclonal IgG purification kit (PIERCE, U.K., Cat. No. 45214) 
was used to purify PC61 from the cell culture supernatants by removing non-relevant 
proteins. The Melon™ gel IgG purification support binds non-antibody proteins, such 
as albumin and transferin, allowing antibodies to flow through in a mild buffer. The 
Melon™ gel IgG purification system uses Protein A and Protein G purification 
methods which have selective binding to IgG species and their subclasses of 
antibodies present in the sample. The Melon™ gel IgG purification system does not 
need elution and uses a mild buffer at physiological pH that is suitable for storage
[391].
Cell culture supernatant samples were dialysed using two 1-hour exchanges of 
Ix Melon™ gel purification buffer, using a volume of dialysis buffer at least 50-fold 
greater than the sample volume. Before use, the Melon™ gel monoclonal IgG 
purification support and purification buffer were equilibrated to room temperature. A 
funnel with filter paper leading to a flask attached to a vacuum supply was set up and 
the filter paper was pre-wet with Ix Melon™ gel purification buffer. A volume of 
Melon™ gel slurry equal to the sample volume was added to the funnel and vacuum 
was applied to drain the buffer from the gel. The funnel containing the gel was 
transferred to a new filter flask and the cell culture supernatant was added to the gel 
and mixed for 30 seconds with a spatula. The gel and the sample were incubated for 5 
minutes at room temperature before the vacuum was applied and the purified sample 
was collected in the filter flask. The concentration of the monoclonal anti-CD25 
antibody PC61 was measured using the Micro BCA™ Protein Assay Reagent kit
169
(PIERCE, Rockford, Cat. No. 23235) and the antibody was detected by Sodium 
Dodecyl Sulphate polyacrylamide gel electrophoresis (SDS-PAGE), described in 
Section 5.2.3 below.
5.2.3. Polyacrylamide gel electrophoresis (PAGE)
One of the primary methods used for the characterisation of proteins is their 
fractionation in polyacrylamide gels. This method is fast and easy to perform. SDS- 
PAGE is used to separate proteins in complex mixture mainly on the basis of MW
[392]. The method is based on the fact that most proteins bind similar amounts of 
SDS and thus have the same charge, but different size. Membrane proteins do not 
always bind the same amount of SDS as the soluble protein used as MW standards, 
thus making the MW an apparent one. Other applications of SDS-PAGE also include 
determination of the size of a protein component, the purity estimation of proteins in 
solution, the purification of a protein species for other procedures and the 
fractionation of a fraction mixture prior to immunoblotting.
5.2.3.1. Gel preparation
Fractionation of proteins according to MW was carried out on SDS-PAGE 
gels containing acrylamiderbisacrylamide (30%, v/v), SDS-PAGE resolving buffer, 
ammonium persulphate (10%, v/v made fresh) and TEMED (0.06%, v/v).
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Reagents were mixed by gentle stirring to avoid the formation of bubbles and 
loaded directly into a gel caster (Bio-Rad, U.K.). The resolving gel was overlaid with 
75% ethanol and gel polymerisation occurred in about 30 minutes. Excess ethanol 
was then removed and the top of the gel was washed with distilled water. The 
stacking gel, containing acrylamide (30%, v/v), SDS-PAGE stacking buffer (25%, 
v/v), ammonium persulphate (10%, v/v), TEMED (0.28%, v/v) and distilled water to 
the appropriate final volume, was then applied and the sample-well comb inserted. 
The stacking gel was allowed to polymerise and, after removal of the comb, the wells 
were washed several times with running buffer.
5.2.3.2. Gel loading
Approximately equal amounts of total protein were loaded into each well of 
the gel. Protein marker (ladder) was loaded in parallel to help determine the apparent 
MW of the sample proteins. Electrophoresis was carried out at 100V at room 
temperature until the dye front (bromophenol blue) entered the running buffer.
5.2.4. Treatment of mice with PC61
The monoclonal anti-CD25 antibody PC61 was isolated and purified as 
described above. ApoE" ' mice 6 to 8 weeks old were put on an 8 week treatment with 
PC61 for depletion protocol with high fat diet (HFD). Throughout the course of the 
experiment, mice were treated with 200pg of purified PC61 every 10 days to ensure 
functional inactivity of CD25+ Treg cells, following protocols previously published
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[387]. The treatment protocol followed was designed to evaluate the effect of Treg 
cells in the development of atherosclerosis (Figure 5.1). There were four groups of 
treated animals. Animals treated with PC61 on a normal diet and HFD, as well as 
non-treated animals on a normal diet and non-treated animals on HFD which were 
used as controls. Plasma was collected to measure levels of IL-4, IL-10 and IFN-y by 
ELISA as described in Chapter 2, Section 2.2.6. Upon termination, splenocytes were 
obtained and labelled with CD4, CDS, CD25, FoxP3 and CD 127 for Flow Cytometry 
analysis, as described in Chapter 2, Section 2.2.5.
Day 0 Day 10 Day 20 Day 30 Day 40 Day 50 Day 60
Figure 5.1. Regulatory T cell treatment protocol followed. PC61 treated animals were 
treated every 10 days to ensure functional inactivity of CD25+ regulatory T cells. On day 60, 
ApoE"7" mice, from all four groups, were euthanized and blood was collected from the aorta. 
The spleen and the heart of each animal were also collected for further analysis.
•  Bleed
•  Immunise
• Termination
•  Collect plasma
• Collect spleen
•  Collect heart
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5.2.5. Cytokine profile analysis
Plasma samples were tested by ELISA for cytokine levels of IL-4, IL-10 and 
IFN-y using a commercial kit from PeproTech Inc. and following the manufacturer’s 
protocol was followed, as previously described in Chapter 2, Section 2.2.6. Samples 
were diluted at a ratio of 1:50 in diluent (0.05% Tween-20, 0.1% BSA in PBS) and 
lOOpl of sample were added to each well in duplicate and incubated overnight at 4°C. 
A detection antibody was added to each well and incubated at room temperature for 
30 minutes. 3,3 ’,5,5’-tetramethylbenzidine dihydrochloride Substrate solution was 
added per well and incubated at RT for colour development. The reaction was stopped 
by adding 50pl of 2M H2SO4 and the colour development was monitored with an 
ELISA plate reader at a wavelength of 405nm.
5.2.6. Lipid profile analysis
Plasma obtained from the ApoE'7' mice upon termination was used to assess 
the levels of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides 
using an automated clinical chemistry analyzer, the ILab 650 (Instrumentation 
Laboratory, U.K.), which uses photometry for in vitro quantification of analytes in 
biological fluids.
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5.2.6.1 Quantification of Total Cholesterol levels
Cholesterol in all lipoprotein sub-classes is measured in order to assess the 
cholesterol levels in the plasma. Total cholesterol measurements alone are not 
classified as an accurate predictor of the CVD risk as it includes both HDL and LDL 
measurements. Hence, it can be used for initial screening, but a complete lipid profile 
is required to assess the risk of CVD [393].
Plasma samples were prepared in a dilution of 1:4 in saline solution (total 
volume of 80pl per sample) for analysis by the ILab 650 (Instrumentation Laboratory, 
U.K.) as recommended by the IL Test™ Cholesterol (IL Test™ Kit configuration: 
P/N 0018250540). The principle of the test is demonstrated in Figure 5.2. The results 
are displayed in mmol/L.
IL Test™ Cholesterol Principle
Cholesterol Esterase
Cholesterol ester + H2O ------------------------ ► Cholesterol + Fatty Acids
Cholesterol Oxidase
Cholesterol ester + O2 ------------------------ ► Cholest-4-en-3-one + H2O2
Peroxidase
2H2O2 + 4-aminoantipyrine + phenol — ► Quinoneimine + 4H20
Figure 5.2. Total cholesterol quantification principle. The end point analysis is based on 
the above reactions. Quinoneimine production is proportional to the cholesterol concentration 
in the plasma sample. The absorbance measurements were taken at a primary wavelength 
and a blanking wavelength of 510/700nm [394].
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S.2.6.2. Quantification of Triglycerides levels
Consisting of fatty acids linked to a glycerol backbone, triglycerides are the 
main component of animal fats and vegetable oils. Elevated levels of triglycerides are 
linked with the increased atherogenicity of HDL and LDL. Triglyceride levels are 
said to be raised after a meal and high levels can affect the accuracy of HDL and LDL 
measurements [393]. Plasma samples were prepared in a dilution of 1:4 in saline 
solution (total volume of 80pl per sample) for analysis by the ILab 650 
(Instrumentation Laboratory, U.K.) as recommended by the IL Test™ Triglycerides 
(IL Test™ Kit configuration: P/N 0018255640). The principle of the test is 
demonstrated in Figure 5.3 below. The results are displayed in mmol/L.
IL Test™ Triglycerides Principle
Lipoprotein Lipase
Triglycerides  ► Glycerol + Fatty Acids
Glycerol Kinase
Glycerol + ATP ------------------------ ► Glycerol-3-phosphate + ADR
Glvcerol-3-DhosDhate Glyc°ro'’hosphate Dihydroxyacetone phosphate
+ &   k +H 20 2
H20 2 + 4-chlorolphenol Peroxidase .............................................
+ 4-aminoantiprytine ------------------- ► Quinoneimine dye + H2Q2
Figure 5.3. Triglyceride quantification principle. The end point analysis is based on the 
above reactions. The concentration of quinoneimine generated in the reaction is proportional 
to the concentration of triglycerides in the sample. The absorbance measurements were 
taken at a reading and a blanking wavelength of 510/700nm [395].
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S.2.6.3. Quantification of HDL levels
HDL is classified as a negative risk for CVD. It transports cholesterol from the 
tissues to the liver for removal from the body and it is therefore described as ‘good 
cholesterol’ [393]. Plasma samples were prepared in a dilution of 1:4 in saline 
solution (total volume of 80pl per sample) for analysis by the ILab 650 
(Instrumentation Laboratory, U.K.) as recommended by the RANDOX direct HDL 
cholesterol kit, a liquid-ready-to-use two-point kinetic assay (RANDOX, Cat. No. CH 
2652 and CH 2655).
In the case of HDL, a clearance method is used for detecting its plasma levels. 
This is due to samples containing abnormal lipoproteins, for example patients with 
elevated triglycerides or liver damage, demonstrating reduced specificity and 
accuracy [393]. Issues caused by these abnormal lipoproteins are overcame by the use 
of the Randox clearance method. In the clearance step, non-HDL lipoproteins are 
removed from the samples with abnormal lipoproteins, hence enhancing the 
specificity of the assay at the detection step (Figure 5.4) [393].
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Clearance Step
Cholesterol Esterase Catalase
c M- LDL- v L DL = = r wa t e r + o x y g e n
Assay Step
HDL ■Ch°'eSler0' ESteraSe> H Cholestenone Colour Development
^   ^ + Hydrogen Peroxide
Cholesterol Oxidase
Figure 5.4. HDL cholesterol quantification reaction principle. A Randox two-step 
clearance method is used to overcome issues of un-specificity and inaccuracy due to 
abnormal lipoproteins in the plasma. The removal of non-HDL lipoproteins enhances the 
specificity of the assay at the detection step [393].
5.2.6.4. Quantification of LDL levels
LDL transports cholesterol to the tissues and is highly associated with the 
development of atherosclerosis. It is therefore described as the ‘bad cholesterol’. Part 
of CVD therapy is to lower the levels of LDL, hence accurate measurements of LDL 
are used for the establishment of CVD risk and are an indication of the CVD therapy 
progress [393]. Here, an estimate of LDL was obtained, by subtracting the HDL 
measurement from the TC measurement of each sample. The values obtained are in 
mmol/L.
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5.2.7. Analysis of atherosclerotic plaques and plaque vulnerability
The proximal 150 pm of the aortic sinus were sectioned into 10 pm sections. 
The following total plaque area was measured in the sections [396, 397].
5.2.7.1. Formalin-fixed, wax-embedded sections stained with Haematoxylin and 
Eosin
The tissue was immersed in fixative (10% neutral phosphate buffered 
formalin) for a minimum of one week before being processed.
5.2.7.2. Tissue selection and preparation for processing
Tissue sections of 2-3 mm in thickness were selected for each sample and any 
rough-cut surface was trimmed off. One or more pieces of tissue were placed in a 
plastic cassette and the metal lid was attached. A mesh insert and a finer mesh lid was 
used to prevent very small pieces of tissue from being washed out through the holes in 
the cassette. The cassette was placed in the basket in the formaldehyde solution.
5.2.7.2.I. Dehydration, clearing and impregnation with wax using Histokinette, a 
Tissue Processor
The automatic tissue processor, Histokinette, British American Co. Ltd., 
Slough) was loaded with the processing reagents and the basket of cassettes was
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attached to it. The Histokinette timer was set to process the tissue according to the 
following schedule:
Dehydration 70% alcohol 2 hours
85% alcohol 2 hours
95% alcohol 2 hours
100% alcohol I 2 hours
100% alcohol II 2 hours
100% alcohol III 2 hours
Clearing Toluene I 2 hours
Toluene II 2 hours
Impregnation Paraffin wax I 2 hours
Paraffin wax II 2 hours
The alcohol solutions were prepared from Ethanol 96, whilst Absolute Alcohol was 
used for the 100% alcohol. The wax used was Fibrowax, BDH Ltd with a melting 
point of 56°C. The wax baths was set at approximately 60°C. The wax reservoir on 
the wax embedding station was switched on to melt the wax overnight.
5.2.7.2.2. ‘Blocking out’ of the tissue to form wax blocks
The basket with the cassettes was removed from the Histokinette carefully to 
avoid wax dripping. The cassettes were slid out of the basket and into the molten wax
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in the wax bath to the embedding station, with the cold plates switched on. The 
cassettes were then removed from the wax bath and the lid was removed carefully to 
prevent any adherence of the tissue to the lid. Some molten wax was dispensed into a 
suitable size of metal base mould and then placed on the hot plate. Using the heated 
forceps, all the tissue pieces were quickly transferred from the cassette into the molten 
wax in the mould. The tissue was appropriately oriented so that the surface to be cut 
was resting on the base of the mould, leaving some space around the circumference of 
the mould. The mould was placed onto the cold plate so as to harden the wax at the 
bottom sufficiently for the tissue to be held in place. The plastic cassette was quickly 
placed onto the mould, topped up with molten wax and placed back onto the cold 
plate to solidify. Once the wax was cold, the blocks were removed from the moulds. 
A solid scalpel was used to scrape any excess wax from the edges of the block, in 
order to enable the block to fit into the holder of the microtome.
S.2.7.2.3. Section cutting using a Microtome
Excess wax was removed from the edges of the wax block and the wax block 
was attached into the block holder on the Microtome 2040 Autocut (Cambridge 
Instrument Co., Inc., New York). The angle of the block in the holder was adjusted as 
necessary so that it was correctly lined up in relation to the blade holder. The section 
thickness was set around 15 pm and using the ‘rough’ blade, excess wax was trimmed 
off until the required portion of tissue was reached. A soft paintbrush was used to 
remove the waste wax sections from the knife. Once the block was trimmed to a 
suitable depth, it was removed and placed face down into a tray of iced water for a 
minimum of 10 minutes (but not more than 30 minutes), in preparation for obtaining
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the final section. This will allow the sections to remain firmer and obtained easier 
from a cold block with the eater helping to maintain an intact section.
In order to cut the tissue sections, the section thickness was changed to 5 pm. 
The chilled block was removed from the iced water and gently blotted with a paper 
towel to dry the surface. The block was then placed in the block holder and adjusted 
to an angle so that very little further trimming is required. The blade was replaced 
with a new one and sections were produced. Fine forceps were used to lift the 
sections, which were then floated onto warm distilled water in the water bath pre­
heated at 40 to 50°C. The sections were then placed onto slides by half submerging 
the slide in the water, positioning it near the sections and withdrawing it so as the 
flatten sections to be brought with it. The slides were placed, section side uppermost, 
onto the slide-drying hot plate and the sections were left for a minimum of 1 to 2 
hours to dry enough to stain.
S.2.7.2.4. Staining with Haematoxylin and Eosin
Haematoxylin reacts and binds to acidic groups, the basophilic components of 
the cell, found in nucleic acids. In acid solution, Haematoxylin has a red colour, 
which when rendered alkaline (in tap water) it turns blue becoming permanently fixed 
to tissues. This is a regressive staining method in which sections are over-stained and 
the stain is then selectively removed in acid alcohol. On the other hand, Eosin is 
manly used as a background stain. It concentrates mainly in the cytoplasm and other 
non-nuclear components referred to as ‘eosinophilic’ or ‘acidophilic’.
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Section slides were placed on a rack and the following staining procedure was 
followed:
• De-wax in xylene 3 min
• Transfer to 100% alcohol 1 min
• Rehydrate in 70% alcohol 1 min
• Rehydrate in 50% alcohol 1 min
• Rehydrate in distilled water 1 min
• Stain in haematoxylin 15 min
• Rinse in running tap water 1 min
• Differentiate in 1% acid alcohol 5-10 sec
• 'Blue' in running tap water 10 min
• Stain in 1% eosin 2 min
• Rinse briefly in tap water to wash away excess stain.
• Dehydrate in 85% alcohol 0.5 min
• Dehydrate in 100% alcohol twice 0.5 min
• Clear in xylene twice 0.5 min
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5.2.8. Morphometric Analysis
5.2.8.1. Photography
For the morphometric analysis, a Leica microscope, connected to a Leica 
camera and the corresponding software to capture the image, was used. All images 
were taken at the same number of pixels (764 width x 574 height) and the same 
objective (lOx) was used for all the pictures.
5.2.8.2. Image analysis
A free software of the Wayne Rasband National Institutes of Health, USA 
Version 1.36b available from http://rsb.info.nih.gov/ii/ was used for the analysis of 
the images. Image! is a Java image program and it was used to measure the area of the 
atherosclerotic plaques in ApoE-/- mice [398, 399].
5.2.8.2.1. Calibration of the image
A measuring calibration graticle was used to set up the scale, as shown in 
Figure 5.5, overleaf.
5.2.8.2.2. Measuring procedure
To measure, the plaque area was marked using a pencil tool. The plaque area 
was selected and the plaque area value was displayed in a pop-up window. The total 
plaque area for each sample was then used to analyse the effect of the treatment.
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Figure 5.5. Calibration system for the Image J software using a calibrated graticule in 
the Leica capture image system. To set the calibration, the following steps were followed: 
A) Using a 100 microns graticule, a photo was taken at the same magnification as the 
intended for the slides, B) using the command “line”, a line of the same size as the scale in 
the graticule was drawn, C) in the menu bar, options ‘Analyse’ and ‘Set Scale’ were selected, 
D) the ‘known distance’ was set to 100 and the ‘unit of length’ was set to microns.
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5.3. Results
5.3.1. Purification and quantification of PC61
PC61 was isolated and purified from a B lymphocyte hybridoma, as described 
above and its concentration was measured using the Micro BCA™ Protein Assay 
Reagent kit. A 10% SDS-PAGE was run to identify this monoclonal antibody based 
on its molecular weight (MW = 55KDa) (Figure 5.6). Kaleidoscope pre-stained 
standards (Bio-Rad, U.K., Cat. No. 161-0324, Control 310002857), BSA (lOOpg, 
MW = 66.4KDa) and the purified monoclonal (lOOpg total protein concentration) 
were run on the gel. The kaleidoscope pre-stained standards and BSA were used as 
reference in order to identify PC61 depending on its molecular weight and band 
position on the gel. The concentration of PC61 was adjusted to 200pg before being 
adoptively transferred to ApoE' " mice in order to investigate the effect of CD25 
depletion in atherosclerosis.
199,743 Da
112,281 Da
60, 568 Da
30, 635 Da
24, 830 Da
12, 359 Da 
6, 426 Da
Figure 5.6. Purification of PC61. The monoclonal antibody PC61 was run on a 10% SDS- 
PAGE gel and identified based on its molecular weight (MW = 55KDa). Kaleidoscope pre- 
stained standards (a) and BSA (d) were used for reference. PC61 was then used for the 
depletion of CD4+CD25+ and CD8+CD25+ T reg cells.
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5.3.2. Short-term treatment with PC61 depleted mice of CD4 CD25 and 
CD8 CD25+ Treg cells
ApoEv" mice were treated with 200pg of purified PC61 and analysed after 72 
hours and 10 days in order to test the short term effect of PC61 on CD4+CD25+ and 
CD8+CD25+ cells. As a control, an untreated ApoE" " mouse was also analysed for the 
percentage of CD4 CD25 and CDS CD25 cells. Compared to the negative control, 
the percentage of CD4+CD25+ cells was decreased after 72 hours and continued to be 
lower even after 10 days of treatment with 200pg of purified PC61 (Figure 5.7). In the 
case of CD8+CD25+, the percentage of cells was decresed after 72 hours of treatment, 
but returned to the original level by day 10 (Figure 5.7). The flow cytometry graphs 
are shown in Figure 5.8.
C D 4 C D 2 5 C D 8+C D 25
Naïve 72 hrs 10 days Naïve 72 hrs 10 days
Figure 5.7. Effect of PC61 on CD4 CD25 and CD8+CD25+ cells. ApoE"7 mice were treated 
with 200pg of PC61. The percentage of CD4+CD25+ and CD8+CD25+ cells was analysed by 
flow cytometry after 72 hours and 10 days of treatment. Naïve, untreated cells were analysed 
as a negative control. Experiment was performed once (n=1).
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Figure 5.8. Flow cytometry plots for the analysis of the short term effect of PC61 on 
CD4+CD25+ and CD8+CD25+ cells. Representative examples for each of the treatments, 
including isotype and un-stained (-/-) controls. The percentage of CD4+CD25+ and 
CD8+CD25+ cells (number of cells in quadrant Q3) for each treatment period was used to 
assess the effect of the monoclonal antibody on the depletion of Treg cells in vivo.
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5.3.3. Long-term treatment with PC61 effectively depletes CD4+CD25+ and
CD8+CD25+ regulatory T cells inducing atherosclerosis in vivo
The effect of PC61 treatment on CD4+CD25+ and CD8+CD25+ regulatory T 
cells was assessed, with the results indicating that PC61 significantly affects the 
depletion and functional status of regulatory T cells in induced atherosclerosis. PC61 
treated ApoE'7' mice, both on normal and high fat diet, had significantly less 
CD4+CD25+FoxP3+ Treg cells when compared to the non-treated normal diet controls 
(*/? < 0.05) (Figure 5.9A). A significant decrease in the number of 
CD4+CD25+FoxP3+ regulatory T cells was also observed in mice treated with PC61 
and on a normal diet when compared to the high fat diet controls (*p < 0.05) (Figure 
5.9A). On the contrary, the number of CD4+CD25+CD127low regulatory T cells was 
significantly increased in PC61 treateded mice on a normal diet, compared to normal 
diet and high fat diet controls (**/? < 0.01; ***%? < 0.005) (Figure 5.9B).
The depletion of CD8+CD25+ regulatory T cells was significantly induced by 
PC61, as mice on a normal diet and on a high fat diet both demonstrated lower 
numbers of CD8+CD25+FoxP3+ regulatory T cells when compared to the normal diet 
controls (***/? < 0.005) (Figure 5.9(2). Significantly lower numbers were also 
observed when comparing mice on a normal and high fat diet (***£> < 0.005), as well 
as in PC61 treated mice on a high fat diet compared to PC61 treated mice on a normal 
diet (*p < 0.05) and to high fat diet controls (*p < 0.05) (Figure 5.9(2). Regarding 
CD8+CD25+CD127low regulatory T cells, a significant decrease was observed in mice 
treated with PC61 on a high fat diet compared to PC61 treated mice on a normal diet 
(***j9 < 0.005), as well as when compared to the normal diet {*p < 0.05) and high fat
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diet controls (***p < 0.005) (Figure 5.9D). Flow cytometry results are displayed in 
Figure 5.10 and Figure 5.11, for CD4+ and CD8+ Treg cells respectively.
A. CD4+CD25+FoxP3+
NORMAL DIET HFD NORMAL PC61 HFD PC61
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Figure 5.9. The effect of PC61 on Treg cells. Purified PC61 was used to treat ApoEmi ce .  
Upon termination, T lymphocytes from the spleen were labelled with anti-CD4, CD8, CD25, 
CD127 and FoxPS fluorescently-tagged antibodies. After gating for CD4+ and CD8+ 
populations, the percentage of CD25+FoxP3+ or CD25+CD127|0W cells was analysed using 
flow cytometry. Non-treated animals and on a normal diet were used as negative controls. 
The results are represented as mean ± SD and the asterisk indicates significant differences 
compared to animals of other groups (*p < 0.05, **p < 0.01, ***p < 0.005).
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Figure 5.10. Flow cytometry plots for the analysis of the role of Treg cells in 
atherosclerosis after their depletion with PC61 followed by apoB-100-derived peptide 
treatment. Representative examples for each of the treatments, including isotype and un­
stained (-/-) controls. The percentage of CD4+CD25+FoxP3+ and CD4+CD25+CD127" cells 
(number of cells in quadrant Q3 and Q4 respectively) for each treatment (A = Normal Diet, B 
= High Fat Diet, C = PC61 + Normal Diet and 0 = PC61 + High Fat Diet) was used to assess 
the effect of the depletion of T reg cells by PC61 followed by apoB-100-derived peptide 
treatment in the process of atheroclerosis in vivo.
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Figure 5.11. Flow cytometry plots for the analysis of the role of Treg cells in
atherosclerosis after their depletion with PC61 followed by apoB-100-derived peptide 
treatment. R e p r e s e n t a t i v e  e x a m p l e s  fo r  e a c h  of t h e  t r e a t m e n t s ,  inc lud ing  is o ty p e  a n d  u n ­
s t a in e d  (-/-) co n tro ls .  T h e  p e r c e n t a g e  o f  C D 8 +C D 2 5 +F o x P 3 + a n d  C D 8 +C D 2 5 +CD127~ c e l l s  fo r  
e a c h  t r e a t m e n t  w a s  u s e d  to  a s s e s s  t h e  e f f e c t  o f  t h e  d e p le t io n  o f  T reg ce l ls  by  P C 6 1  fo l lo w ed  
by  a p o B - 1 0 0 - d e r iv e d  p e p t id e  t r e a t m e n t  in th e  p r o c e s s  o f a th e r o c l e r o s i s  in vivo.
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5.3.4. Analysis of the effect of PC61 on the levels of IFN-y, IL-4 and IL-10 in
plasma samples of treated ApoE mice
The levels of IFN-y (Thl-associated cytokine), IL-4 and IL-10 (Th2- 
associated cytokines) in the plasma of the treated animals were measured using 
commercially available ELISA kits, in order to assess the pro- vs. anti-inflammatory 
cytokine pattern induced by PC61 treatment.
In the case of IFN-y, treatment with PC61 increased the plasma levels of the 
cytokine both on a normal diet as well as on a high fat diet when compared to the 
untreated normal diet control (**/? < 0.01), as well as compared to the untreated high 
fat diet control (***/? < 0.005) (Figure 5.12). When comparing the pre-treatment and 
termination serum levels of IFN-y, no significant changes were observed (Figure 
5.12).
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Figure 5.12. Effect of PC61 treatment on the IFN-y cytokine levels in plasma samples of 
treated ApoE'/- mice. IFN-y levels were observed in pg/ml and are represented graphically as 
mean ± SD (**p < 0.01, ***p < 0.005).
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Conversely, a significant decrease in the plasma levels of IL-10 was observed 
after PC61 treatment on a normal diet (*p < 0.05) compared to the pre-treatment 
plasma levels of the group, as well in the untreated controls both on normal diet and 
high fat diet (*/? < 0.05). IL-10 was also significantly decreased after PC61 treatment 
in mice on a high fat diet compared to the untreated high fat diet controls (*p < 0.05) 
(Figure 5.13).
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Figure 5.13. Effect of PC61 treatment on the IL-10 cytokine levels in plasma samples of 
treated ApoE^' mice. The levels of IL-10 from the plasma of the ApoE"A animals treated with 
PC61 were quantified using a commercially available ELISA kit. Levels of the cytokine were 
observed in pg/ml and are represented graphically as mean ± SD, with the asterisk indicating 
the significant differences compared to pre-immunised plasma levels and to each of the 
conditions (*p < 0.05).
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In addition, the plasma levels o f the anti-inflammatory cytokine IL-4 were 
significantly decreased within the groups. After the 8 weeks of induced 
atherosclerosis, the levels of IL-4 were significantly lowered in the plasma of mice 
treated with PC61 and on a high fat diet as well as in the mice on a normal diet and a 
high fat diet (*p < 0.05) (Figure 5.14). These results, in addition to the decrease in IL- 
10 levels, indicate a greater shift towards the Thl phenotype due to the depletion of 
regulatory T cells due to PC61.
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Figure 5.14. Effect of PC61 treatment on the IL-4 cytokine levels in plasma samples of 
treated ApoE 7' mice. The levels of IL-4 from the plasma of the ApoE'7' animals treated with 
PC61 were quantified using a commercially available ELISA kit. Levels of the cytokine were 
observed in pg/ml and are represented graphically as mean ± SD (*p < 0.05).
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5.3.5. Analysis of the effect of PC61 on the levels of Triglycerides, LDL, HDL and
Total Cholesterol in plasma samples of treated ApoE " mice
Lipid profile analysis was performed to observe any changes in the levels of 
Triglycerides, LDL, HDL and total cholesterol in the plasma of PC61 treated ApoE'7' 
mice as well as their controls. The levels were quantified with the use of ILab 650 
(Instrumentation Laboratory, U.K.).
5.3.5.I. PC61 treatment and HFD cause an increase in Triglyceride plasma levels
The levels of triglycerides in the plasma of the ApoE"7" animals treated with 
PC61, and their controls, were quantified using the ILab 650 (Instrumentation 
Laboratory, U.K.).
A significant increase in triglycerides in the plasma levels after PC61 
treatment in mice on a high fat diet (*/? < 0.05) was observed compared to the pre­
treatment plasma (Figure 5.15). An increasing trend in the triglycerides level can also 
be observed for the rest of the groups (Figure 5.15). This increase indicates a lipid 
profile prone to atherosclerosis.
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Figure 5.15. Effect of PC61 treatment on the Triglycerides levels in plasma samples of 
treated ApoE ' mice. T rig ly c e r id e s  le v e l s  w e r e  o b s e r v e d  in m m ol/L  a n d  a r e  r e p r e s e n t e d  
g ra p h ic a l ly  a s  m e a n  ± S D ,  with t h e  a s t e r i s k  ind ica t ing  t h e  s ig n if ic a n t  d i f f e r e n c e s  c o m p a r e d  to  
p r e - im m u n is e d  p l a s m a  lev e ls  a n d  to  e a c h  o f  t h e  c o n d i t io n s  (*p < 0 .0 5 ) .
5.3 5.2. PC61 treatment causes an increase in LDL plasma levels
Quantification of the LDL levels in the plasma of A p o E an im a ls  treated with 
PC61, as well as their controls, were calculated by subtracting the value for HDL 
from the Total Cholesterol value, as observed by the ILab 650 (Instrumentation 
Laboratory, U.K.).
A significant increase in LDL in the plasma levels of mice put on a high fat 
diet (*/> < 0.05), as well as after PC61 treatment in mice on a normal diet (***p < 
0.005) and on high fat diet (***p < 0.005) was observed compared to the pre­
treatment plasma (Figure 5.16). When compared to the normal diet control, a
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significant increase in the LDL level was observed for mice on a high fat diet, PC61 
treated mice on a normal diet and PC61 treatment mice on a high fat diet (***p < 
0.005, for all three conditions). A significant increase in the LDL plasma level was 
also observed in mice treated with PC61 and on a high fat diet compared to the 
untreated high fat diet controls (**£> < 0.01) (Figure 5.16).
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Figure 5.16. Effect of PC61 treatment on the LDL levels in plasma samples of treated 
ApoE"'" mice. LDL le v e l s  w e r e  o b s e r v e d  in m m o l/L  a n d  a r e  r e p r e s e n t e d  g ra p h ic a l ly  a s  m e a n  
± S D ,  with t h e  a s t e r i s k  ind ica t ing  t h e  s ig n if ican t  d i f f e r e n c e s  c o m p a r e d  to  p r e - t r e a t e d  p l a s m a  
lev e ls  a n d  to  e a c h  of t h e  c o n d i t io n s  (*p < 0 .0 5 ,  **p < 0 .0 1 ,  ***p < 0 .0 0 5 ) .
197
S.3.5.3. PC61 treatm ent causes an increase in HDL plasma levels
HDL levels in the plasma of the ApoEv" animals treated with PC61 and their 
controls were quantified using the ILab 650 (Instrumentation Laboratory, U.K.).
A significant increase in HDL in the plasma levels after PC61 treatment in 
mice on a normal diet (*j9 < 0.05) and on high fat diet (***p < 0.005) was observed 
compared to the pre-treatment plasma (Ligure 5.17). When compared to the normal 
diet control, a significant increase in the HDL level was observed for mice on a high 
fat diet (**/? < 0.01), PC61 treated mice on a normal diet (*p < 0.05) and PC61 treated 
mice on a high fat diet (**/? < 0.01) (Ligure 5.17).
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Figure 5.17. Effect of PC61 treatment on the HDL levels in plasma samples of treated 
ApoE ' mice. HDL levels were observed in mmol/L and are represented graphically as mean 
± SD, with the asterisk indicating the significant differences compared to pre-treated plasma 
levels and to each of the conditions (*p < 0.05, **p < 0.01, ***p < 0.005).
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S.3.5.4. PC61 treatment and HFD cause an increase of total cholesterol levels in 
plasma
A significant increase in total cholesterol levels in the plasma of mice after 
PC61 treatment in mice on a normal diet (***^> < 0.005) and on high fat diet (***p < 
0.005) was observed compared to the pre-treated plasma (Figure 5.18). When 
compared to the normal diet control, a significant increase in the total cholesterol 
levels was observed for mice on a high fat diet, PC61 treated mice on a normal diet 
and PC61 treated mice on a high fat diet (***p < 0.005 for all three conditions) 
(Figure 5.18).
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Figure 5.18. Effect of PC61 treatment on the total cholesterol levels in plasma samples 
of treated ApoE'7' mice. Total cholesterol levels were observed in mmol/L and are 
represented graphically as mean ± SD, with the asterisk indicating the significant differences 
compared to pre-treated plasma levels and to each of the conditions (***p ^ 0.005).
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5.3.6. PC61 treatment enhances the formation of atherosclerotic plaques in the 
aortic sinus of ApoE mice
The lOjum sections of the aortic sinus from ApoE" " mice treated with PC61 
were analysed for atherosclerotic plaques using the Imaged Java image processing 
program. The area of plaques was measured and the results are shown in Figure 5.20. 
Images of the sections are also displayed below, Figure 5.19.
a. b.
Figure 5.19. Cross-sections of the aortic sinus of mice demonstrate that PC61 
treatment and HFD enhance the formation of atherosclerotic plaques. lOprn aortic sinus 
sections from ApoE'7' mice treated as follows: a. Normal Diet, b. HFD, c. PC61 treatment on a 
Normal Diet and c. PC61 treatment on a HFD. Images were taken at the same number of 
pixels (764 width x 574 height) and the same objective (10x) was used for all the pictures.
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Figure 5.20. PC61 treatment and HFD enhance the formation of an atherosclerotic 
plaque. Using the Imaged Java image processing program, the total plaque area (pm2) at the 
aortic sinus of treated animals was estimated. Results are represented graphically as mean ± 
SD (**p < 0.01 and ***p < 0.005). A minimum of n = 3 mice were analysed per group and the 
measurements were based on 3 consecutive sections of the aortic sinus of each mouse.
A significant increase in total plaque area in the aortic sinus of mice was 
observed when the ApoE'7' mice were on a high fat diet (**p < 0.01), when treated 
with PC61 (**p < 0.01) and when treated with PC61 and put on a high fat diet (***p 
< 0.005), compared to the untreated normal diet controls (Figure 5.20). When 
comparing the plaque area of PC61 treated mice on a normal diet to the plaque are of 
PC61 treated mice on a high fat diet, a significant increase was also observed (**p < 
0.01), indicating the further effect on atherosclerotic plaque formation after PC61 
depletion of Treg cells (Figure 5.20).
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5.4. Discussion
ApoE'7" mice generated by gene targeting [400, 401] have elevated plasma 
cholesterol and triglycerides and reduced high-density lipoprotein [402] and develop 
atherosclerotic lesions similar to those present in human, even when fed a normal 
chow diet [403]. Apolipoprotein E is one of the protein components of all 
lipoproteins, except low density lipoprotein in humans, and it serves as a ligand for 
the clearance of lipids from the plasma [403] and very low density lipoproteins [400], 
acting via a receptor-mediated pathway in the liver [403]. In addition, diets high in 
cholesterol and saturated fatty acids significantly elevate the levels of plasma 
cholesterol [403] and hence accelerate the risk of atherosclerosis. After long periods 
of feeding with a high fat diet mice are expected to develop arterial lesions [402]. In 
advanced lesions, mixed plaques were shown to contain smooth muscle and lipid- 
filled cells, necrotic debris, extracellular cholesterol deposits and calcification [402].
After its isolation and its purification, PC61, a monoclonal anti-CD25 
antibody, based on its molecular weight (55 KDa), was used to treat ApoE'7" mice, 6-8 
weeks old, in order to investigate the role of regulatory T cells in atherosclerosis. 
Based on the findings that PC61 depletes the CD25+FoxP3+ population of cells [360, 
381, 386] and on the results of the short term effects of PC61 on regulatory T cells in 
vivo (Figure 5.8), the monoclonal anti-CD25 antibody was used to deplete the 
population of regulatory T cells in ApoE"7" mice, which were put on normal or high fat 
diet and compared to untreated animals in order to investigate the role of regulatory T 
cells in the process of atherosclerosis and atherosclerotic plaque development. Such 
depletion was assessed in the concept of atherosclerosis by the use of ApoE'7' mice
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which were fed with a high fat diet (HFD). High fat diet induces inflammation and 
decreases regulatory T cells. This effect of high fat diet and based on the findings that 
PC61 also decreases the number and functionality of regulatory T cells, the role of 
this subtype of T cells will be assessed in an environment which is prone to 
atherosclerosis.
After PC61 treatment and after inducing an environment prone to 
atherosclerosis, the numbers of regulatory T cells in the spleen were assessed by flow 
cytometry analysis. PC61 significantly affects the depletion and functional status of 
CD4+CD25+ and CD8+CD25+ regulatory T cells in induced atherosclerosis. 
Significantly less CD4+CD25+FoxP3+ regulatory T cells were observed in PC61 
treated ApoE"7" mice, both on normal and high fat diets, when compared to the 
untreated normal diet controls (*/? < 0.05). CD4+CD25+FoxP3+ regulatory T cell 
numbers were also significantly decreased in mice treated with PC61 and on a normal 
diet when compared to the high fat diet controls (*p < 0.05). In contrast, 
CD4+CD25+CD127low regulatory T cell numbers were significantly increased in PC61 
treated mice on a normal diet, compared to normal diet and high fat diet controls (**p 
< 0.01 and < 0.005 respectively) (Figure 5.9). PC61 also induced the depletion 
of CD8+CD25+ regulatory T cells. PC61 treated ApoE"7' mice on a normal diet and on 
a high fat diet both demonstrated significantly lower numbers of CD8+CD25+FoxP3+ 
regulatory T cells, compared to the untreated normal diet controls (***/> < 0.005). 
Mice on a normal and high fat diet (***£>< 0.005), as well as in PC61 treated mice on 
a high fat diet compared to PC61 treated mice on a normal diet (*/? < 0.05) and to 
high fat diet controls (*jo < 0.05) also demonstrated significantly lower regulatory T 
cell numbers. In the case of CD8+CD25+CD127low regulatory T cells, mice treated
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with PC61 on a high fat diet had a significantly decreased population of regulatory T 
cells compared to PC61 treated mice on a normal diet (***p < 0.005), as well as when 
compared to the normal diet (*/> < 0.05) and high fat diet controls (***p < 0.005) 
(Figure 5.9). The results indicate that PC61 is capable of depleting the CD4+CD25+ 
and CD8+CD25+ population of regulatory T cells, when compared to the untreated 
controls both on normal and high fat diets (Figure 5.9).
The cytokine milieu was as well affected after PC61 treatment, also depending 
on the diet of the ApoE'7' mice. The pro-inflammatory cytokine IFN-y was increased 
after the 8 week treatment protocol amongst all groups and significantly for PC61 
treated animals on both normal and high fat diets compared to both normal (**p < 
0.01) and high fat diet controls (***p < 0.005) (Figure 5.11). On the contrary, both 
anti-atherogenic Th2-related cytokines, IL-4 and IL-10, were significantly decreased 
after the 8 weeks of induced atherosclerosis. IL-10 cytokine levels were decreased 
amongst groups when comparing pre-treatment plasma with post-termination plasma. 
After 8 weeks of induced atherosclerosis IL-10 levels were lower in mice on a normal 
and high fat diet, as well as in PC61 treated mice on a normal diet (*/> < 0.05). 
Cytokine levels were also decreased in PC61 treated mice on a high fat diet, although 
the decrease was not significant (Figure 5.12). These results, with increased IFN-y 
and decreased IL-4 and IL-10 levels, indicate a shift towards the pro-atherogenic Thl 
phenotype due to the depletion of CD25+FoxP3+ cells by PC61.
Increased levels of total cholesterol, triglycerides and LDL in combination 
with decreased levels of HDL are the characteristics of an atherogenic lipid profile. 
An increasing trend in the level of triglycerides was observed amongst the groups
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with the PC61 treated mice on a high fat diet being significantly increased in post­
termination plasma (*p < 0.05). The triglyceride level in post-termination plasma of 
mice on a high fat diet was significantly higher than that of PC61 treated mice on a 
normal diet (*/? < 0.05) (Figure 5.15). The levels of LDL were significantly increased 
amongst the groups of high fat diet (* p  < 0.05), as well as PC61 treated mice on 
normal < 0.005) and high fat diet (***p < 0.005) when comparing pre­
treatment and post-termination plasma. A significant increase in the levels of LDL 
was also observed when post-termination plasma levels of PC61 treated animals on a 
normal diet (***p < 0.005) as well as high fat diet (***/> < 0.005) were compared to 
normal diet controls. A significant increase was also observed when the normal diet 
control level was compared to the high fat diet control level after termination (***p < 
0.005). The LDL level observed in mice on a high fat diet was also significantly 
higher than PC61 treated mice on a high fat diet (**p < 0.01), indicating the 
effectiveness of high fat diet on a high lipid profile (Figure 5.16). Total cholesterol 
levels in the plasma of mice after PC61 treatment was significantly increased in mice 
on a normal diet (***p < 0.005) and on high fat diet (***p < 0.005) was observed 
compared to the pre-treatment plasma. A significant increase in the total cholesterol 
levels was also observed for mice on a high fat diet, PC61 treated mice on a normal 
diet and PC61 treated mice on a high fat diet (***p < 0.005) when compared to the 
normal diet control (Figure 5.18).
PC61 treatment significantly increased the HDL plasma levels in mice on a 
normal diet (*p < 0.05) and on high fat diet (***p < 0.005) compared to the pre­
treatment plasma. A significant increase in the HDL level was observed for mice on a 
high fat diet (**p < 0.01), PC61 treated mice on a normal diet (*p < 0.05) and PC61
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treated mice on a high fat diet (**p < 0.01) when compared to the normal diet control 
(Figure 5.17). HDL levels were not decreased as expected in an atherogenic lipid 
profile. This may be due to HDL levels being much higher in mice than in the normal 
levels observed in humans. This is one of the reasons ApoE'7' mice are widely used as 
a model for atherosclerosis, as the mutation, on average, overwrites this phenomenon 
and results in moderate HDL levels. Hence, instead of a decrease in HDL levels, a 
small increase is observed in the study.
The increased total cholesterol levels results come to verify the results for 
increased triglycerides and LDL levels and further indicate the role of PC61 and high 
fat diet towards an atherogenic lipid profile. These results also demonstrate the role of 
PC61 and high fat diet towards an atherogenic lipid profile.
The proximal 150 pm of the aortic sinus were sectioned into 10 pm sections 
and the total plaque area was measured in the sections, in order to investigate the 
effect of PC61 treatment as well as the effect of a high fat diet on the atherosclerotic 
plaque formation in ApoE'7' mice. A significant increase in total plaque area in the 
aortic sinus of ApoE'7" mice was observed in mice on a high fat diet, in mice treated 
with PC61 (**p < 0.01), as well as in mice treated with PC61 (**/? < 0.01) and put on 
a high fat diet (***p < 0.005), when compared to the untreated normal diet controls 
(Figure 5.20). The plaque area of PC61 treated mice on a normal diet to the plaque 
area of PC61 treated mice on a high fat diet, was also significantly different with the 
combination of PC61 and HFD causing the formation of a larger atherosclerotic 
plaque (**p < 0.01) (Figure 5.20). This can also be indicated as an increase of plaque 
area at the level of 135% for mice on a HFD, 75% for mice treated with PC61 and
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176.9% for mice treated with PC61 and put on a HFD. In the case of mice treated 
with PC61 on a HFD, there was an increase of 17.6% in plaque area compared to 
mice treated with PC61 on a normal diet. These results come to add on the previous 
findings that after depletion of regulatory T cells by PC61 treatment and the 
introduction of a high fat diet, a pro-atherogenic environment is created, which also 
results in the formation of larger atherosclerotic plaques. PC61 treatment, as well as 
the high fat diet, indicates the importance of regulatory T cells and their protective 
role in the prevention of atherosclerosis.
In this study it was demonstrated that PC61 has the capability of depleting and 
affecting the functional status of regulatory T cells and in combination with induced 
atherosclerosis, based on HFD as well as the tendency of ApoE'7' mice in developing 
atherosclerosis after 6 to 8 weeks, an environment which is prone to atherosclerosis in 
terms of a cellular as well as a cytokine and lipid profile level is provoked. It is 
observed that PC61 and HFD reduce the number of CD4+CD25+ and CD8+CD25+ 
regulatory T cells at the same time that the levels of anti-atherogenic Th2 cytokines 
IL-4 and IL-10 are reduced and the level of the pro-atherogenic Thl IFN-y cytokine is 
increased. It can be concluded that perhaps due to the depletion of regulatory T cells, 
there is no longer a balance between Thl and Th2, but instead a shift towards the Thl 
phenotype is observed. This shift towards an atherogenic phenotype is further 
documented by the changes in the lipid profile of the post-termination plasma samples 
of the ApoE'7* mice. Other than the increased HDL which is due to mice normaly 
having high levels of HDL, a typical athero-prone lipid profile is observed. Total 
cholesterol levels are increased in post-termination plasma, containing higher levels 
of triglycerides and LDL. Hence, it can be concluded that immunisation with PC61
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not only depletes or functionally inactivates the regulatory T cell population, but it 
can also be used to induce atherosclerosis in ApoE'7' mice, as it disturbs the Thl vs. 
Th2 balance, causing a shift towards the atherogenic Thl phenotype and furthermore 
results in a lipid profile which is prone to atherosclerosis development. This was also 
verified by the plaque sizes observed in the aortic sinuses of the treated ApoE'7', 
which demonstrated that the absence of regulatory T cells also enhances the formation 
of atherosclerotic plaques.
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CHAPTER 6.
STUDY OF IMMUNE RESPONSES AGAISNT APOB-IOO- 
DERIVED PEPTIDES IN CARDIOVASCULAR PATIENTS AND 
ITS ASSOCIATION WITH ETHNICITY AND DIABETES
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6.1. Introduction
6.1.1. Socioeconomic and racial influences on cardiovascular disease
Social status, typically income and formal education, is thought to influence 
the development of cardiovascular disease, in the same manner as blood pressure, 
cholesterol or smoking. This observation adds to the concept of public health that 
wants health outcomes to be ordered by social position [404]. In addition to the social 
status, an enormous attention in literature has been devoted to the role of ethnicity and 
race, a concept that depends on genetic and biological attributes, as well as social 
status and cultural practices [405-407]. Changes in lifestyle, such as urban migration 
and ‘Westernisation’, can also partly explain the acceleration of metabolic and 
vascular dysfunction in certain ethnic groups [408].
6.1.2. Atherosclerosis and Cardiovascular disease prevalence in Trinidad and 
Tobago, West Indies
Cardiac, mainly CHD, and cerebrovascular diseases are the main causes of 
death in adults over 44 years of age in the population of Trinidad and Tobago [409, 
410], with the disease being particularly common amongst men of Indian descent 
[409, 411]. Recent socioeconomic development in Trinidad and Tobago, with the 
gross national product and central government revenue increasing more than eightfold 
and twelvefold respectively, improved living and health standards, with infant 
mortality per 1000 live births declined from 39.8 in 1969 to 21.0 in 1977, and the
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expectation of life for men aged 20 to 25 years increased from 41 to 48 years between 
1946 and 1970 [411,412].
Trinidad and Tobago is the second largest of English-speaking Caribbean 
countries with population 1,229,953 in 2009 (July estimate) of whom approximately 
37.5% are of African descent, 40% of Indian sub-continent descent with the 
remaining 22.5% being mainly of mixed ethnicity [413].
Cancer, cerebrovascular disease, ischaemic heart disease and diabetes mellitus 
are the leading causes of death in the Caribbean [414]. The epidemiology of 
hypertension has been extensively studied in the Caribbean region due to its 
commonness in black populations of West African origin [415], and because of the 
exceptionally high rates of cerebrovascular mortality observed in the Caribbean [416] 
and in populations of a Caribbean origin [417]. Ischaemic heart disease is also 
important among people of Indian subcontinent descent living in the Caribbean [418]. 
Diabetes mellitus and hypertension have been associated with each other as important 
precursors of adult atherosclerotic vascular disease [419]. Some believe that this 
association is based on insulin-resistance [420] and others that this may be due to 
impaired nutrition and growth in early life [421].
Different studies have shown that the life expectancy amongst blacks is 
shorter and the mortality from cardiovascular disease is higher when compared to 
whites [422]. The rate of mortality from cardiovascular disease (CVD) varies 
substantially among blacks also based in their place of birth [422].
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The prevalence of coronary heart disease (CHD) in Trinidad has been studied 
throughout the years. It has been demonstrated that Indians have significantly lower 
HDL cholesterol concentrations, significantly higher LDL cholesterol concentrations 
[423] and higher triglyceride levels [424] than other ethnic groups. A survey 
undertaken in Trinidad demonstrated that death from CVD was significantly higher in 
individuals of an Indian origin than those of a Mixed descent, with those being 
accounted for by a high prevalence of diabetes in Indians [425]. Miller et ah later 
performed a study at St. James in Trinidad about the role of ethnicity and other 
characteristics which are predictive of CHD. This ten-year community survey 
revealed that in both sexes, adults of Indian origin had higher prevalence rates of 
diabetes mellitus, lower concentrations of HDL cholesterol and recent abstinence 
from alcohol than Africans, Europeans or adults of Mixed descent [426]. The relative 
risk of a cardiac event due to CHD was at least twice as high in Indian men and 
women, with blood pressure, diabetes mellitus and LDL cholesterol concentration 
being positively and independently related to CHD risk in men, whereas alcohol 
consumption and HDL cholesterol concentration were inversely associated with the 
CHD risk [426]. In the case of African men and women, relatively low concentrations 
of LDL cholesterol and triglyceride levels have been observed [427]. A more recent 
study performed by Ezenwaka et ah demonstrated that patients of Indian descent had 
a significantly higher prevalence of diastolic hypertension and hypertriglyceridemia 
compared with patients of African origin or Mixed race [428]. Female diabetic 
patients were found to be at a greater risk of cardiovascular morbidity and mortality 
than males [428].
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Gulliford et al. looked at the social inequalities in morbidity from diabetes 
mellitus in Trinidad and Tobago. It was observed that morbidity in persons with 
diabetes was associated with a lower socio-economic status and this association was 
partly explained by confounding with older age, female gender, longer duration of 
diabetes and Indo-Trinidadian ethnic group [429]. It has also been demonstrated that 
there is a greater risk of CVD in men than in women, as there is increased body mass 
and relative hyperlipidemia (increased blood cholesterol, TG and LDL), with those 
risk factors being more prevalent in men than women [430].
6.1.3. Risk factor associated with Atherosclerosis and Cardiovascular Disease in 
people of Trinidad and Tobago
In relation to white subjects, Afro-Caribbeans and people of African descent 
show higher prevalence to stroke, whereas South Asians have a higher incidence rate 
for coronary heart disease [431, 432]. Studies show that Indian populations have a 
higher incidence and death rate from CHD than any other ethnic groups [433].
As generally noted, high blood pressure, high LDL cholesterol concentration, 
low HDL cholesterol, diabetes mellitus and abstinence from alcohol are associated 
with the increased risk of CHD in Trinidadians [433-437]. The level of plasma 
glucose, which plays an important role in atherogenesis, may also be important in the 
prevalence of CHD in different ethnic groups, as South Africans of Indian descent 
have significantly higher insulin concentrations compared to the indigenous Africans 
[433, 438, 439]. A study that looked at serum lipoprotein concentrations in men and
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women of Trinidad, reported that LDL cholesterol was significantly higher in 
Trinidadians, which also demonstrated unchanged levels of HDL and high levels of 
vLDL triglycerides, especially in males [411]. This study also showed that Indian men 
in Trinidad are at higher risk of CHD than men in India due to the increased levels of 
LDL cholesterol concentration, which is not further accompanied by an increase of 
HDL cholesterol concentration [411, 435].
Inflammation, homocysteine, lipoproteins (a), adiponectin, and increased 
levels of prothrombotic factors such as plasminogen activator inhibitor 1 (PAI-1) and 
haemostatic factors including tissue plasminogen activator (t-PA), are also some 
novel risk factors associated with the increased incidence of CVD in some 
populations [408]. PAI-1, a predictor of diabetes, is associated with the development 
of vascular disease in people with insulin resistance and has been shown to have 
increased levels in people of South Asian origin, compared to Europeans [408, 440, 
441]. A significantly higher level has also been demonstrator for the endogenous 
inhibitor of PAI-1, t-PA antigen, in South Asians, compared to Europeans [408, 442].
A marker of inflammation, circulating high sensitivity C-reactive protein 
(hsCRP), has been demonstrated to be predictive of cardiovascular events and 
diabetes, with population of South Asian origin, especially women, showing higher 
levels correlating with visceral adiposity and insulin resistance, compared to 
Europeans [408,443, 444].
Higher homocysteine concentrations, thought to contribute to the vascular 
endothelial dysfunction initiating atherosclerosis, as well as the levels of circulating
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lipoprotein (a) are found to be higher in South Asian men, compared to Europeans, 
providing another explanation for the increased CVD risk in this ethnic group [408, 
445, 446]. On the contrary, plasma levels of adiponectin, the bioactive adipocyte 
derived protein, are found to be lower in Indo-Asians compared to Europeans, with a 
positive correlation between adiponectin and HDL cholesterol also being 
demonstrated [408, 447,448].
6.I.3.I. Age and Gender
Aging is associated with alterations in the immune response due to regulatory 
T cells damage, which function in order to regulate autoimmune responses to self- 
antigens [449]. The ability to metabolise lipids also lessens in aging individuals, 
resulting in a decrease in LDL metabolism [450]. It is also documented that with age, 
collagen becomes more glycosylated through Browning reaction, a nonenzymatic 
process, leading to decreased protein solubility and altered properties, explaining the 
stiffness and severity of atherosclerosis in aging individuals [450].
Incidences of atherosclerotic lesions have been shown to increase with age, 
especially after the third decade, which may also be related to the increase of blood 
pressure [12]. They are more common in males than females, but following 
menopause, atherosclerosis accelerates in women, so that by the age of 70 there is 
little difference between the sexes. This is possible due to protection by oestrogens in 
younger women [12], with Hormone Replacement Therapy (HRT) reducing the risk 
of ischemic heart disease in post-menopausal women [12]. Another factor that has 
been postulated as a cause is that men store more fat in central abdominal regions than
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women [12]. A study by Lemieux et al showed that men had significantly higher 
values of visceral abdominal adipose tissue (AT) volume and higher abdominal 
visceral AT areas than women [451]. These findings demonstrate that excess fatness 
in men is associated with greater health hazards than in women, something that can be 
explained by the fact that more body fat can be accumulated by premenopausal 
women before reaching the amounts of visceral AT found in men, than men of the 
same age [451].
The incidence of coronary heart disease, myocardial infarction and angina 
pectoris increases with age in both men and women, being significantly higher in men 
than women, for each age group [452]. In the case of peripheral artery disease (PAD), 
which is a manifestation of systemic atherosclerosis and is associated with an 
increased death risk and ischemic events [453], the pattern was similar to that of 
coronary artery disease, with the incidence increasing with age and being higher in 
men than women for each age group [452]. In general, PAD patients show prevalent 
atherosclerotic risk factors, but these patients receive a less intensive treatment for 
lipid disorders and hypertension than CVD patients [453].
6.I.3.2. Diabetes
Diabetes increases the risk of developing coronary artery disease. Glycaemic 
control is important for reducing the development of all forms of vascular disease, 
without abolishing the risk completely. Type 2 diabetes mellitus, a disorder of glucose 
metabolism affecting 2-4% of adults in the United Kingdom, is thought to be caused 
primarily by insulin resistance due to obesity, as about 90% of cases are attributed to
216
increased body weight [12]. This is also associated with an increase in cardiovascular 
mortality of about threefold in men and fivefold in women [12].
Insulin resistance and associated dyslipidaemia and hypertension, 
microvascular disease, increased advanced glycated endproducts, postprandial 
hyperglycaemia and hyperlipidaemia, as well as increased sorbitol metabolism and 
oxidative stress are some factors which contribute to the increased vascular disease in 
diabetes [12]. Diabetes mellitus causes microvascular complications (retinopathy, 
neuropathy and renal disease) and increases the frequency of macrovascular disease 
(myocardial infarction, stroke and peripheral vascular disease) [12].
6.1.4. CVD and Diabetes: Sharing a ‘common ground’
Diabetes mellitus is a strong risk factor for all atherosclerotic vascular 
diseases, coronary heart disease, cerebrovascular disease and peripheral vascular 
disease [454]. Patients of diabetes mellitus are at an increase risk for CVD [455], with 
a 2-fold increased risk for cardiovascular death compared to persons without diabetes 
[456-458]. More than 75% of deaths amongst diabetes mellitus patients are due to 
CVD [458, 459].
Diabetes is classified into two subtypes: insulin-dependent diabetes mellitus 
(type 1) and non-insulin-dependent diabetes mellitus (type 2) [454]. Type 1 diabetes 
mellitus is commonly associated with systolic/diastolic hypertension, independently 
of age and obesity. Evidence also suggests hyperinsulinemia is what links diabetes
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and hypertension, as patients suffering from hypertension have a high plasma insulin 
response to glucose. It has been demonstrated that insulin resistance of essential 
hypertension is located in peripheral tissues, is limited to nonoxidative pathways of 
glucose disposal (glycogen synthesis), and correlates directly with the severity of 
hypertension [460]. Insulin resistance and hyperinsulinemia are also associated with 
an atherogenic plasma lipid profile, as elevated plasma insulin concentrations seem to 
enhance the synthesis of very-low-density lipoprotein (VLDL) [460] and increases 
plasma triglyceride and LDL cholesterol levels [461], leading to hypertriglyceridemia 
[460]. Gradual elimination of lipid and apolipoproteins from VLDL leads to an 
increase in the formation of the atherogenic intermediate-density and low-density 
lipoproteins [460]. Despite the fact that it is still controversial whether insulin itself is 
a risk factor [462], it is classified to be atherogenic, as it acts to enhance the 
cholesterol transport to arteriolar SMCs and also increases the synthesis of 
endogenous lipid by these SMCs [460]. The proliferation of arteriolar muscle cells is 
also stimulated by the hormone, augmenting the synthesis of collagen in vascular 
walls, increasing the formation and decreasing the regression of lipid plaques and 
stimulating the production of various growth factors [460]. CVD is also a major 
burden in patients with type 2 diabetes [463], with patients being at an increased risk 
of CVD [464]. In the case of Type 2 (non-insulin-dependent) diabetes, the association 
with coronary heart disease is still high with patients facing a high risk of myocardial 
infarction [465].
Environmental conditions, related to a less-than-optimal nutrition in fetal and 
early life, are associated with an enhanced risk of diabetes and CVD [462]. Such 
conditions are also associated with obesity and insulin-resistance-syndrome (1RS).
218
IRS is characterized by glucose intolerance, hyperinsulinemia, dyslipidemia (high 
triglyceride and low HDL cholesterol levels) and hypertension [462]. All these 
characteristics been documented as risk factors for type 2 diabetes, with some, but not 
all, also classified as CVD risk factors, especially hypertension and low HDL levels 
[462]. A list of the risk factors that are contributing to an increased CVD occurrence 
in diabetic patients is given in Figure 6.1 below. Hypertension is twice as frequent in 
patients with diabetes compared to patients without the disease [466]. Also, according 
to a the Framingham study, which looked upon the relation of diabetes and impaired 
tolerance to CVD, the incidence of CVD and the levels of cardiovascular risk factors 
are higher in diabetic than in non-diabetic men and women [467].
Risk Factors Contributing to Increased CVD in Diabetic Patients
Hypertension Platelet hyperaggregability
Obesity Coagulation abnormalities
Atherosclerosis Diabetic cardiomyopathy
Dyslipidemia Physical Inactivity
Hyperlipidemia Heredity
Hyperuricemia Sex
Microalbuminuria Advancing age
Endothélia dysfunction Cigarette smoking
Figure 6.1. Risk factors contributing to increased CVD in diabetic patients. A list of the 
risk factors which add to an increased CVD rate in diabetic patients [466, 468-471].
It is suggested that diabetes and atherosclerosis have common genetic and
environmental antecedents, rather than the notion that atherosclerosis may precede the
development of diabetes [462]. This is believed due to the clear correlation between
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the two diseases, which leads to the speculation that they many share common 
pathogenetic processes [472]. Evidence supports this notion as it has been 
demonstrated that core metabolic defects, impaired glucose tolerance, insulin 
resistance and pro-inflammatory and pro-thrombotic states that mark diabetes also 
lead to endothelial dysfunction and the acceleration of atherogenesis [472]. Diabetes 
is associated with changes in cardiac and vascular function leading to hypertension, 
left ventricular dysfunction and cardiac autonomic neuropathy (arrhythmia, silent 
infarction and sudden death) [472]. Strategies to reduce cardiovascular risk factors 
and also slow down the progression of diabetes may actually improve the long-term 
outcomes for the individuals who are at risk [472]. This can be done by treating 
hypertension and dyslipidemia, improving the diet, weight loss, exercise and 
pharmacologic interventions [472].
6.1.5. Relationship of IgG and IgM antibody levels with atherosclerosis and 
cardiovascular disease
Studies animal models of atherosclerosis have associated antibodies against 
oxidised LDL with atherosclerotic lesion development [473]. IgM anti-oxLDL 
antibodies are classified as anti-atherogenic, whereas IgG anti-oxLDL antibodies are 
pro-atherogenic [473].
In general, modified lipoproteins are immunogenic and play a key pathogenic 
role in vascular disease [474]. IgG antibodies to oxLDL are mostly of a pro- 
inflammatory nature [474]. A study performed by Virella et ah, which measured IgG
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and IgM oxLDL antibodies in immune complexes (IC) isolated from 36 patients with 
type 1 diabetes, demonstrated that IgG antibodies predominated over IgM antibodies 
by an 8:1 ratio [474]. IgG antibody concentrations were higher in the nephropathy 
cases, hence associating the predominance of pro-inflammatory IgG oxLDL 
antibodies with existence of diabetic nephropathy [474].
Increased levels of IgM are associated with decreased risk of CVD, whereas 
increased IgG levels are associated with increased risk of CVD. Several studies have 
demonstrated that IgM levels are inversely correlated with atherosclerosis [475], also 
suggesting the possibility of IgM in preventing oxLDL uptake [476], hence having a 
protective effect against the development or activity of atherosclerosis.
Natural (low-affinity, pre-immune) IgM plays an important role in defending 
the immune system against infections [477]. It also has a protective role against 
autoimmunity [477]. IgM antibodies are inversely associated with the presence of 
angiographically determined Coronary Artery Disease (CAD), whereas IgG 
antibodies are positively associated with the disease [478]. Patients with increased 
levels of IgM antibodies are also diagnosed with a lower probability of 
angiographically determined CAD (>50% diameter stenosis) [478]. These 
relationships were emphasized in the characteristics of hypercholesterolemia, with the 
highest IgM levels showing the lowest risk of CAD [478].
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6.1.6. Immune responses against ApoB-100 peptides associated with 
atherosclerosis and ethnicity: A pilot study in Indo and Afro-Trinidadian 
patients with Diabetes and Ischemic Heart Disease
Coronary heart disease (CHD) is the most common cause of death in Trinidad 
and Tobago with 3000 fatalities per year [479]. Furthermore, Trinidad and Tobago 
has been shown to have one of the highest prevalence rates for CHD in the Americas 
[479]. An important risk factor for the development of heart disease in this population 
is diabetes mellitus which affects approximately 14% of Trinidadian adults between 
the ages of 35-69 [480] and is especially common among Indo-Trinidadians.
A ten year prospective survey of the incidence of CHD in over 2000 adults 
living in the Port-of-Spain showed that there were significant ethnic differences in the 
development of CHD as well as in the mortality from cardiac disease. In the male and 
female citizens of East Indian ancestry, the adjusted relative risk for the development 
of a cardiac event was at least twice as high as seen in other ethnic groups [433]. 
Further, in comparison to Affo-Trinidadians, Indo-Trinidadians had an age-adjusted 
risk for death from cardiac disease of 2.6 [481]. It was also shown that there were 
significant differences in the biochemical risk factors for the development of CHD in 
the different ethnic groups; Indo-Trinidadians had significantly lower levels of high- 
density-lipoprotein (HDL)-cholesterol and significantly higher levels of low-density- 
lipoprotein (LDL)-cholesterol than other racial groups [409].
The native LDL particle contains several molecules of phospholipids, free 
cholestérols, cholesterol esters and a single molecule of apolipoprotein B (ApoB)-lOO
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[482]. LDL does not normally elicit an immune response. However, during 
atherogenesis, both the lipid constituents and ApoB-100 of this particle are 
susceptible to oxidation under inflammatory conditions and thereby lead to the 
generation of modified LDL particles [482]. These particles have very similar 
properties to modified LDL particles that may be synthesised in vitro, such as 
malondialdehyde (MDA)-conjugated LDL. These contain lipid hydroperoxides and 
fragmented and modified ApoB-100 [482]. The products of this LDL modification are 
potent activators of macrophages, subsequently leading to further leukocyte 
recruitment and activation, antigen presentation and a lymphocyte response directed 
against these neoantigens [483]. Elevated levels of auto-antibodies to oxLDL have 
been reported to be a predictive determinant of accelerated atherosclerosis [484]. 
Interestingly, immunisation of murine and rabbit models of accelerated 
atherosclerosis (ApoE and LDL-receptor knockout mice) with oxLDL appears to 
inhibit atherosclerosis.
In diabetes, there is increased glycation and glyoxidation of many proteins, 
including LDLs, hence increasing the amount of oxidised LDLs available for uptake 
by macrophages in these patients. Antibodies to oxidised LDLs have been described 
in diabetics and have been shown to increase further the uptake of LDL-associated 
cholesterol through the formation of LDL-containing immune complexes [485]. In 
our population, Indo-Trinidadians had higher levels of LDL-cholesterol and a higher 
prevalence of coronary artery disease than other ethnic groups. One possible 
explanation could be that the quality and quantity of the immune response against 
oxLDL in Indo-Trinidadians is higher than in other ethnic groups which may lead to 
the accelerated development of atherosclerosis in patients of this ethnicity.
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Furthermore, diabetes is reportedly higher among Indo-Trinidadians than Afro- 
Trinidadians possibly rendering them even more prone to accelerated atherosclerosis 
in the presence of auto-antibodies against oxLDL peptides.
The peptide library from the human ApoB-100 polypeptide sequence 
generated by Fredrikson et al identified epitopes that evoke an antibody response in 
patients with cardiovascular risk factors [203]. In collaboration with this group, the 
reactivity of serum from well ethnically defined patient groups against these peptides 
was assessed.
In this Chapter it was hypothesised that (a) in the Trinidadian population, there 
are significant differences in the levels of pro-atherogenic auto-antibodies to oxLDL 
peptides among Indo-Trinidadians with Coronary Heart Disease and (b) the levels of 
these auto-antibodies are related to the severity of Coronary Heart Disease and/or 
diabetes disease state.
Possible ethnic differences in immune responses to oxidised LDL could 
further enhance the understanding of differences in susceptibility to CHD between 
racial groups within the population and help in the development of therapeutic 
approaches for the treatment and prevention of atherosclerosis.
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6.2. Experimental Procedures
6.2.1. Subjects
Subjects were adult diabetics with previous evidence of ischemic heart disease 
and who had previously participated in studies in which lipid and blood glucose levels 
were measured. Volunteers from Trinidad and Tobago were of Indian, African and/or 
Mixed ethnicity with clinical evidence of ischemic heart disease were recruited and 
matched for age, sex, hypertension and smoking habits. Patient ethnicity was 
determined using the ‘three of four’ rule in which investigators ascertained 
information about parental and grand-parental ethnicity and then classified patients. 
Those with three or four grandparents of the same ethnicity were assigned the 
particular racial group. All other participants were assigned to a ‘Mixed’ racial 
grouping [481]. There were 30 males and 45 females, out of which 9 males and 23 
females of African descent; 14 males and 14 females of East Indian origin and 7 
males and 8 females of mixed/other ethnic origins. The average age of the population 
studied was 60 years. The subjects were grouped based on their ethnicity (Table I), 
family history in diabetes (Table II) and age (Table III).
Table I. Subjects grouped as per ethnicity. From a total of 75 subjects, males and 
females are further divided into groups depending on their ethnicity.
MALE 14 9 7 30
FEMALE 14 23 8 45
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Table II. Subjects grouped as per diabetes family history. The 75 subjects are 
grouped depending on diabetes family history.
MALE 15 15 30
FEMALE 24 21 45
Table III. Subjects grouped as per age. The 75 subjects are grouped depending on 
their age.
MALE 6 15 5 4 30
FEMALE 6 23 11 5 45
Plasma samples were provided by Dr. Michelle Monteil, Consultant Clinical 
Immunologist and head of the Immunology Department at the University of the West 
Indies, Trinidad and Tobago.
6.2.2. Measurement of Antibodies to ApoB-100 peptides ELISA
Plasma concentrations of IgG and IgM antibodies directed against ApoB-100 
peptides were measured by ELISA (Figure 6.2) [241]. 96-well flat bottom microtiter 
plates (Microplate Nunc Immuno MaxiSorp 96 well flat bottom, Fisher, Cat. No. DIS- 
971-030J) were washed with 200pl of 0.05% Tween-20 in PBS and each well was 
coated with lOOpl of 20pg/ml of MDA modified peptides in PBS, incubated 2 hours
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at RT and then overnight at 4°C, tightly wrapped to avoid evaporation. The plates 
were washed with 200pl per well of 0.05% Tween-20 in PBS, blocked with 250pl per 
well of Superblock blocking buffer in TBS (Pierce, Cat. No. 37535) and incubated for 
10 minutes at RT and then emptied by inversion, repeated three times. Serum samples 
were diluted 1:100 in Superblock 1:10 in TBS, 0.1% Tween-20 and lOOpl were 
applied per well and incubated for 2 hours at RT. After washing the plates with 200pl 
per well of 0.05% Tween-20 in PBS, lOOpl of the detection antibody, goat anti-human 
IgM biotinylated (SIGMA, Cat. No. B1265) or rabbit anti-human IgG2 biotinylated 
(SIGMA, Cat. No. B1140), diluted 1:10000 (0.12pg/ml) and 1:1000 (0.2pg/ml) 
respectively in Superblock 1:10 in TBS, 0.1% Tween-20 were added and the plates 
were incubated for 2 hours at RT. The plates were then washed with 200pi per well of 
0.05% Tween-20 in PBS and incubated with lOOpl per well of conjugated 
Streptavidin-Alkaline Phosphate (Sigma-Aldrich, U.K., Cat. No. E2636-5ML) diluted 
1:2000 in Superblock 1:10 in TBS, 0.1% Tween-20 at room temperature for 1 hour. 
Following a final wash with 200pl per well of 0.05% Tween-20 in PBS, lOOpl per 
well of substrate (lp-NPP tablet/4ml ultrapure water/1ml of diethanolamine, Pierce, 
Cat. No. 37620) were applied and the plates were incubated for 90 minutes in the dark 
and the reaction was stopped by adding 50pl per well of 2M NaOH. Absorbance was 
read at a wavelength of 405 nm, using a plate reader (Bio-Tek Instruments, Inc., 
Ontario, Canada, Model No. Bio-Tek ELxSOO) and supportive software (KC4 
Programme, Bio-Tek V3.4, Bio-Tek Instruments, Inc., Ontario, Canada).
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Figure 6.2. ELISA assay design. Peptide-coated plates incubated with serum for 2 hrs were 
then incubated with IgM or lgG2 detection Ab. The samples were then incubated with 
Streptavidin-Alkaline Phosphate solution, followed by incubation with the substrate in the 
dark. Fluorescence was monitored at 405nm, to determine the reactivity of serum from patient 
groups against ApoB-100 peptides.
6.2.3. Statistical Analysis
The results obtained were analysed and statistically significant differences 
between the three study groups, ‘Indo-Trinidadian’, ‘Afro-Trinidadian’ and ‘Mixed’ 
volunteers with ischemic heart disease were identified, with the use of GraphPad 
Prism Software version 5 [486]. Results were presented as medians with ranges and 
proportions as appropriate.
One-way analysis of variance (one-way ANOVA) was used to assess the 
numerical data. One-way ANOVA compares the mean of three or more matched 
groups [486]. Paired t-test was also performed when comparing groups with the same
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sample number. All probability values were two-tailed and significance was set at a ^  
value < 0.05 (*p < 0.05, < 0.01, ***p < 0.001). A correlation test was also
performed in order to describe the degree of relationship between the variables (r 
value). This is displayed in the form of a correlation matrix, with the r value closer to 
1 indicating a strong correlation between the variables (Table IV).
Table IV. Definitions of Correlation levels observed by one-way ANOVA.
None -0.09 to 0.00 0.00 to 0.90
Small -0.30 to -0.10 0.10 to 0.30
Medium -0.50 to -0.30 0.30 to 0.50
Large -0.10 to -0.50 0.50 to 1.00
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6.3. Results
6.3.1. IgG and IgM antibodies against ApoB-100 peptides according to ethnicity
The plasma concentrations of IgG and IgM antibodies directed against the 
ApoB-100 peptides P2, P45 and P210 were measured by ELISA and graphically 
presented, based on family ethnicity. As mentioned in Section 6.2.1, on page 10 of 
this Chapter, patient ethnicity was determined using the ‘three of four’ rule. Those 
with three or four grandparents of the same ethnicity were assigned the particular 
racial group and all other participants were assigned to a ‘Mixed’ racial group. As 
shown in Table I, amongst the patients there were 32 patients of African descent; 28 
patients of East Indian origin and 15 patients of mixed/other ethnic origins.
Levels of anti-P2, anti-P45 and anti-P210 IgG and IgM antibodies are 
displayed graphically based on ethnicity: a) East Indian (Figure 6.3), b) African 
(Figure 6.4) and c) Mixed (Figure 6.5). Significance values, p  values, are also 
displayed in Table V for East Indian, Table VI for African and Table VII for Mixed 
ethnicity patients.
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Figure 6.3. Plasma concentrations of IgG and IgM antibodies against ApoB-100 
peptides in East Indian patients. The plasma concentrations of IgG and IgM were 
measured by ELISA and the results were observed as O.D. values at a wavelength of 405nm. 
Results are represented graphically as mean ± SD.
Table V. The p  values for the IgG and IgM antibody reactivity against P2, P45 
and P210 in plasma of East Indian patients, observed by one-way ANOVA.
EAST INDIAN
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.000028 1
IgG P210 6.12x10" 2.46x1 O'8 1
IgM P2 0.000001 0.022850 2.327x10"4 1
IgM P45 0.005174 0.000312 1.178x10"4 5.304x10"7 1
IgM P210 0.000398 0.003345 1.324x10 8 1.475x1 O'6 1.114x10"" 1
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Figure 6.4. Plasma concentrations of IgG and IgM antibodies against ApoB-100 
peptides in African patients. The plasma concentrations of IgG and IgM were measured by 
ELISA and the results were observed as O.D. values at a wavelength of 405nm. Results are 
represented graphically as mean ± SD.
Table VI. Thep  values for the IgG and IgM antibody reactivity against P2, P45 
and P210 in plasma samples of African patients, observed by one-way ANOVA.
AFRICAN
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 4.37x1 O'6 1
IgG P210 9.38x10"8 3.02x1 O'8 1
IgM P2 0.004 0.165 0.008 1
IgM P45 0.058 0.262 0.012 1.033x1 O'9 1
IgM P210 0.069 0.092 0.008 2.602x10 9 1.886x1 O'9 1
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Figure 6.5. Plasma concentrations of IgG and IgM antibodies against ApoB-100 
peptides in patients of Mixed ethnicity. The plasma concentrations of IgG and IgM were 
measured by ELISA and the results were observed as O.D. values at a wavelength of 405nm. 
Results are represented graphically as mean ± SD.
Table VII. The p  values for IgG and IgM antibody reactivity against P2, P45 and 
P210 in plasma of patients with Mixed ethnicity, observed by one-way ANOVA.
MIXED
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.005 1
IgG P210 0.036 2.46x10'8 1
IgM P2 0.000 0.005 0.036 1
IgM P45 0.005 0.000 3.243x10 8 0.005 1
IgM P210 0.036 3.24x1 O'5 0.000 0.0356 3.243x10"5 1
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Patients of all three ethnicities, East Indian, African and Mixed have higher 
levels of anti-P45 and anti-P210 IgG antibodies, when compared to their levels of 
anti-P2 IgG antibodies (***p < 0.005) (Figure 6.6a). Patients of East Indian descent 
have significantly higher anti-P45 IgG antibody levels than those in patients of Mixed 
descent (*p < 0.05) as well as higher anti-P2lO IgG antibody levels than those in 
patients of African descent (***/? < 0.005) (Figure 6.6a). Patients of Mixed descent 
were also found to have significantly higher anti-P210 IgG antibody levels than anti- 
P45 IgG antibody levels (***p < 0.005) (Figure 6.6a).
Patients of all three ethnicities, East Indian, African and Mixed have higher 
levels of anti-P45 and anti-P2lO IgG antibodies, when compared to their levels of 
anti-P2 IgG antibodies (***p < 0.005) (Figure 6.6a). Patients of East Indian descent 
have significantly higher anti-P45 IgG antibody levels than those in patients of Mixed 
descent (*/? < 0.05) as well as higher anti-P2lO IgG. antibody levels than those in 
patients of African descent (***p < 0.005) (Figure 6.6a). Patients of Mixed descent 
were also found to have significantly higher anti-P2lO IgG antibody levels than anti- 
P45 IgG antibody levels (***/? < 0.005) (Figure 6.6a).
In the case of IgM antibody levels, patients of African descent have 
significantly lower levels of anti-P2 IgG antibodies than patients of East Indian and 
Mixed descent (**/? < 0.01 and ***p < 0.005 respectively) (Figure 6.6b). In addition, 
patients of African descent have significantly lower levels of anti-P45 IgG antibodies 
than patients of East Indian and Mixed descent (**/? < 0.01 for both), as well as 
significantly lower levels of anti-P2lO IgG antibodies than patients of East Indian and 
Mixed descent (***/? < 0.005 and **p < 0.01 respectively) (Figure 6.6b).
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Figure 6.6. Significant differences in plasma concentrations of IgG and IgM antibodies 
against ApoB-100 peptides based on ethnicity. The plasma concentrations of a) IgG and
b) IgM were measured by ELISA as O.D. values. Results are represented graphically as 
mean ± SD, with the asterisk indicating the significant differences between different groups 
(*p < 0.05, **p <0.01, **p < 0.005).
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A one-way ANOVA was performed to observe the correlation between the 
three the ethnicities and the anti-peptide antibody levels. The data (Table 6.8, in a 
correlation matrix form) representing the relationship of the peptide plasma 
concentrations according to ethnicity is displayed below. There was significant 
correlation between IgG and IgM antibody levels against P2, P45 and P210 for East 
Indians (***/? < 0.0001; ***/? = 0.0003; ***p < 0.0001) (Appendix Figure A2), P2 
and P210 for Africans (**p < 0.0041; **p < 0.0080, respectively) (Appendix 
Figure A3) and P2, P45 and P210 in patients of Mixed descent (***p < 0.0001 for all) 
(Appendix Figure A4). Based on the results obtained after one-way ANOVA, levels 
of anti-peptide antibodies in plasma samples of patients with East Indian, African or 
Mixed ethnicity vary significantly with a p  value of less than 0.0001 (***/> < 0.001) 
(Table VIII).
The correlation between ethnicity and the antibody response against each of 
the peptides was also assessed and the results are displayed here. No correlation was 
observed against P2 for IgG or IgM (Appendix Figure A5 and A6), or against P45 for 
IgG or IgM (Appendix Figure A7 and A8) or against P210 for IgG or IgM (Appendix 
Figure A9 and A10).
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Table VIII. Correlation matrices according to ethnicity.
a. EAST INDIAN
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.705 1
IgG P210 0.826 0.839 1
IgM P2 0.776 0.429 0.641 1
IgM P45 0.514 0.632 0.664 0.791 1
IgM P210 0.623 0.535 0.774 0.872 0.896 1
b. AFRICAN
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.698 1
IgG P210 0.771 0.820 1
IgM P2 0.479 0.244 0.446 1
IgM P45 0.328 0.198 0.427 0.832 1
IgM P210 0.316 0.293 0.447 0.882 0.825 1
c. MIXED
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.683 1
IgG P210 0.545 0.864 1
IgM P2 1.000 0.683 0.545 1
IgM P45 0.683 1.000 0.864 0.683 1
IgM P210 0.545 0.864 1.000 0.545 0.864 1
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6.3.2. IgG and IgM antibodies against ApoB-100 peptides according to Diabetes 
family history
The plasma concentrations of IgG and IgM antibodies directed against the 
ApoB-100 peptides P2, P45 and P210 were measured by ELISA and graphically 
presented, based on family history in diabetes. As shown in Table II, amongst the 
patients there were 39 patients with and 36 patients without family history in diabetes. 
Levels of anti-P2, anti-P45 and anti-P210 IgG and IgM antibodies are displayed 
graphically based on diabetic background: a) Diabetic background (Figure 6.7) and b) 
Non-Diabetic background (Figure 6.8). Significance values, p  values, are also 
displayed in Table IX for patients with a diabetic background and Table X for patients 
with a non-diabetic background.
Figure 6.7. Plasma concentrations of IgG and IgM antibodies against ApoB-100 
peptides in patients with a diabetic background. The plasma concentrations of IgG and
IgM were measured by ELISA and the results were observed as O.D. values at a wavelength 
of 405nm. Results are represented graphically as mean ± SD.
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Table IX. The p  values for the IgG and IgM antibody reactivity against P2, P45
and P210 in plasma of patients with a diabetic background, observed by one-way
ANOVA.
DIABETIC
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.000006 1
IgG P210 3.20x1 O’7 1.47x10 9 1
IgM P2 7.16x1 O’9 0.097275 4.586x1 O'6 1
IgM P45 0.000168 0.016245 4.173x1 O'7 5.739x10*13 1
IgM P210 0.000026 0.006082 1.994x1 O'9 3.608x1 O'13 5.462x10"14 1
N o n  D i a b e t i c
1.0-,
0. 8 -
Figure 6.8. Plasma concentrations of IgG and IgM antibodies against ApoB-100 
peptides in patients with a non-diabetic background. The plasma concentrations of IgG 
and IgM were measured by ELISA and the results were observed as O.D. values at a 
wavelength of 405nm. Results are represented graphically as mean ± SD.
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Table X. The p  values for the IgG and IgM antibody reactivity against P2, P45
and P210 in plasma of patients with a non-diabetic background, observed by
one-way ANOVA.
NON-DIABETIC
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 2.38x1 O'9 1
IgG P210 6.9x10’11 1.82x1 O'11 1
IgM P2 1.27x1 O’4 0.001 7.688x1 O'5 1
IgM P45 0.010 1.14x1 O'4 6.269x10'5 2.209x10"10 1
IgM P210 0.004 0.001 7.950x10‘6 1.342x10’12 1.883x10'16 1
Patients with a family history in diabetes, as well as patients with no family 
history in diabetes, have significantly higher levels of anti-P45 and anti-P210 IgG 
antibodies, compared to their anti-P2 IgG antibody levels (***p < 0.005) (Figure 
6.9a). Similarly, patients with a family history in diabetes, as well as patients with no 
family history in diabetes, have significantly higher levels of anti-P45 and anti-P210 
IgM antibodies, compared to their anti-P2 IgM antibody levels (***p< 0.005) (Figure 
6.9b). In addition, anti-P2lO IgM antibody levels were significantly higher that anti- 
P45 IgM antibody levels in both patients with and without family history in diabetes 
(***p < 0.005) (Figure 6.9b).
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Figure 6.9. Significant differences in plasma concentrations of IgG and IgM 
antibodies against ApoB-100 peptides based on Diabetes family history. The plasma 
concentrations o f a) IgG and b) IgM were measured by ELISA and the results were observed as O.D. 
values at a wavelength o f 405nm. Results are represented graphically as mean ± SD, with the asterisk 
indicating the significant differences between different groups (*p < 0.05, **p < 0.01, ***/> < 0.005).
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A one-way ANOVA was performed to observe the correlation between the 
two groups and the anti-peptide antibody levels. The data (Table XI, in a correlation 
matrix form) representing the relationship of the peptide plasma concentrations 
according to diabetic background are displayed below. There was significant 
correlation between IgG and IgM antibody levels against P2, P45 and P210 for 
patients with a diabetic background (***p < 0.0001; *p = 0.0162; ***/> < 0.0001) 
(Appendix Figure A ll), patients with no diabetic background (***p < 0.0001 for all) 
(Appendix Figure A12). Based on the results obtained after one-way ANOVA, levels 
of anti-peptide antibodies in plasma samples of patients with diabetic or non-diabetic 
background vary significantly with a p  value of less than 0.0001 (***/> < 0.0001) 
(Table XI).
The correlation between diabetic background and the antibody response 
against each of the peptides was also assessed. No correlation was observed against 
P2 for IgG (Appendix Figure A13), whereas for IgM there was correlation of **/> = 
0.002 (Appendix Figure A13). Correlation was observed against P45 for both IgG 
(Appendix Figure A14) and IgM (Appendix Figure A14) (*/? = 0.03; ***/> = 0.0008). 
No correlation was observed against P210 for IgG (Appendix Figure A15) whereas 
for IgM there was correlation of **p = 0.002 (Appendix Figure A15).
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Table XI. Correlation matrices according to diabetes family history.
a. DIABETIC
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.612 1
IgG P210 0.672 0.754 1
IgM P2 0.733 0.247 0.619 1
IgM P45 0.527 0.353 0.667 0.835 1
IgM P210 0.578 0.399 0.750 0.838 0.853 1
b. NOT DIABETIC
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.816 1
IgG P210 0.854 0.866 1
IgM P2 0.603 0.522 0.618 1
IgM P45 0.431 0.606 0.624 0.842 1
IgM P210 0.479 0.554 0.667 0.887 0.935 1
6.3.3. IgG and IgM antibodies against ApoB-100 peptides according to age
The plasma concentrations of IgG and IgM antibodies directed against the 
ApoB-100 peptides P2, P45 and P210 were measured by ELISA and graphically 
presented, based age. As shown in Table 6.3, amongst the patients, 12 were in the 30- 
49 age group; 38 in the 50-69 age group; 16 in the 70+ age group and 8 were of 
unknown age. Levels of anti-P2, anti-P45 and anti-P210 IgG and IgM antibodies are 
displayed graphically based on age: a) 30-49 (Figure 6.10) and b) 50-69 (Figure 6.11),
c) 70+ (Figure 6.12) and d) Unknown (Figure 6.13) years of age. Significance values,
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p  values, are also displayed in Table XII for patients aged 30-49, Table XIII for 
patients aged 50-69 and Table XIV for patients aged 70+. The significant values for 
Unknown age were not calculated.
Patients at the age of 50-69 have significantly higher levels of anti-P45 and 
anti-P210 IgG antibodies, when compared to their levels of anti-P2 IgG antibodies 
(***p < 0.005) (Figure 6.14a). Patients at the age of 70+ have significantly higher 
levels of anti-P210 IgG antibodies, when compared to their levels of anti-P2 IgG 
antibodies (*p < 0.05). In the case of patients with an unknown age, significantly 
higher levels of anti-P45 and anti-P210 IgG antibodies, were observed when 
compared to their levels of anti-P2 IgG antibodies (**/> < 0.01 and *p < 0.05 
respectively) (Figure 6.14a).
In the case of IgM antibodies, patients at the age of 30-49 have significantly 
higher levels of anti-P45 and anti-P210 IgM antibodies, when compared to their levels 
of anti-P2 IgM antibodies (*/? < 0.05 and ***p < 0.005 respectively), patients at the 
age of 50-69 have significantly higher levels of anti-P45 and anti-P210 IgM 
antibodies, when compared to their levels of anti-P2 IgM antibodies (***p < 0.005) 
and patients at the age of 70+ have significantly higher levels of anti-P45 and anti- 
P210 IgM antibodies, when compared to their levels of anti-P2 IgM antibodies (*p < 
0.05 and ***p < 0.005) (Figure 6.14b). In the case of patients with an unknown age, 
significantly higher levels of anti-P45 and anti-P210 IgG antibodies, were observed 
when compared to their levels of anti-P2 IgG antibodies (*p < 0.05 and ***p < 0.005 
respectively) (Figure 6.14a). Anti-P2 IgM antibody levels were significantly higher in 
patients aged 30-49 and 50-69, than in patients aged 70+ (***p < 0.005 and <
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0.01 respectively) (Figure 6.14b). Anti-P45 IgM antibody levels were significantly 
higher in patients aged 50-69 than in patients aged 70+ (***p < 0.005) and patients of 
unknown age (*p < 0.05). Anti-P210 IgM antibody levels were also significantly 
higher in patients aged 50-69, than in patients aged 70+ (***£>< 0.005) and patients of 
unknown age (*p< 0.05) (Figure 6.14b).
0 . 8 -
0 . 6 -
0 . 4 -
Figure 6.10. Plasma concentrations of IgG and IgM antibodies against ApoB-100 
peptides in patients of 30-49 years of age. The plasma concentrations of IgG and IgM were 
measured by ELISA and the results were observed as O.D. values at a wavelength of 405nm. 
Results are represented graphically as mean ± SD.
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Table XII. The p  values for the IgG and IgM antibody reactivity against P2, P45
and P210 in plasma of patients aged 30-49, observed by one-way ANOVA.
30-49
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 2.38x1 O'9 1
IgG P210 6.9x10"11 1.82x1 O'11 1
IgM P2 1.27x1 O'4 0.001 7.688x10"5 1
IgM P45 0.010 1.14x1 O'4 6.269x1 O'5 2.209x1 O'10 1
IgM P210 0.004 0.001 7.950x1 O'6 1.342x1 O'12 1.883x1 O'16 1
50-69
1.0 -,
0 .8 -
0 . 6 -
Figure 6.11. Plasma concentrations of IgG and IgM antibodies against ApoB-100 
peptides in patients of 50-69 years of age. The plasma concentrations of IgG and IgM were 
measured by ELISA and the results were observed as O.D. values at a wavelength of 405nm. 
Results are represented graphically as mean ± SD.
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Table XIII. The p  values for the IgG and IgM antibody reactivity against P2, P45
and P210 in plasma of patients aged 50-69, observed by one-way ANOVA.
50-69
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 2.38x1 O'9 1
IgG P210 6.9x1 O'11 1.82x10"11 1
IgM P2 1.27x1 O'4 0.001 7.688x10"5 1
IgM P45 0.010 1.14x1 O'4 6.269x10"5 2.209x1 O’10 1
IgM P210 0.004 0.001 7.950x10'6 1.342x10'12 1.883x1 O'16 1
o.e-
Figure 6.12. Plasma concentrations of IgG and IgM antibodies against ApoB-100 
peptides in patients of 50-69 years of age. The plasma concentrations of IgG and IgM were 
measured by ELISA and the results were observed as O.D. values at a wavelength of 405nm. 
Results are represented graphically as mean ± SD.
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Table XIV. The p  values for the IgG and IgM antibody reactivity against P2, P45
and P210 in plasma of patients aged 70+, observed by one-way ANOVA.
70+
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 2.38x1 O'9 1
IgG P210 6.9x1 O'11 1.82x10'11 1
IgM P2 1.27x1 O'4 0.001 7.688x10'5 1
IgM P45 0.010 1.14x10^ 6.269x1 O'5 2.209x10"10 1
IgM P210 0.004 0.001 7.950x10'6 1.342x10'12 1.883x1 O'16 1
U n k n o w n
Figure 6.13. Plasma concentrations of IgG and IgM antibodies against ApoB-100 
peptides in patients of unknown age. The plasma concentrations of IgG and IgM were 
measured by ELISA and the results were observed as O.D. values at a wavelength of 405nm. 
Results are represented graphically as mean ± SD.
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Figure 6.14. Significant differences in plasma concentrations of IgG and IgM antibodies 
against ApoB-100 peptides based on age. T h e  p l a s m a  c o n c e n t r a t i o n s  of a )  IgG a n d  b) IgM 
w e r e  m e a s u r e d  by  ELISA  a n d  t h e  r e s u l t s  w e r e  o b s e r v e d  a s  O .D . v a l u e s  a t  a  w a v e le n g t h  of 
4 0 5 n m .  R e s u l t s  a r e  r e p r e s e n t e d  g ra p h ic a l ly  a s  m e a n  ± S D ,  with t h e  a s t e r i s k  ind ica t ing  t h e  
s ig n if ic an t  d i f f e r e n c e s  b e t w e e n  d if fe ren t  g r o u p s  (*p < 0 .0 5 ,  **p < 0 .0 1 ,  ***p < 0 .0 0 5 ) .
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A one-way ANOVA was performed to observe the correlation between the 
two groups and the anti-peptide antibody levels. The data (Table XV, in a correlation 
matrix form) representing the relationship of the peptide plasma concentrations 
according to age is displayed below. There was significant correlation between IgG 
and IgM antibody levels against P2 and P210 for patients aged 30-49 (*p = 0.0396; 
***p = 0.0003) (Appendix Figure A16) and against P2, P45 and P210 for patients 
aged 50-69 (***p < 0.0001 for all) (Appendix Figure A17). On the contrary, there 
was no significant correlation between IgG and IgM antibody levels against the 
peptides for patients aged 70+ (Appendix Figure A18). Based on the results obtained 
after one-way ANOVA, median levels of anti-peptide antibodies in plasma samples of 
patients at the age of 30-49 did not vary significantly (p = 0.1370), whereas median 
levels of anti-peptide antibodies in plasma samples of patients at the age of 50-69 and 
70+ did vary significantly (***p< 0.001; *p = 0.023) (Table XV).
The correlation between age and the antibody response against each of the 
peptides was also assessed. P2 at age 30-49 and 70+ was correlated with *p = 0.0382 
for IgG (Appendix Figure A19), whereas no correlation was observed against P2 for 
IgM (Appendix Figure A20). P45 at age 30-49 and 70+ was correlated with *p = 
0.0332 for IgG (Appendix Figure A21), whereas for IgM there was no correlation 
(Appendix Figure A22). Correlation of *p = 0.0332 was observed against P210 for 
IgG at age 30-49 and 70+ (Appendix Figure A23), whereas there was no correlation 
for IgM (Appendix Figure A24).
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Table XV. Correlation matrices according to patient age.
a. 30-49
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.816 1
IgG P210 0.616 0.720 1
IgM P2 0.599 0.470 0.812 1
IgM P45 0.437 0.504 0.816 0.899 1
IgM P210 0.389 0.406 0.860 0.893 0.935  1
b. 50-69
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.677 1
IgG P210 0.777 0.857 1
IgM P2 0.970 0.632 0.773 1
IgM P45 0.679 0.918 0.859 0.720 1
IgM P210 0.766 0.802 0.971 0.806 0.879 1
c. 70+
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.826 1
IgG P210 0.877 0.846 1
IgM P2 0.213 0.126 0.112 1
IgM P45 0.104 0.009 0.093 0.856 1
IgM P210 0.316 0.151 0.155 0.913 0.849 1
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6.3.4. IgG and IgM antibodies against ApoB-100 peptides according to gender
The plasma concentrations of IgG and IgM antibodies directed against the 
ApoB-100 peptides P2, P45 and P210 were measured by ELISA and graphically 
presented, based on gender. As mentioned in Section 6.2.1, 30 of the patients were 
males and the rest 45 were females.
Levels of anti-P2, anti-P45 and anti-P2lO IgG and IgM antibodies are 
displayed graphically based on gender: a) male (Figure 6.15) and b) female (Figure 
6.16). Significance values, p  values, are also displayed in Table XVI for the patients 
and in Table XVII for female patients.
Male
1. 0 -
0 . 8 -
Figure 6.15. P lasm a co n cen tra tio n s o f IgG and IgM a n tib od ies a g a in st A poB -100  
p ep tid es in m ale p atien ts. The plasma concentrations of IgG and IgM were m easured by 
ELISA and the results were observed a s  O.D. values at a wavelength of 405nm . Results are 
represented graphically a s  mean ± SD.
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Table XVI. The p  values for the IgG and IgM antibody reactivity against P2, P45
and P210 in plasma of male patients, observed by one-way ANOVA.
MALE
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.000013 1
IgG P210 9.51x1 O'8 0.000001 1
IgM P2 0.000001 0.003983 8.469x10"6 1
IgM P45 0.000375 0.000135 1.044x10’7 3.853x1 O'9 1
IgM P210 0.000166 0.000065 6.665x10 8 2.568x1 O'10 3.036x10'12 1
Female
1.0-,
0 . 8 -
0 . 6 -
Figure 6.16. P lasm a co n cen tra tio n s o f IgG and IgM a n tib od ies a g a in st A poB -100  
p ep tid es in fem ale p atien ts. The plasma concentrations of IgG and IgM were m easured by 
ELISA and the results were observed a s  O.D. values at a wavelength of 405nm . Results are 
represented graphically a s  mean ± SD.
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Table XVII. The p  values for the IgG and IgM antibody reactivity against P2,
P45 and P210 in plasma of female patients, observed by one-way ANOVA.
FEMALE
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 6.52x10‘9 1
IgG P210 6.02x10-10 1.81x10"15 1
IgM P2 3.13x1 O'6 0.019 4 .344x10"5 1
IgM P45 0.004 0.008 1.033x10"4 6.007x1 O'13 1
IgM P210 0.001 0.005 2.362 x10'6 6.508x10"15 3.773x10"16 1
Both male and female patients have significantly higher levels of anti-P45 and 
anti-P210 IgG antibodies, when compared to their levels of anti-P2 IgG antibodies 
(***p < 0.005) (Figure 6.17a). A similar trend is observed for IgM, with both male 
and female patients having significantly higher levels of anti-P45 and anti-P2lO IgM 
antibodies, when compared to their levels of anti-P2 IgM antibodies (***p < 0.005) 
(Figure 6.17b). In addition, both male and female patients have significantly higher 
levels of anti-P2lO IgM antibody, when compared to their levels of anti-P45 IgM 
antibodies (***p < 0.005) (Figure 6.17b).
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Figure 6.17. S ign ificant d ifferen ces in p lasm a con cen tra tio n s o f  IgG and IgM an tib o d ies  
a g a in st A poB -100 p ep tid es b a sed  on gen d er. The plasma concentrations of a) IgG and b)
IgM were m easured by ELISA and the results were observed a s O.D. values at a wavelength  
of 405nm . Results are represented graphically a s  mean ± SD, with the asterisk indicating the 
significant differences between different groups (*p < 0.05, **p < 0.01, ***p < 0.005).
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A one-way ANOVA was performed to observe the correlation between the 
two groups and the anti-peptide antibody levels. The data (Table XVIII, in a 
correlation matrix form) representing the relationship of the peptide plasma 
concentrations according to gender is displayed below.
There was significant correlation between IgG and IgM antibody levels 
against P2, P45 and P210 for both male (***/? < 0.001 for all) (Appendix Figure A25) 
and female patients (***%? < 0.001; **p = 0.008; ***/? < 0.001, respectively) 
(Appendix Figure A26). Also, based on the results obtained after one-way ANOVA, 
median levels of anti-peptide antibodies in plasma samples of both male and female 
patients did vary significantly (***p < 0.001) (Table XVIII).
The correlation between gender and the antibody response against each of the 
peptides was also assessed. Peptide P2 showed no significant correlation for IgG or 
IgM (Appendix Figure A27). Peptide P45 showed significant correlation of *p = 
0.0245 for IgG (Appendix Figure A28), but no significant correlation for IgM 
(Appendix Figure A28). Peptide P210 showed no significant correlation for IgG or 
IgM (Appendix Figure A29).
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Table XVIII. Correlation matrices according to gender.
a. MALES
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.706 1
IgG P210 0.803 0.757 1
IgM P2 0.764 0.510 0.716 1
IgM P45 0.607 0.641 0.801 0.846 1
IgM P210 0.635 0.663 0.808 0.875 0.910 1
b. FEMALES
IgG P2 IgG P45 IgG P210 IgM P2 IgM P45 IgM P210
IgG P2 1
IgG P45 0.740 1
IgG P210 0.771 0.882 1
IgM P2 0.633 0.348 0.570 1
IgM P45 0.426 0.391 0.546 0.839 1
IgM P210 0.485 0.413 0.639 0.872 0.889 1
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6.4. Discussion
Strong correlation between atherosclerosis development and antibody 
production against peptides designed from the ApoB-100 protein sequence of the 
LDL particle have been recently reported [241]. These peptides have been shown to 
induce or suppress atherosclerosis in animal models [241]. In humans, serum levels of 
antibodies against these peptides positively correlate with the development of the 
disease and its outcome [241]. However, these studies have been carried out only in 
cardiovascular patients without clinical history of any other disease. Since diabetes 
has been strongly associated with atherosclerosis and cardiovascular disease we 
hypothesised that diabetes patients may exert similar or different type of immune 
responses against these peptides. This study was designed in order to evaluate the 
presence and the clinical significance of antibodies directed to ApoB-100-derived 
peptides in cardiovascular disease patients, also looking in any diabetes medical 
background, as well as any implications due to ethnicity, gender and age.
This study included 75 patients (45 female and 30 male, mean age 60 years 
old). Thirty nine were also classified as having family background of diabetes. All 
samples were tested for anti-peptide IgG and IgM antibodies against the ApoB-100- 
derived peptides P2, P45 and P210 using an in-house developed ELISA (Figure 6.2). 
Clinical significance and association of these antibodies to cardiovascular disease and 
diabetes, as well as to ethnicity, age and gender were investigated.
Levels of IgG and IgM antibodies directed to the ApoB-100 derived peptides 
were different between patients of different ethnicities. Patients of all three ethnicities,
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East Indian, African and Mixed have higher levels of anti-P45 and anti-P210 IgG 
antibodies, when compared to their levels of anti-P2 IgG antibodies (***/? < 0.005) 
(Figure 6.6a). Patients of East Indian descent have significantly higher anti-P45 IgG 
antibody levels than those in patients of Mixed descent (*/? < 0.05) as well as higher 
anti-P210 IgG antibody levels than those in patients of African descent (***p< 0.005) 
(Figure 6.6a). Patients of Mixed descent were also found to have significantly higher 
anti-P2lO IgG antibody levels than anti-P45 IgG antibody levels (***p < 0.005) 
(Figure 6.6a). One-way ANOVA showed that there was no significant correlation 
between ethnicity and IgG or IgM antibody response against any of the peptides 
(Appendix Figures A5 -  A10).
Levels of antibodies to ApoB-100 derived peptides (given as optical density 
values) were not significantly different between patients with cardiovascular disease 
only or those with cardiovascular disease and diabetes family history. When looking 
at responses to individual peptides, both CVD patients with and without diabetic 
family history have higher levels of anti-P210 IgG and IgM antibody levels, followed 
by anti-P45 and then anti-P2 (anti-P210 > anti-P45 > anti-P2 antibody levels) (Figure 
6.9). Lower levels of IgM with increased levels of IgG antibodies come to verify an 
atherogenic immune response, leading to increased CVD risk. One-way ANOVA 
showed that there was significant correlation between diabetes and antibody response 
against the peptides. P2 (Figure 6.12), P45 (Figure 6.13) and P210 (Figure 6.14) IgM 
levels, as well as P45 (Figure 6.13) IgG levels were significantly correlated to a non­
diabetic background.
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Based on age distribution, when looking at responses to individual peptides, 
patients aged 30-49 years have significantly higher levels of anti-P210 IgM antibody 
levels, followed by anti-P45 and then anti-P2 (anti-P210 > anti-P45 > anti-P2 
antibody levels) (***p < 0.005 and *p < 0.05 respectively) (Figure 6.14). Patients 
aged 50-69 years have significantly higher levels of anti-P210 IgG and IgM antibody 
levels, followed by anti-P45 and then anti-P2 (anti-P210 > anti-P45 > anti-P2 
antibody levels) (***/? < 0.005), whereas patients aged 70 and above have 
significantly higher levels of anti-P210 for IgG and IgM (*p < 0.01 and ***/> < 0.005 
respectively) (Figure 6.14). In regards to anti-peptide IgM antibody levels, significant 
differences were also observed when comparing individual peptide responses of the 
different age groups. Anti-P2 IgM antibody levels were significantly higher in 
patients 30-49 and 50-69 years, compared to patients aged 70 and above (***p < 
0.005 and **p < 0.01) (Figure 6.14). Anti-P45 and anti-P210 IgM antibody levels 
were significantly higher in patients aged 50-69 years, also when compared to patients 
aged 70 and above (***p < 0.005 for both) (Figure 6.14). In general, it is observed 
here that patients aged 50-69 years of age, followed by patients aged 30-49 have 
higher levels of pro-atherogenic antibodies. One-way ANOVA did not show any 
significant correlations between age and antibody response against the peptides 
(Appendix Figures A19 -  A23), with the only exception at the 70+ age group, which 
was correlated with P2, P45 and P210 IgG levels (Appendix Figure A24).
Anti-peptide antibody levels did not show any significant differences 
depending on the gender of the patients. Both male and female patients have lower 
levels of anti-P2 IgG as well as IgM, compared to the corresponding levels of anti- 
P45 and anti-P210 antibody levels (anti-P210 > anti-P45 > anti-P2 antibody levels)
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(***p < 0.005) (Figure 6.17). One-way ANOVA did not show significant correlations 
between gender and antibody response against the peptides (Appendix Figures A27 -  
A29), with the only exception of females was correlated P45 IgG levels (Appendix 
Figure A29).
In this Chapter, the immune response against the same antigens used in vitro 
(Chapter 3) and in vivo (Chapters 4 and 5) was assessed in a population study. 
Correlations of the different antibodies and the type of the T cell immune response in 
these patients was observed. Antibodies to ApoB-100 derived peptides were found in 
patients with CVD and diabetes. Higher levels of anti-peptide IgG and lower levels of 
anti-peptide IgM antibody levels, especially for antibodies to P45 in East Indian 
patients, may be associated with the increased risks of cardiac events and CVD cases, 
in both males and females. A similar trend was also observed in patients of African 
descent, but not in those of Mixed descent which have increased levels of IgM 
antibodies to P2, P45 and P210, compared to the levels of IgG.
From this study, there is evidence that the diabetic state may result in elevation 
of IgG antibodies, which is then related to an atherogenic immune response, hence 
promoting CVD. The data also provides indications that East Indian patients of 
Trinidad and Tobago have more coronary atherosclerosis and a higher incidence of 
clinical CHD than do patients of African or Mixed descent of similar age, irrelevant to 
gender. Lower levels of IgM antibodies to P45 and in some cases P210 may be 
associated with higher risks of CVD. These findings may support the hypothesis that, 
at least, immune responses against P45 and P210 may play a protective role in
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atherosclerosis and could be a potential target for immunomodulatory treatment in 
these patients.
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CHAPTER 7.
GENERAL DISCUSSION, CONCLUDING REMARKS AND
SUGGESTIONS FOR FURTHER STUDY
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7.1. General Discussion
In 2003, Fredrikson et al identified over 100 different human antibodies 
reacting against MDA apoB-100 sequences [241]. Out of these, three apoB-100- 
derived peptides (P2, P45 and P210) were selected and used in the current study in 
order to demonstrate their potential role in the induction of regulatory T cells in the 
process of atherosclerosis.
The rationale for this study is based on previous findings showing that after 
immunisation of apoE-null mice these peptides inhibited the development of 
atherosclerosis by mainly favouring the production of athero-protective antibodies 
and cytokines. However, by the time of writing this thesis their role in T cell mediated 
immune responses was not yet elucidated. We hypothesised that MDA-modified 
peptides P2, P45 and P210 have the ability to affect T lymphocyte numbers in 
proliferating cultures and also to affect the expression of Toll-like receptors by DCs. 
In order to further investigate the role of TregS in an atherosclerosis prone environment, 
CD4+CD25+ and CD8+CD25+ TregS were depleted in vivo by using PC61. This was 
done on the hypothesis that such depletion may affect cytokine plasma levels in 
apoE7' mice as well as to induce changes on the lipid profile and enhance the 
formation of atherosclerotic plaques. Finally, based on evidence that susceptibility to 
CHD is different between racial groups in relation to other risk factors, a well-defined 
Trinidadian population was used to evaluate the hypothesis that the differential 
immune response and the severity of CHD and/or diabetes may be correlated to 
significant differences in the levels of pro-atherogenic auto-antibodies to oxLDL 
peptides amongst the patients.
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The potential immunosuppressive nature of the apoB-100-derived peptides, 
P2, P45 and P210, was tested by using an in vitro cell proliferation assay, where the 
inhibitory effect of peptide-induced TregS was assessed against oxLDL and SEB- 
induced T cell proliferation. In both cases, the peptides were capable of significantly 
decreasing the numbers of proliferating cells. P210 significantly reduced the number 
of T cells for both oxLDL and SEB cultures while P45 inhibited that from 
proliferating T cells induced by oxLDL only. These observations highlight the anti­
inflammatory nature of these apoB-100-derived peptides.
We hypothesized that the reduction in T cell numbers observed in our 
experiments could have been a result of apoptosis. Although no apoptosis specific 
assays were used to confirm this assumption, this possibility was inferred based on the 
results derived from the T cell proliferation assay. Proliferation of T cells was 
significantly lower in the presence of 0.5x106 and 0.25x106 P45 iTregS or 0.5xl06 and 
0.25x106 P210 iTregs than that incubated with natural TregS. These results may suggest 
a mechanism by which peptide-induced TregS can reduce T cell proliferation within 
atherosclerotic plaques, a hypothesis that deserves future experimental confirmation. 
With regards to the in vitro context, the use of sorted TregS would have added more 
specificity and refinement to these experiments. Another important comparison would 
have been the assessment of the inhibitory effect of these peptide-specific TregS on 
copper sulfate and MDA-induced T cell proliferation, as it is known that the type of 
oxidation may influence the outcome and the quality of the immune response. It has 
been previously reported that MDA-induced oxidation is more prone to elicit humoral 
immune responses, whereas copper-induced modifications are more prone to trigger 
cell-mediated immune responses [487].
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Our results also showed a transient expression of FoxP3 by peptide-induced 
CD4+CD25+ Treg cells, with the maximum expression at 12 hours after stimulation in 
vitro with anti-CD3 and anti-CD28 Abs. The expression of FoxP3 was significantly 
increased after 12 hours of treatment, but it was downregulated after 24 hours 
compared to the 6 hours treatment. When treatment was performed using P45 no 
significant differences were observed, whereas treatment with P210 demonstarted a 
significantly higher expression of FoxP3 only after 72 hours of treatment. These 
results follow recent findings with regards to the transient expression of FoxP3, in 
which this starts as early as 6 to 12 hours after stimulation, implying the need for the 
recognition and engagement of other important intracellular and surface molecules 
necessary for Treg function as FoxP3 alone may not be sufficient to achieve its 
characteristic effects [303, 304]. While FoxP3 was first postulated as a specific 
marker for naturally occurring TregS, it has also been argued that other FoxP3- 
independent mechanisms, mediated by IL-10 may also contribute to the induction and 
suppressor functions of Trl cells [488]. Hori et. al have postulated that the regulatory 
T cell lineage may be determined by a higher-order regulatory process that ensures 
stability and high levels of FoxP3 expression [489]. Markers such as GITR 
(Glucocorticoid-induced Tumor necrosis factor receptor family-Related), CTL-4 
(CD 152) and CD45RB involved in cellular processes such as cell growth, 
differentiation, mitosis and oncogenesis; essential regulators of T and B cell antigen 
receptor signaling have been proposed [490-492]. Additionally, CD101 expression 
has been correlated with the potency of suppression mediated by the TregS populations 
[493].
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In our study, we used the absence or low expression of CD 127, in combination 
with the high expression of CD25 and FoxP3 to identify TregS. CD 127 complexes with 
CD 132, the common y chain (yc), and forms the DL-7 receptor and it is transiently 
down-regulated upon T cell activation [494]. This receptor plays a crucial role in IT-7 
signaling which is essential in the development of lymphocytes and controls the 
homeostatic proliferation of T cells in the periphery [494].
It has been recently demonstrated that TregS can be ‘alerted’ of the presence of 
pathogens directly by engagement of TLRs on their surface [495]. TregS have been 
reported to respond to ligands for TLR2, TLR4, TLR5 and TLR8, each having 
differential effects on TregS resulting in more suppression or annihilation of 
suppression [495]. Recent findings suggest that TregS respond directly to pro- 
inflammatory bacterial products and contribute to the control of inflammatory 
responses [243]. Interestingly, it has been reported that TLR4 agonists promote the 
production of Thl-associated IL-12 p70 and a IFN-y inducible protein (IP)-10, while 
TLR2 induces the release of IL-12 inhibitory p40 homodimer shifting the balance to 
the development of Th2 responses [270].
In addition to the effect on T ^ ,  our experiments show that the expression of 
TLR2 by DCs was significantly induced by P45 and that the expression of TLR4 
remained the same in response to peptide treatment. This could also be an indication 
that the peptides are favoring the development of Th2 immune responses and 
therefore could explain the previously reported atheroprotective effects. This also 
agrees with recent findings showing that TLR 2 expressed by CD4+ T cells is
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important in FoxP3 expression and hence the induction of anti-inflammatory 
responses [496].
The discovery that the apoB-100 can induce immune responses that inhibit 
atherosclerosis development was a major step to suggest that they could be used as 
therapeutic tools to treat the disease [203]. However, their effect on the induction of 
Tregs and consequently the effect of this peptide-specific TregS on atherosclerotic 
plaque development have never been assessed. In this study we evaluated the immune 
response triggered by the peptides in the absence of alum and using BSA as a carrier 
protein. BSA was used instead of alumn as this is known to enhance antigen 
presentation, the expression of co-stimulatory molecules CD80 and CD86, as well as 
the secretion of IL-ip and IL-18 cytokines by DCs and macrophages [331-333] and 
the secretion of IT-4, IL-5 and IFN-y by naïve CD4+ T cells [332, 334]. Studies also 
demonstrated that alum may affect the compartmentalization of the immune response 
by influencing the migration of antigen presenting cells [334]. Under these 
experimental conditions, we observed a differential effect of the peptides on both 
humoral and T-cell mediated immune responses when P2, P45 and P210 were 
administered alone or when loaded on to DCs. P45 and P210 triggered Th2-associated 
immune responses after immunisation (both alone and loaded onto DCs) characterized 
by the synthesis of peptide-specific IgGl, which has been previously shown to be 
athero-protective [203]. P45 and P210 also promoted the proliferation of Tregs and the 
increased synthesis of IL-10, especially by P45, which supports previous observations 
linking the expression of this cytokine with the proliferation and survival of Tregs 
[337] and the suppression of pro-inflammatory responses [338, 339].
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Immunisation of ApoEv" mice with BSA-conjugated P2, P45 and P210 
peptides, significantly increased the numbers of CD4+CD25+FoxP3+ natural Treg in 
vivo. Interestingly, P2 and P45 induced a similar effect on CD8a+CD25+FoxP3+ Treg 
cells. Proliferation of CD4+CD25'FoxP3+ inducible Treg cells was significantly 
enhanced after treatment with BSA-conjugated P2, P45 and P210 peptides, whereas 
the proliferation of CD8a+CD25"FoxP3+ iTreg cells was significantly induced only by 
P2 and P45 peptides. Of significant importance was the positive effect of P45 and 
P210 on the levels of IL-10 cytokine and IgGl, both of which are classified to as Th2 
anti-inflammatory factors. The data provides evidence for the co-existence of a CD8+ 
T-cell-mediated immune response and the induction of CD8+ Tregs by the peptides. As 
CD4+ Tregs, CD8+ Tregs seem to express IL-10 and act in an immunosuppressive 
environment, suppressing autoimmunity [497]. Based on previous findings, CD8+ 
Tregs are induced independently of CD4+CD25+ Tregs and they function through IL-10 
secretion [498], signifying the importance of this induction of CD8+ Tregs by the apoB- 
100-derived peptides.
A unique methodology used in this study was the use of peptide-loaded DCs 
to assess the effect on Tregs in the context of atherosclerosis. P210-loaded DCs 
significantly increased the number of CD4+CD25+FoxP3+ Tregs as well as the plasma 
level of IL-10, compared to control animals suggesting that this peptide can modulate 
DC-mediated effects. P45-loaded DCs increased the numbers of CD4+CD25+FoxP3+ 
but also CD8+CD25+FoxP3+ Tregs accompanied by a significant increase in the 
synthesis of IL-10 suggesting that this peptide can also modulate potential tolerogenic 
effect of DCs and the enhancement of CD4+ T cell-mediated immune responses. P2-
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loaded on the other hand seem to have a contrasting effect, suggesting a more 
complex mechanism that requires further investigation.
Hence, this evidence suggests that apoB-100-derived peptides used in vaccine 
preparation may exert anti-inflammatory and potential athero-protective effects, 
through the induction of Tregs in response to antigen-specific stimulation. An 
important question that we tried to address in this study was the effect of this antigen 
stimulation on the tissue distribution of the APCs used. It is known that molecular and 
functional changes of APCs by antigens, while transported to effector organs, may 
affect the compartmentalization of immune responses [341-345]. Hence, peptide- 
loaded DCs labelled with DiICig(3) were used to immunise ApoE"7" mice in order to 
assess their distribution in lymphoid organs and the heart. We detected a higher 
number of peptide-loaded DCs bearing the CD8a+ (tolerogenic) phenotype in the 
regional lymph nodes, the spleen and in the heart. This demonstrates the tendency of 
these APCs to localize within “T cell zones” [499]. P2, P45 and P210 are 
autoantigens, products of the natural degradation of ApoB-100 during atherosclerosis 
and that may induce tolerogenic immune responses when presented by DCs which 
participate during their migration to the local lymphoid tissue in the generation of 
anti-inflammatory responses.
All these previous results strongly prompt us to investigate the role of Tregs on 
atherogenesis in vivo. Several approaches can be used to study the Tregs in the aspect 
of controlling the development and progression of atherosclerosis [500]. In 2003, 
Mallat et ah indicated that the induction of regulatory T cell type 1 responses reduce 
the development of atherosclerosis in ApoE" ' mice, as the administration of OVA-
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specific Trl cells to female ApoE'7' mice resulted in decreased levels of IgG2a and 
IFN-y and at the same time increased levels of IL-10 in the spleen and lymph nodes 
compared to controls [159]. In 2006, Ait-Oufella et al demonstrated that FoxPS Treg 
cell responses play a crucial role in the modulation of atherosclerosis by the Inducible 
Costimulatory Molecule (ICOS), as ICOS deficiency accelerates atherosclerosis, 
increases CD4 T cell levels and decreases FoxP3+ Tregs [161]. ICOS deficiency also 
led to a 2-fold increase in lesion size at the aortic root in mice [161]. Steffens et al 
showed that anti-CD3 antibody therapy reduced plaque development when 
administered before high-cholesterol diet and also decreased lesion progression, 
resulting from increased production of TGF-(3 and enhanced expression of FoxP3 
[501]. Induction of oral tolerance through oral administration of oxLDL to LDLr"7" 
mice resulted in a significance decrease of initiation and progression of 
atherosclerosis, along with increased production of TGF-|3 and an increase in the 
number of CD4+CD25+FoxP3+ cells in the spleen and mesenteric lymph nodes, as 
demonstrated by van Puijverde et al [502]. In 2007, Groyer et al pointed the role of 
CD31 receptor globulin, by demonstrating its key role in the regulation of immune 
responses linked to atherosclerosis [503]. As the loss of CD31 at the surface of 
circulating T cells was positively correlated with atheroscthrombosis in mice and 
abdominal aortic aneurysm in humans, it was demonstrated here that CD31Rg-treated 
mice had smaller lesions at the aortic root compared to the controls and the Treg 
content in the blood of the treated mice was enhanced [503]. We decided to assess this 
issue by depleting Tregs using PC61, an anti-CD25 monoclonal antibody that blocks 
the interleukin-2 receptor a chain (IL-2Ra) and therefore impedes the proliferation of 
Tregs in vivo and in vitro. ApoE'7' mice, treated with PC61 depleted CD4+CD25+ and
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CD8+CD25+ Tregs in animals put on a normal or high fat diet compared to untreated 
animals.
The doses used in our study to treat animals only managed to achieve a 40% 
depletion of Tregs in the spleens and not the >80% as expected [504, 505]. This 
decreased performance may be due to the fact that only cells in the spleen were 
examined. Also, the duration of the treatment plays a role, implying that maybe it 
would have been better if the mice were terminated earlier. Based on these limitations 
it can be concluded that if the levels of depletions were higher, then the results could 
have been clearer.
As expected, treatment with PC61 also affected the synthesis of cytokines by 
ApoE'7' mice. Plasma levels of IFN-y were highly increased in all treated groups, 
while levels of IE-4 and IL-10 significantly decreased. Increased IFN-y and decreased 
IL-4 and IL-10 plasma levels, indicate a shift towards the pro-atherogenic Thl 
phenotype, highlighting the important role of CD25+FoxP3+ cells in the control of 
Thl-mediated immune responses in vivo.
Interestingly, treatment of mice wth PC61 also has an effect on the lipid 
profile. Triglyceride levels were significantly increased, as well as those of LDL. 
These results point to the already existing observations that high plasma levels of 
LDL are directly correlated with the development of coronary artery disease [506] and 
that increases in trygliceride levels contribute to the increased risk of coronary events, 
the progression of coronary artery disease and to the formation of new lesions [507- 
509]. Even though atherosclerosis does not result simply from lipid accumulation, an
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association between lipid profile and the severity of coronary disease can be observed, 
validating the existence of high risk profiles [510]. Therefore, the lipid profile of 
patients can be used to identify those at a higher potential risk [510].
Depletion of Tregs increased total plaque area in the aortic sinus of ApoE'7' 
mice was observed in mice by 135% increase in animals on high fat diet diet and by 
75% in animals fed on a normal rodent diet when compared to the untreated normal 
diet controls. Amongst mice treated with PC61, those on a HFD demonstrated a 
17.6% increase in plaque size compared to those on a normal diet. These results 
strengthen the previous findings and further indicate that the absence of functional 
Tregs promotes a pro-atherogenic environment resulting in the development of larger 
atherosclerotic plaques and once more highlights the protective role of Tregs in 
atherogenesis.
Finally, our study addressed the question of whether the presence of auto­
antibodies against apoB-100-derived peptides in the plasma of patients could be 
correlated with disease, gender and race status. Plasma samples from a well defined 
Trinidad and Tobago population were used and investigated at the level of anti­
peptide IgG and IgM antibodies. The reactivity of serum against peptides P2, P45 and 
P210 was assessed, using an in-house developed ELISA, in order to identify possible 
ethnic differences in immune responses to oxidised LDL, hence enhancing the 
understanding of differences in susceptibility to CHD between racial groups within 
the population and help in the development of therapeutic approaches for the 
treatment and prevention of atherosclerosis.
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High antibody levels of P45 and P210 apoB peptides are associated with less 
severe coronary calcifications [511]. In addition, patients with increased anti-P45 IgG 
have been shown to have reduced progression of coronary calcification [511]. Hence, 
high levels of anti-P4 and anti-P210 IgG are associated with a lower risk of acute 
cardiovascular events [512, 513]. Here, antibodies to ApoB-100 derived peptides 
were observed in patients with CVD and diabetes. Higher levels of anti-peptide IgG 
and lower levels of anti-peptide IgM antibody levels, especially for antibodies to P45 
in East Indian patients, may be associated with the increased risks of cardiac events 
and CVD cases. Patients of African descent demonstrate a similar trend, whereas 
patients of Mixed descent have increased levels of IgM antibodies to P2, P45 and 
P210, compared to the levels of IgG.
Levels of IgG and IgM antibodies directed to the ApoB-100 derived peptides 
were not significantly different between patients with cardiovascular disease only or 
those with cardiovascular disease and diabetes family history. Both CVD patients 
demonstrate higher levels of anti-P210 IgG and IgM antibody levels, followed by 
anti-P45 and then anti-P2 (anti-P210 > anti-P45 > anti-P2 antibody levels), no matter 
of their diabetic background. The atherogenic immune response, leading to increased 
CVD risk was verified by the lower levels of IgM and the increased levels of IgG 
antibodies. Significant correlation between diabetes and antibody response against the 
peptides was confirmed by one-way ANOVA, with P2, P45 and P210 IgM levels, as 
well as P45 IgG levels being significantly correlated to a non-diabetic background. 
These observations come to agree with the recent findings of Fredrikson et al. that 
demonstrate that the levels of IgG agaisnt MDA-modified apoB epitopes P45 and 
P210 are increased in type 2 diabetic patients, suggesting that oxidation of LDL may
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be involved in the development of diabetic microvascular complications [511]. Based 
on these observations Fredrikson et al suggests that due to this correlation, vaccines 
for cardiovascular disease could also be effective in patients with diabetes [511].
In regards to age, patients aged 30-49 years demonstrated significantly higher 
levels of anti-P210 IgM antibody levels, followed by anti-P45 and then anti-P2. 
Patients aged 50-69 years showed significantly higher levels of anti-P210 IgG and 
IgM antibody levels, followed by anti-P45 and then anti-P2, whereas patients aged 70 
and above had significantly higher levels of anti-P210 for IgG and IgM. Significant 
differences were also observed when comparing individual peptide responses of the 
different age groups to anti-peptide IgM. Anti-P2 IgM antibody levels were 
significantly higher in patients 30-49 and 50-69 years, compared to patients aged 70 
and above, whereas anti-P45 and anti-P210 IgM antibody levels were significantly 
higher in patients aged 50-69 years, also when compared to patients aged 70 and 
above. Overall, patients aged 50-69 years, followed by patients aged 30-49 were 
observed to have higher levels of pro-atherogenic antibodies. One-way ANOVA did 
not show any significant correlations between age and antibody response against the 
peptides, with the only exception at the 70+ age group, which was correlated with P2, 
P45 and P210 IgG levels.
Anti-peptide antibody levels according to gender did not show any significant 
differences, as both male and female patients were observed to have lower levels of 
anti-P2 IgG as well as IgM, compared to the corresponding levels of anti-P45 and 
anti-P210 antibody levels. One-way ANOVA did not show significant correlations
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between gender and antibody response against the peptides, with the only exception 
of females was correlated P45 IgG levels.
Hence it can be concluded here that this study provides evidence that the 
diabetic state may result in elevation of IgG antibodies, which is then related to an 
atherogenic immune response, hence promoting CVD. East Indian patients of 
Trinidad and Tobago were shown to have more coronary atherosclerosis and a higher 
incidence of clinical CHD than patients of African or Mixed descent of similar age, 
irrelevant to gender. Lower levels of IgM antibodies to P45 and in some cases P210 
may be associated with higher risks of CVD. These findings are important as they 
come to support the hypothesis that, at least, immune responses against P45 and P210 
may play a protective role in atherosclerosis and could be a potential target for 
immunomodulatory treatment in these patients. However, in order to complete the 
study, a control group of healthy individuals should be included and the results 
incorporated in order to verify that these differences are totally due to disease 
association, as well as as control group of central Europeans in order to confirm any 
association of response with ethnic background.
7.2. Concluding Remarks
The understanding around the mechanisms involved in the development of 
atherosclerotic plaques and acute cardiovascular events has progressed significantly 
over the past years. The role of inflammation at all stages of the disease is recognized
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[2, 514] and hence the attention has been focused on the immune system for a 
possible novel target for the prevention and treatment of cardiovascular disease [46].
Manipulation of the immune system can be done either by immunosuppressive 
drugs or immunization [46]. Immunization can either be active, inducing an immune 
response through antigen exposure, or passive, in which antibodies will be 
administered directly [46]. Available immunosuppressive drugs, such as anti­
inflammatory corticosteroids, inhibit T cell activation, are used to prevent acute 
rejection after organ transplantation and to treat certain autoimmune diseases [46]. 
Although, most of these immunosuppressive drugs, have adverse affects on 
cardiovascular risk factors such as dyslipidemia, hypertension, and diabetes [46].
A number of studies have shown activation of the immune system throughout 
various stages of atherosclerosis. Activation of immune responses may promote 
atherosclerosis by inducing and perpetuating arterial inflammation, whereas selective 
activation of certain immune functions may inhibit atherosclerosis as well as arterial 
inflammation [46]. Hence, new approaches for atherosclerosis prevention and 
treatment may be possible through the selective suppression of pro-atherogenic 
immune responses or the selective activation of anti-atherogenic immune responses 
[46]. Antigens, which have been shown to activate immune responses, which in turn 
affect the development of atherosclerosis can be used to modulate immune responses 
[46].
Active immunization with some of the epitopes in the human apolipoprotein 
B100 component of LDL cholesterol has reduced atherosclerosis in hyperlipidémie
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mice [515]. Findings from the present study also demonstrate that Tregs play a 
significant role in athero-protection, as well as in the halt of the progression of 
atherosclerosis development. In addition, apoB-100-derived peptides, P2, P45 and 
P210 have been shown to be able to induce TregS. This ability to generate regulatory T 
cells holds a promise for the development of new therapies to enhance regulation and 
to treat autoimmune diseases. It is hence believed that a vaccine based on 
apolipoprotein B100-related peptides could be used in reducing atherosclerosis [515]. 
Understanding the mechanisms by which Tregs exert their function will define 
parameters that can be manipulated therapeutically to intervene in the disease process 
[493]. Studies so far suggest that immunization can reduce the development of 
atherosclerosis by 50% to 60%, but it will not completely prevent development of the 
disease, as in the case with immunization against many infectious diseases [46]. 
Consequently, any effective atherosclerosis vaccine will be most likely be used in line 
with other well-established treatments, such as statins and other risk-modifying 
interventions [46].
7.3 Further Studies
The role of regulatory T cells in the process of atherosclerosis has been 
demonstrated and current studies are carried out to shed more light on the importance 
of this subtype of T cells. After demonstrating the importance of these ApoB-100- 
derived peptides and their role in the proliferation and functional status of regulatory 
T cells, these peptides can be used in immunization studies to further confirm their
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ability to induce antigen-specific regulatory T cells, before proceeding with their use 
in pre-clinical studies.
In order to investigate the de novo induction of Tregs, apoE'7' mice could be 
depleted using PC61 before treatment with the peptides alone or loaded onto DCs. 
An alternative approach could be to use irradiated mice in which the bone marrow 
could be reconstituted with lymphoid progenitors from young animals from the same 
species which could be subsequently immunised as explained above.
To further strengthen this study and demonstrate the importance of Tregs, the 
analysis and observation of any plaque formation in the aortas obtained from the 
treated apoE'7' mice after depletion with PC61 was also scheduled, but was not carried 
out due to time and resource constrains. The fact that the aortas were fixed in formalin 
poses a strong limitation a we could not carry out the detection of cells and other 
importamt molecules as the antibodies available would only work in frozen samples.
It would also be interesting to see the effects of immunisation with ApoB-1 OO- 
peptide-induced Tregs on the plaque formation in the aortic sinus and the aortas of 
PC61 treated apoE*7' mice. This would indicate any possible protective effect of the 
peptide-induced Tregs in the process of atherosclerosis.
Before proceeding with further Treg depletion with PC61, the depletion 
protocol to be used should have been optimized more thoroughly as we realized that 
the protocol described in the original papers describing this methodology were not 
completely adequate for our conditions. By optimizing, we propose possible changes
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in the duration of treatment with PC61, either earlier termination or more frequent 
vaccination, as well as to analyse a population of cells that would not only include 
spleenic cells, in order to achieve a higher depletion percentation (closer to 80%).
Detection of antigen-specific Tregs induced by the different treatments is 
another important issue that could be performed. These days this can be carried out by 
flow cytometry using labeled MHC class I or II penta-, hexa or octomers that can be 
custom designed by several companies. This methodology provides massive 
specificity and signal, but it depends mainly on whether the chosen peptides have, or 
can be recognized by the available MHC class I or II locus complexes. This is an 
expensive methodology worth pursuing if the resources were available.
In order to establish a possible relationship between ethnicity and different 
immune responses to oxidised LDL and to further enhance the understanding of 
differences in susceptibility to CHD between racial groups, which would help in the 
development of therapeutic approaches for the treatment and prevention of 
atherosclerosis, two extra control groups should be added in the study. One group 
would include healthy individuals and the results should be incorporated in order to 
verify that the differences are due to disease association. The other control group 
should include central Europeans for confirmation of any association of response with 
ethnic background. However, the main limitation in our study was the number of 
patients available, which may have affected the analysis and interpretation of our 
results. This can be sorted in future by recruiting more patients.
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Figure A1. Dilc18(3) Spectra. Absorption and fluorescence emission spectra of DilC18(3), 
as per www.invitrogen.com.
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Figure A1. One-way AN OVA correlation graphs against ApoB-100 peptides for IgM 
against IgG antibody levels for patients of East Indian ethnicity. An analysis of variance 
was performed in order to observe any correlations between East Indian ethnicity and the 
antibody response against each of the ApoB-100-derived peptides.
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Figure A2. One-way AN OVA correlation graphs against ApoB-100 peptides for IgM 
against IgG antibody levels for patients of African ethnicity. An analysis of variance was 
performed in order to observe any correlations between African ethnicity and the antibody 
response against each of the ApoB-100-derived peptides.
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Figure A3. O ne-w ay AN OVA correlation grap h s a g a in st A poB -100 p ep tid es  for IgM 
ag a in st IgG antibody lev e ls  for p atien ts o f  Mixed ethnicity . An analysis of variance was 
performed in order to observe any correlations between Mixed ethnicity and the antibody 
response against each of the ApoB-100-derived peptides.
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Figure A4. Correlation between ethnicity and IgG antibody response against P2
peptide. An analysis of variance was performed in order to observe the correlation between
ethnicity and the antibody response against each the P2 ApoB-100-derived peptide.
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Figure A5. Correlation between ethnicity and IgM antibody response against P2
peptide. An analysis of variance was performed in order to observe the correlation between
ethnicity and the antibody response against each the P2 ApoB-100-derived peptide.
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Figure A6. Correlation between ethnicity and IgM antibody response against P45
peptide. An analysis of variance was performed in order to observe the correlation between
ethnicity and the antibody response against each the P45 ApoB-100-derived peptide.
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Figure A7. Correlation between ethnicity and IgM antibody response against P45
peptide. An analysis of variance was performed in order to observe the correlation between
ethnicity and the antibody response against each the P45 ApoB-100-derived peptide.
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Figure A8. Correlation between ethnicity and IgG antibody response against P210
peptide. An analysis of variance was performed in order to observe the correlation between
ethnicity and the antibody response against each the P210 ApoB-100-derived peptide.
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Figure A9. Correlation between ethnicity and IgM antibody response against P210
peptide. An analysis of variance was performed in order to observe the correlation between
ethnicity and the antibody response against each the P210 ApoB-100-derived peptide.
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Figure A10. One-way AN OVA correlation graphs against ApoB-100 peptides for IgM 
against IgG antibody levels for patients with a diabetic background. An analysis of 
variance was performed in order to observe any correlations between a diabetic background 
and the antibody response against each of the ApoB-100-derived peptides.
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Figure A11. One-way AN OVA correlation graphs against ApoB-100 peptides for IgM 
against IgG antibody levels for patients with a non-diabetic background. An analysis of 
variance was performed in order to observe any correlations between a non-diabetic 
background and the antibody response against each of the ApoB-100-derived peptides.
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Figure A12. Correlation between diabetic background and antibody responses against 
P2 peptide. An analysis of variance was performed in order to observe the correlation 
between ethnicity and the antibody response against the P2 ApoB-100-derived peptide.
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Figure A13. Correlation between diabetic background and antibody responses against 
P45 peptide. An analysis of variance was performed in order to observe the correlation 
between diabetic background and the antibody response against the P45 ApoB-100-derived 
peptide.
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Figure A14. Correlation between diabetic background and antibody responses against 
P210 peptide. An analysis of variance was performed in order to observe the correlation 
between diabetic background and the antibody response against the P210 ApoB-100-derived 
peptide.
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Figure A15. One-way AN OVA correlation graphs against ApoB-100 peptides for IgM 
against IgG antibody levels for patients at 30-49 years of age. An analysis of variance 
was performed in order to observe any correlations between a non-diabetic background and 
the antibody response against each of the ApoB-100-derived peptides.
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Figure A16. One-way AN OVA correlation graphs against ApoB-100 peptides for IgM 
against IgG antibody levels for patients at 50-69 years of age. An analysis of variance 
was performed in order to observe any correlations between a non-diabetic background and 
the antibody response against each of the ApoB-100-derived peptides.
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Figure A17. One-way AN OVA correlation graphs against ApoB-100 peptides for IgM 
against IgG antibody levels for patients at 70+ years of age. An analysis of variance was 
performed in order to observe any correlations between a non-diabetic background and the 
antibody response against each of the ApoB-100-derived peptides.
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Figure A18. Correlation between age and IgG antibody responses against P2 peptide.
An analysis of variance was performed in order to observe the correlation between age and
the antibody response against the P2 ApoB-100-derived peptide.
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Figure A19. Correlation between age and IgM antibody responses against P2 peptide.
An analysis of variance was performed in order to observe the correlation between age and
the antibody response against the P2 ApoB-100-derived peptide.
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Figure A20. Correlation between age and IgG antibody responses against P45 peptide.
An analysis of variance was performed in order to observe the correlation between age and
the antibody response against the P45 ApoB-100-derived peptide.
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Figure A21. Correlation between age and IgM antibody responses against P45 peptide.
An analysis of variance was performed in order to observe the correlation between age and
the antibody response against the P45 ApoB-100-derived peptide.
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Figure A22. Correlation between age and IgG antibody responses against P210
peptide. An analysis of variance was performed in order to observe the correlation between
age and the antibody response against the P210 ApoB-100-derived peptide.
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Figure A23. Correlation between age and IgM antibody responses against P210
peptide. An analysis of variance was performed in order to observe the correlation between
age and the antibody response against the P210 ApoB-100-derived peptide.
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Figure A24. One-way AN OVA correlation graphs against ApoB-100 peptides for IgM 
against IgG antibody levels for male patients. An analysis of variance was performed in 
order to observe any correlations between a non-diabetic background and the antibody 
response against each of the ApoB-100-derived peptides.
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Figure A25. One-way AN OVA correlation graphs against ApoB-100 peptides for IgM 
against IgG antibody levels for female patients. An analysis of variance was performed in 
order to observe any correlations between a non-diabetic background and the antibody 
response against each of the ApoB-100-derived peptides.
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Figure A26. Correlation between gender and antibody responses against P2 peptide.
An analysis of variance was performed in order to observe the correlation between gender 
and the antibody response against the P2 ApoB-100-derived peptide.
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Figure A27. Correlation between gender and antibody responses against P45 peptide.
An analysis of variance was performed in order to observe the correlation between gender 
and the antibody response against the P45 ApoB-100-derived peptide.
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Figure A28. Correlation between gender and antibody responses against P210 peptide.
An analysis of variance was performed in order to observe the correlation between gender 
and the antibody response against the P210 ApoB-100-derived peptide.
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